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ABSTRACT
Ribonucleotide reductase (RNR) converts ribonucleotides to deoxyribonucleotides,
the building blocks for DNA replication and repair. The E. coli class Ia enzyme
requires two subunits to catalyze the radical-based reduction reaction. p2 houses a
diferric-tyrosyl radical cofactor and a2 contains the active site and two allosteric
effector binding sites. Allosteric control of RNR fine-tunes both the relative ratios
(via substrate specificity regulation) and the total amount (via activity regulation)
of deoxyribonucleotides (dNTPs) in the cell. The molecular basis of this regulation
has been enigmatic, largely due to a lack of structural information about how the a2
and p2 subunits interact. Here, we present the structure of a complex between the a2
and 12 subunits in the presence of negative activity effector dATP, revealing an a4p4
ring-like structure. Using electron microscopy (EM), small-angle X-ray scattering
(SAXS), and analytical ultracentrifugation (AUC) we show how activity regulation
is achieved by modulating the distributions of active a2@2 and inhibited a4@4, an
interconversion that requires dramatic subunit rearrangements. The X-ray crystal
structure of the dATP-inhibited RNR and a second structure obtained using a
mechanism based inhibitor reveal that a4@4 rings can interlock to form an (a4@4)2
megacomplex. We use SAXS to understand the solution conditions that contribute
to the observed concatenation and present a mechanism for the formation of these
unusual structures. We also present the first X-ray crystal structures of a2 with
ATP or dATP bound at both allosteric sites, and discuss how observed differences in
their binding influence the modulation between c2@2 and a4@4. Finally, we present
structures that comprise a full set of cognate substrate/specificity effector pairs
bound to the E. coli class Ia RNR. These structures allow us to describe how binding
of dNTP effectors at the specificity site promotes binding of a preferred substrate.
With these structural data, we describe in molecular detail, how the binding of allosteric
effectors influences RNR activity and substrate specificity.
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Chapter I
Introduction to Ribonucleotide Reduction
15
I.A. Nucleotide Metabolism in Biology
Deoxyribonucleoside triphosphates (dNTPs, Fig. 1.1) are the building blocks used for
all DNA synthesis and repair. A cells de novo source of dNTPs is via reduction of
ribonucleotide di- or triphosphates (NDPs or NTPs), converting the ribose sugar to
2'-deoxyribose. This reaction is carried out by the enzyme ribonucleotide reductase
(RNR). As the sole source of the precursors needed to copy and maintain genetic
material, RNR is an essential enzyme. The origins of the DNA world from an RNA
world and the relative emergence of protein catalysts are speculative (1, 2), but the
role of RNR as the provider of DNA building blocks is clearly an important part of
this transformation to the biological world we know today.
dNTP production requires multiple steps, with RNR playing a central role (Fig. 1.2).
The substrates of RNR are obtained through de novo purine and pyrimidine
synthesis pathways (3-5). Inosine monophosphate (IMP) is the common precursor of
adenosine monophosphate (AMP) and guanosine monophosphate (GMP). De novo
pyrimidine biosynthesis generates uridine monophosphate (UMP). Cytidylate is
then synthesized from the triphosphate form of uridine by cytidylate synthetase to
give cytidine triphosphate (CTP) (6, 7). Whereas dATP and dGTP biosynthesis can
be traced directly from de novo purine synthesis, the origins of dCTP and TTP are
less direct. The thymine base is unique to DNA and found only in
deoxyribonucleotides. It is synthesized from dUMP by thymidylate synthase with
the methyl group coming from A 5-AO-methylenetetrahydrofolate (8). In addition,
cytidine and uridine can be interconverted through enzymatic amination and
deamination reactions catalyzed by cytidylate synthetase, dCDP deaminase, and
dCTP deaminase (7, 9, 10). The action of multiple nucleotide kinases, some specific
and some non-specific (11-13), modulates the phosphorylation state of
(deoxy)nucleotides. Multiple steps throughout this pathway are subject to
regulation and disruption of this regulation, even at single steps, can lead to
increased mutation rates during DNA replication and reduced cell viability (14-16).
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In addition to the de novo pathways described, salvage pathways allow for recycling
of free bases by the action of phosphoribosyl transferases. In addition, "house
cleaning" enzymes remove "abnormal" nucleotides that result from oxidative
damage or improper methylation of free nucleotides (such as 8-oxo-dGTP, dUTP, 2-
oxo-dATP, and dITP) to prevent their incorporation into DNA (15-17).
The importance of DNA replication fidelity is revealed in the multitude of
regulatory mechanisms used by the cell to insure accurate copies are made. DNA
polymerases contribute by choosing correct Watson-Crick base pairs and performing
exonuclease editing. If a base eludes proofreading by the polymerase, mismatch
repair machinery can correct the error after polymerization. In addition,
maintenance of deoxynucleoside triphosphate (dNTP) pools in the cell is required
for replication fidelity. Mutation rates have been shown to increase both in vitro
and in vivo if dNTP pools are unbalanced or become too large (14, 18-20). Because
RNR is responsible for the conversion of ribonucleotides to deoxyribonucleotides, it
is the central regulator of dNTP pools.
I.B. Classification of RNRs
There are three general classes of RNRs that are categorized according to the
cofactor used to generate an active site thiyl radical required for catalytic activity
(Fig. 1.3) (21). All aerobic organisms utilize a class I RNR. Class I RNRs require two
subunits, a2 and P2. The P2 subunit houses a di-metal cofactor that generates a
stable radical that must be transferred to a cysteine in the substrate-binding a2
subunit to form the catalytic thiyl radical (21). The identity of the metals in the P2
subunit is the basis for a sub-classification within class I. Ia reductases use a di-iron
center to generate a tyrosyl radical, class Ib reductases use a di-manganese cofactor
to generate a tyrosyl radical, and class Ic reductases use an iron-manganese
cofactor (22). All of these clusters require 02 to generate the initial radical. The
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composition, assembly, and maintenance of these different clusters is currently an
active area of research.
Anaerobes use one of the two non-oxygen-dependent classes of RNR, class II or class
III (23). Class II reductases use adenosylcobalamin to generate a 5'-deoxyadenosyl
radical. The cofactor binds adjacent to the active site in order to perform direct
electron transfer between the cofactor radical and the active site cysteine (24, 25).
Class III enzymes use a stable glycyl radical cofactor adjacent to the active site.
This glycyl radical cofactor is formed by an activating enzyme that uses a [4Fe-4S]
cluster and S-adenosylmethionine to generate a 5'-deoxyadenosyl radical. The
genomes of many organisms, including facultative anaerobes such as E. coli, include
genes encoding multiple RNRs of different classes (26, 27). Meanwhile, in some
eukaryotes, there are genes for multiple variants of the class Ia enzyme, some
preferentially expressed in response to of DNA damage (28).
I.C. Mechanism of Ribonucleotide Reduction
Before the widespread use of radicals in biological processes was appreciated, it was
found that the chemistry catalyzed by RNRs involved protein radicals (29). Because
of the intriguing nature of this reactivity, the mechanism has been studied
extensively and is well established through the use of labeling studies, substrate
analogs, mechanism based inhibitors, and model reactions (Fig. 1.4) (30). Substrate
(NDP or NTP) binding allows for formation of a thiyl radical on an active site
cysteine. This transient radical abstracts a hydrogen atom from the 3' carbon of the
nucleotide ribose (25). The reaction proceeds via a rearrangement forming a 3'-keto-
2'-deoxynucleotide radical species after loss of the 2' hydroxyl group as a water. This
intermediate is reduced via two single-electron reduction steps from two active site
cysteines that become oxidized to a disulfide. Abstraction of a hydrogen by an
intermediate with a radical on the 3' position of the deoxyribose reforms the thiyl
radical and completes the reduction of the product to a 2'-deoxyribonucleotide. This
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mechanism is conserved for class I and II RNRs whereas class III enzymes show
some variation. The initial steps are believed to be the same for class III RNRs, but
they lack one of the active site redox active cysteines and instead use formate in the
reduction steps (31). As discussed above, in all three classes, formation of the
transient cysteine radical is performed by a cofactor that stores the radical between
rounds of catalysis.
In the case of class I and class II enzymes, to perform another round of catalysis,
the active site disulfide must be reduced. Another pair of cysteine residues on the
intrinsically disordered C-terminal tail of the a2 subunit is used to perform a
disulfide exchange. This tail can then leave the active site and interact with
thioredoxin/thioredoxin reductase using NADPH as the ultimate source of reducing
equivalents (32). In the absence of thioredoxin, glutaredoxin can also serve to
reduce the C-terminal disulfide (33-35) and in vitro, the enzyme can be re-reduced
with small molecule reductants such as dithiothreitol (DTT) or tris(2-
carboxyethyl)phosphine (TCEP) (32).
In the class II and post-translationally modified class III enzymes, the cofactor is
found within electron transfer distance of the active site cysteine and direct electron
transfer to the cofactor can generate the thiyl radical intermediate (24, 31). In the
class I enzyme, however, the radical is stored in a separate subunit (called p2) which
must interact with the active site containing subunit (a2) to transfer the radical.
Structures of both the catalytic and radical generating subunits have been solved
(and will be discussed in more detail in section E) (14, 36). When these structures
were first reported, it was unclear how the radical generated in P2 was passed
between the subunits. An initial model invoked a long-range radical transfer over
30-35 A within a protein complex (14). This was entirely unprecedented at the time
and is still considered a remarkable chemical feat. Since this first proposal,
extensive study of the radical transfer between the two subunits has substantiated
the initial model and provided the details of this highly regulated process (37-42). A
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long-range proton coupled electron transfer (PCET) moves the radical generated in
the P2 subunit to the active site cysteine in the a2 subunit using specific protein
residues from both subunits (Fig. 1.5). Initiation of radical propagation is tightly
gated and the rate limiting step of the reaction is a conformational change that
depends on substrate and allosteric effector binding (43, 44). Intriguingly, class I
RNRs are dimers but exhibit half-sites reactivity (45-50). Site-specific incorporation
of unnatural amino acids along the PCET pathway has allowed for detection of
radical intermediates. Studies using these mutants have indicated that there is an
asymmetry in the active complex (i.e. a dimer does not form two competent electron
transfer pathways simultaneously) (49, 50).
I.D. Allosteric Regulation
When the class Ia ribonucleotide reductase from E. coli was first isolated and
characterized by Reichard and coworkers in the 1960s, the phenomenon of allosteric
regulation was just beginning to be understood. The observation of multiple forms
of regulation affecting both enzyme activity and substrate specificity was
unprecedented at the time (51). Binding studies of individual nucleotides found that
ATP and dATP both bind to multiple sites on the catalytic a2 subunit. dATP was
observed to bind at two sites per a monomer and the affinity for each site could be
distinguished. dATP bound to a high-affinity site, or "h-site" with a K1 of 0.3 IM
and a second low-affinity, or "1-site" with a Ka of 1 pM at 25*C. ATP could compete
for binding at both sites but had much lower affinity for both sites (52). The average
Ka for ATP at all sites was later measured to be -80 iM at 25*C (53). TTP and
dGTP were known to affect the substrate specificity and were both found to have
one binding site per a and both competed with dATP for binding at the h-site with
Kas measured to be 1-5 iM and 0.77 piM respectively at 25*C (52, 53). Additional
studies found that binding of substrates is enhanced in the presence of specificity
effectors (54) and binding of specificity effectors is enhanced in the presence of
substrates (55). Subsequent biochemical and nucleotide binding studies supported
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and elaborated on these results and it is now widely accepted that RNR uses two
distinct nucleotide binding sites to affect two different methods of allosteric
regulation: specificity regulation and activity regulation. The h-site is the allosteric
specificity site, where ATP or dNTPs (dATP, dGTP, or TTP) bind to affect substrate
specificity and the 1-site is the allosteric activity site, where ATP and dATP bind to
affect overall enzyme activity.
The affinities of ATP and dATP at the different allosteric sites are easily understood
in a physiological context. In E. coli the cellular concentration of ATP is -3 mM and
the concentration of dATP is -180 pM (56). Because the concentration of dATP is
much lower, to sense changes in ATP/dATP ratios, the affinities for dATP must be
higher. The difference in affinity for dATP at the two allosteric sites is also easily
explained in a physiological context. At low concentrations, dATP binds
preferentially at the specificity site to affect substrate preference and when the
concentrations are sufficiently high, it then can also bind to the activity site to
inhibit the enzyme. Because the affinity for ATP is so low, there are limited
techniques that can be used to accurately measure Kas. For this reason, it has been
difficult to measure the difference between the affinities at the activity vs.
specificity sites. This issue is revisited in chapter IV of this thesis.
By using allosteric specificity regulation, relative ratios of the different
deoxyribonucleotides are maintained - this is essential because RNR is the single
enzyme responsible for production of all dNTPs but fidelity of DNA replication
relies on proper dNTP ratios (16, 57). The specificity rules utilize a type of feedback
mechanism (Fig. 1.6), whereby binding of dATP or ATP at the allosteric specificity
site promotes CDP or UDP production reduction. As CDP and UDP are reduced,
TTP concentrations will increase. Binding of TTP at the specificity site then
promotes GDP reduction and binding of dGTP promotes ADP reduction. Buildup of
dATP will either restart the cycle if it binds to the specificity site or lead to
inactivation by binding to the allosteric activity site. Allosteric specificity regulation
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will be discussed in detail in chapter V where we present the first set of substrate
and specificity effector bound structures of the E. coli class Ia RNR.
In addition to dNTP ratios, DNA replication fidelity is sensitive to the total
abundance of dNTPs which changes in a cell cycle dependent manner (58). Class Ia
and class III RNRs are subject to allosteric activity regulation whereby ATP
increases the activity of RNR and dATP at high concentrations inhibits activity.
Early sedimentation studies of the E. coli class Ia RNR revealed formation of a
complex between the a2 and P2 subunits, consistent with an a2P2 stoichiometry, in
the presence of ATP. In contrast, in the presence of dATP, a heavier complex was
formed, concomitant with a loss of enzymatic activity (Fig. 1.7) (59). These
correlated changes in complex size and enzyme activity remained enigmatic for
almost four decades. A recently reported study used electrophoretic mobility
techniques to characterize complexes formed in the presence of different nucleotides
(60). These studies were limited by the buffer conditions required for the technique
that did not allow for addition of nucleotides at concentrations higher than 100 PM.
They did, however, confirm that in the presence of 50 pM dATP, a large complex
was formed that required the presence of both subunits. The observed complex had
a molecular weight equivalent to an a4p4 complex and its formation was reversible.
In the presence of ATP, this large complex was not observed and the a2P2 complex
was observed as a minor population in a mixture with free as and P2 subunits.
A recent resurgence of interest in allosteric activity regulation of RNR has led to
much progress in understanding the underlying molecular mechanisms both in the
E. coli system and other class Ia RNRs (60-63). In E. coli, the active complex is
transient and difficult to trap for the relatively long time scales required for high-
resolution techniques. As we report in Chapter II, observations that the a4@4
complex formed in the presence of the negative effector dATP is long lived have led
to progress in the characterization of this inhibited state of RNR. Allosteric activity
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regulation and the role of interconverting states of the class Ia RNR from E. coli will
be discussed in detail in chapters II and IV.
It has been suggested that there is cross-talk between the two types of allosteric
sites. When mutations were made at the activity site in the mouse RNR, it had an
effect on specificity effector binding (64). The protein used in these studies however
was not pure and it is possible the observed effects were due to misinterpretation of
binding data. Whether there is communication between the two subunits, is not
resolved (21, 62, 64).
In addition to allosteric regulation, RNR activity can be regulated in the cell at the
level of transcription, translation, protein stabilization and subunit localization (23,
65). In S. cerevisiae there are two genes for the catalytic subunit, Rnrl and Rnr3,
the latter of which is only expressed in response to DNA damage (66). There is
further level of regulation based on subunit localization. In S. cerevisiae, the
catalytic subunits are found in the cytoplasm whereas the radical generating
subunits can be localized to the nucleus or the cytoplasm in response to cellular
stress (67). In addition to spatial regulation, temporal regulation has been observed.
In mammals, genes for the a2 and f2subunits are located on different chromosomes.
The c has a relatively constant protein level over the cell cycle with a long half-life
(68, 69) whereas the P2 subunit has a much shorter half-life and protein levels vary
during cell cycle progression (70). Additionally, in humans there are two variants of
the class I radical generating subunit, one of which (p53R2) is responsive to DNA
damage (28). As a final example of cellular regulation, in S. cerevisiae a small (11.8
kDa) protein, SmlI, has been shown to inhibit RNR activity by binding directly to
the catalytic subunit (71, 72).
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I.E. Structures of Ribonucleotide Reductase
X-ray crystal structures have been obtained for RNRs of all three classes. All RNR
structures currently deposited in the RCSB protein databank are listed in
Tables 1.1 and 1.2. A comparison of structures from the different classes reveals
many conserved structural features, including the active site and allosteric effector
binding sites (Fig. 1.8) (24). The active site is housed within a ten-stranded p/a
barrel. Each half of the barrel is comprised of five parallel p-strands with four
connecting a-helices, and the two halves of the barrel are situated anti-parallel to
one another. Between the two halves, a 20-residue loop, called the "finger loop",
extends into the center of the barrel (Fig. I.8B). The cysteine that provides the
transient radical needed for hydrogen abstraction (Cys439 in E. col) is located at
the very tip of the finger loop and the residues surrounding it (Glu441 and Asn437
in E. coh) are important for substrate binding and stabilizing intermediates during
catalysis (14, 73). When the class Ia structure was first solved, this barrel was a
novel fold and has since then only been found in RNRs and glycyl radical enzymes
such as pyruvate-formate lyase, an enzyme responsible for formation of acetyl CoA
in anaerobic metabolism (74). The structural similarity of this unique barrel in all
three classes of RNR provides a strong argument for divergent evolution from a
common precursor, presumably the class III reductase.
Substrate bound structures have been solved for three class Ia RNRs (E. coli, S.
cerevisiae, and human) (73, 75, 76) and one class II RNR (T. maritima) (77, 78).
Substrate binding is stabilized by interactions with strands of the p/a barrel and
residues on the finger loop. The 3' carbon of the ribose is positioned near the
cysteine where the radical is formed (Cys439 in E. coh), within a distance sufficient
for hydrogen atom abstraction at this position. The two redox-active cysteines
(Cys225 and Cys462 in E. coh) are located on adjacent p-strands on the opposite
side of the ribose from Cys439, consistent with the proposed mechanism. Structures
of the E. col a2 with Cys225 and Cys462 in reduced and oxidized, states reveal that
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in the reduced state, Cys462 undergoes a change in conformation causing a shift in
the Ca of about 2 A further from Cys225 and a shift of the sulfur atom of about 6 A
further from Cys225 (73). These shifts are localized to the active site but cause the
cystine formed upon oxidation to sit closer to the substrate-binding site than the
oxidized cysteines.
Along with conservation of the active site, the allosteric specificity site, found at the
dimer interface, is conserved for class I and II enzymes. The catalytic subunit of
RNR is typically a dimer. The only exceptions are monomeric class II enzymes. A
crystal structure of a class II monomer from L. leichmannii revealed the insertion of
an additional domain maintains features of the class II dimer interface without
requiring a second subunit (Fig. I.8C) (24). The class I and class II dimer interface
comprises two helices from each monomer that form a four-helix bundle. The
stability of this dimer interface is variable within class Ia enzymes with the E. coli
c2 found almost always as a dimer in solution whereas many eukaryotic RNRs are
found as monomers and dimers in the absence of effectors (63, 79, 80). The allosteric
specificity site is located at the dimer interface (Fig. 1.9), consistent with the
observation that binding of allosteric specificity effectors stabilizes dimer formation
in RNRs that are found to be monomers in solution. In contrast to the class I and II
enzymes, the dimer interface of the class III enzyme is much more extensive (Fig
I.8C) (31). Again, dimer formation creates allosteric effector binding sites but these
sites are structurally distinct from those seen in the class I enzymes.
In class I and II RNRs, the allosteric specificity site is separated by approximately
15 A from the active site on the a2 subunit, thus the communication between
specificity effector nucleotides and the active site can be achieved by local
rearrangements in this region of the protein. However, attempts to obtain
structures of a2 with substrates and effector nucleotides bound that could define
these rearrangements has proved challenging. In early structures of the E. col C2
subunit, it was observed that three loop regions became more ordered when the
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specificity effector TTP was bound (73). This implicated these loop regions, termed
"loop 1", "loop 2" and "loop 3" as being important in substrate binding or a2p2
formation. Loop 1 (residues 263-277 in E. coh) is involved in specificity effector
binding, loop 2 (residues 292-301 in E. coh) is a bridge between the specificity site
and activity site, and loop 3 (residues 319-332 in E. coli) interacts with loop 2 and
loop 3 of the of the other subunit of the dimer, but not directly with effector or
substrate making the role of this loop less clear. These structures indicated what
regions of the protein were involved in substrate specificity regulation, but did not
reveal the details of how specificity is conferred. Two sets of substrate/effector
bound structures have been reported from the class II enzyme from T. maritima (77)
and the class Ia enzyme from S. cerevisiae (76). For both sets, loops 1 and 2 are not
fully ordered and analysis of the structures did not lead to a clear understanding of
how specificity is controlled allosterically.
In class III enzymes, it is proposed that similar to class I and II enzymes, allosteric
specificity effector binding orders loops that form stabilizing interactions with
substrates (81). The specificity site is further removed from the active site,
(approximately 25 A away), however, and there are no structures of substrates
bound to a class III enzyme. Details of the mechanism for substrate specificity
regulation in the class III RNR remain to be determined.
All RNRs that exhibit allosteric activity regulation contain a conserved N-terminal
domain, often termed an "ATP-cone" (Fig. 1.9). The ATP cone is a four-helix bundle
with a three-stranded p-cap (Fig. 1.10). This domain appears to be necessary but not
sufficient for activity regulation, as RNRs lacking it do not exhibit this regulation
while RNRs have been described that do have this domain but do not employ this
type of regulation (82, 83). In addition, RNRs have been reported (for example, the
RNR in P. aruginosa) with duplications of this domain (84). In this case, despite the
presence of multiple ATP cones, only one is responsive to allosteric activity
regulators. The ATP-cone houses the allosteric activity site, where the binding of
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ATP or dATP controls enzyme activity. This domain is not in direct contact with the
active site or allosteric specificity site and based on this observation, was believed to
be involved in a-p interactions (73). There is one structure of the ATP analog AMP-
PNP bound at the activity site of the E. coli class Ia a2 (73) and recently structures
were reported for the human a2 subunit with both ATP and dATP bound at the
activity site (75). These structures have highlighted some of the residues that are
important for binding nucleotides and in the case of the human structures, revealed
differences in the binding of ATP vs. dATP. The D57N mutant of the mouse a2 has
been shown in biochemical studies to be resistant to negative regulation by dATP.
Asp57 in mouse is conserved in the human RNR and corresponds to His59 in the E.
coli RNR. Crystal structures revealed that this residue is proximal to the 3' position
of the ribose. In the human RNR structures, however, this residue is not ordered
and with only one structure of E. coli RNR with an ATP analog bound, the role of
this residue in causing the observed effects can not yet be rationalized from a
structural perspective. In addition, these structures do not reveal any large
rearrangements due to nucleotide binding and because they are structures of the a2
subunit alone, any downstream affects of dATP vs. ATP binding on a-p interactions
cannot be determined.
Multiple structures of the radical generating subunit of class Ia and Ib RNRs have
also been reported. The structure of the class Ia p2 from E. coli has been reported in
multiple oxidation states and structures of the radical generating subunit from
many species are available including multiple eukaryotic as well as viral RNRs (85-
95). Structures of all reported class I P2 subunits are listed in Table 1.2.
All radical generating subunits with known structures have a conserved
architecture (Fig. 1.11). Like the a2 subunit, P2 is a homodimer. Its structure is
almost exclusively helical, typically containing 13 a-helices. The dimer interface is
extensive. The E. coli class Ia p2 dimer interface has a surface area of approximately
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3,000 A2 and the overall structure resembles a heart shape (14). The E. coli p2 has a
p-hairpin at the base of the heart that is not found in many of the other RNRs (Fig.
I.11). Each monomer houses a di-metal center coordinated by histidine, glutamate
and aspartate ligands provided from four of the helices. The tyrosine that houses
the tyrosyl radical is adjacent to the metal cluster (Fig. 1.12) and in the E. coli P2 is
buried in the protein, at least 10 A from the protein surface, consistent with its
observed stability (14). The metal centers of each monomer are about 25 A apart. A
notable feature of the di-iron site is the inclusion of a r-helix that includes one of
the iron ligands (Glu204 in E. coll). This structural feature creates a "bulge" in the
helix and it has been proposed that this allows flexibility in the structure to allow
access for 02 during cofactor assembly (96).
Interactions between the C2 and p2 subunits are mediated by C-terminus of the p-
subunit. Truncation of the last 30 residues of the C-terminus has been shown to
result in loss of activity (45) and short peptides that compete for it's binding site can
also inhibit the reaction (97). This C-terminal tail is flexible and has never been
observed in structures of the P2 subunit from any organism. Among the flexible
residues is Tyr356 (E. coli numbering), the residue required for radical transfer
across the a-p interface (48). The E. coli a2 subunit was crystallized in the presence
of a 20-mer peptide corresponding to the C-terminus of the p2 subunit. The resulting
structure revealed the binding site for this peptide and showed it does not adopt
much secondary structure upon binding (Fig. 1.13) (14). Knowing the location of this
peptide binding site, however, is extremely valuable for thinking about how an
anchor formed at this site can help establish the active a2p2 species.
From the structures of the individual subunits a model was proposed for the active
a2p2 complex (14) (Fig. I.14). Alignment of the 2-fold symmetry axes of the
individual structures positions the lobes of the heart-shaped P2 towards the concave
active site barrels of C2. Importantly, the subunit arrangement in this model places
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the conserved aromatic residues required to form a PCET path along a conduit,
with the surface-exposed Trp48 of P2 within -23 A from Tyr731 of a2, a reasonable
distance for PCET if bridged by Tyr356 on the flexible C-terminal tail of P2. Because
the initial proposal of this model, spectroscopic data obtained from mutant forms of
the a2 or P2 subunit with unnatural amino acids incorporated along the PCET
pathway have allowed for the measurement of distances between the tyrosyl radical
of one @ subunit and a second radical trapped on an unnatural amino acid (50).
These measurements are consistent with the compact docking model.
One structure containing both the a2 and 12 subunits has been reported for the class
Ib RNR from S. typhimurium (Fig. 1.15) (98). As a class Ib enzyme, this a2 does not
have an ATP-cone. In the crystal lattice, two different interactions between the c2
and P2 subunits were observed. Based on the proximity of conserved and
catalytically important residues, one conformation was chosen as the most relevant
(Fig. I.15A). Even in this conformation, the two subunits are not close enough to
perform chemistry. In this 4.0 A resolution structure, one of the two C-terminal
tails of the p2 subunit is seen bound to an a subunit. It is bound at the same site as
the C-terminal peptide that was added to the crystallization conditions for the E.
coli structure, however, with slightly different interactions due to species specific
differences in the residues. Additionally, the tyrosine on the P C-terminus that is
responsible for radical transfer at the interface of the active complex was not
ordered. The authors proposed that this was an intermediate state in the conversion
of a2 and p2 to the active a2@2 complex that was stabilized by crystal contacts. This
structure did not yield additional information about the active state of the enzyme,
but it did define the @ C-terminal peptide binding site in a class Ib enzyme and also
highlighted the difficulty in obtaining a crystal structure of the complex in the
transient active state using non-modified proteins.
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I.F. Ribonucleotide Reductase as a Drug Target
Because of its essential role in cell division, RNR has long been a target for cancer
therapies as well as anti-viral and anti-microbial drugs. There are multiple classes
of drugs that target different aspects of RNR regulation or chemistry. The radical
mechanism used by RNR has been a target for many of these classes of inhibitors.
Hydroxyurea, first approved by the FDA in 1967, is one of the most widely known
RNR inhibitors and is used in the treatment of leukemias and other cancers, often
in combination therapies (Fig. I. 16A). Its mechanism of action is believed to be via
quenching of the tyrosyl radical in the P2 subunit, rendering RNR inactive (99).
Hydroxyurea can be used in vitro to reduce the tyrosyl radical in the E. coli P2
subunit to tyrosine, leaving the metal cluster in an Fe3+-Fe3+ form. Called met-@2,
this form of the enzyme has been valuable for studying RNRs under non-turnover
conditions (61).
Along with radical quenchers, a second class of drugs targeting the P2 subunit
consists of metal chelators. As one example, thiosemicarbazones are believed to
inhibit RNRs by destroying the metal center of P2 or by quenching of the tyrosyl
radical (100-102). One such molecule, Triapine (Fig. I.16B), is currently in late stage
clinical trials for the treatment of head and neck, and lung cancers (103, 104).
In addition to molecules that target the p2 subunit, a third class of RNR inhibitors
includes rationally designed inhibitors that target the a2 subunit. The nucleoside
analog, gemcitabine, targets the chemistry of the enzyme and is used clinically
against multiple cancer types (Fig. I.16C) (105-107). Gemcitabine is a cytosine
analog that is converted to the diphosphate form in the cell (F2CDP). This substrate
mimic can hijack the power of radical chemistry, creating unstable radicals that
react in the active site non-specifically and essentially destroy the enzyme active
site (108).
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Similarly, 2'-azido- and 2'-halo-2'-deoxyribonucleotides (Fig. I.16D & E) are
mechanism-based inhibitors that have been used to investigate the catalytic
mechanism of RNR in vitro (30, 109). Enzyme inactivation by these molecules
requires hydrogen atom abstraction, similar to the natural substrates, but
substitutions at the 3' position of the sugar lead to reactivity of the radical
intermediates that inhibits the enzyme irreversibly. The specific details depend on
the substitution and these mechanisms have been studied in detail and are
reviewed in (30). These molecules are not used clinically but have provided much
insight into details of how radical chemistry is controlled in the enzyme. Because
these molecules target chemistry steps, which are conserved for all RNRs, they
target RNRs non-discriminately.
A fourth class of inhibitors includes nucleoside analogs such as clofarabine (Fig.
I.16F), fludarabine, and cladribine that have been used in the treatment of
lymphomas and leukemias and are proposed to inhibit human RNR but are not
mechanism based inhibitors (110). Studies carried out on the drug clofarabine have
shown that the diphosphate form is not turned over by human RNR but binds to the
enzyme reversibly to act as an active site competitor (111).
A fifth class of RNR inhibitors targets a2-P2 interactions. Sequence alignments
reveal that the residues of the C-terminal tail of P2 that mediates interaction
between a2 and P2 are not conserved and short peptides corresponding to this tail
are sufficient to inhibit the catalytic activity (97, 112). Early studies were carried
out at Merck and Boehringer Ingelheim to develop peptide inhibitors specific for the
RNR from herpes simplex virus (113, 114). Subsequent studies optimized the
binding and inhibition properties of short peptide inhibitors of this RNR (as
reviewed in (115)). More recently, inhibition studies of the RNR from chlamydia
using peptidomimetics were reported, but were less successful than peptide
inhibition of the herpes simplex virus RNR (116). Despite efforts in this area, there
are currently no C-terminal peptidomimetic inhibitors of RNR in the clinic.
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One final class of RNR inhibitors uses antisense RNA technology to target protein
expression. The Si-RNA therapeutic GTI-2040, developed by Lorus Therapeutics,
has been shown to decrease human P2 mRNA and protein levels as is currently in
clinical trials for multiple cancer types (117).
RNR continues to be a target for fighting many diseases. Although RNR inhibitors
are being used successfully for human cancer indications and in HIV combination
therapies, there is always room for improvement. Also, a species-specific RNR
inhibitor that could be used against pathogens remains to be developed. The
multiple layers of complexity associated with this enzyme are one reason this
endeavor has proved so difficult. As we unravel more of RNRs mysteries, including
its mechanism of allosteric regulation, we will approach this task from a more
complete perspective and may discover new ways to target the enzyme for
pharmaceutical use.
I.G. Goals of this Thesis
RNR is of interest for a multitude of reasons, from questions on the evolution of the
DNA world, to metallo-cofactor assembly, complex radical transfer processes, and
the development of novel therapeutics. In this thesis, we focus on gaining a
molecular level understanding of allostery in this highly regulated enzyme by using
structural techniques to study the E. coli class Ia RNR. As the long-standing
prototype for RNRs, the E. coli class Ia enzyme has been extensively characterized
and is amenable to both high- and low-resolution structural techniques that can
address fundamental questions of how structure relates to the function of allosteric
regulation. Using low-resolution techniques, the structure of the dATP-inhibited
enzyme was revealed and will be presented in Chapter II. The work described in
this chapter also reveals how changes in the equilibrium of oligomeric states of RNR
leads to activity regulation. In chapter III, we describe another structure of the E.
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coli RNR, treated with the mechanism-based inhibitor F2CDP and discuss the
insight gained from this structure about RNR complex formation under conditions
typically used in crystallization experiments. In chapter IV, high-resolution X-ray
crystal structures of the a2 subunit with ATP or dATP bound at both allosteric sites
are described. These structures reveal, for the first time, differences in nucleotide
binding at the allosteric activity site that are important for distinguishing between
them. We also describe how the differential binding of these nucleotides may affect
formation of active and inhibited RNR complexes. In chapter V, we present the first
full set of substrate and specificity effector bound E. coli RNR structures that reveal
the molecular details of allosteric specificity regulation. Finally, in chapter VI, we
put these new results into context and propose future directions for obtaining a still
better understanding of allosteric regulation by this fascinating enzyme.
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Figure 1.1. Structures of canonical purine and pyrimidine dNTPs and NTPs. The
structures of all four DNA nucleotides (dATP, dGTP, dCTP and TTP) and the
nucleotide unique to RNA, UTP, are shown. (Note: TTP is not denoted as dTTP
because it is only present as the deoxyribonucleoside form). Purine bases are colored
blue and pyrimidine bases, maroon. On the right, the basic purine, pyrimidine, and
ribose structures are shown with atoms numbered based on standard nomenclature.
The difference between ribonucleotides and deoxyribonuleotides is the presence or
absence of the hydroxyl group at the 2' position of the ribose.
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Figure 1.2. Simplified scheme for dNTP biosynthesis. Regulation steps are not
shown. NDPs, formed by phosphorylation of de novo purine and pyrimidine
biosynthesis products, are the substrates for most RNRs. The ribonucleotide
reduction step is shown with red arrows. The dNDP products are phosphorylated by
deoxynucleotide kinases to the dNTP form. Enzymatic conversion of uracil and
cytidine can be mediated at multiple steps, shown with green arrows. TTP is
synthesized from dUMP by thymidylate synthase, shown with a purple arrow.
dUMP can be produced via deamination of dCTP or dCMP, or from reduction of
UDP.
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Figure 1.3. Radical generating cofactors used by RNRs are the basis of their
classification. Class I enzymes use di-metal centers to generate stable radicals that
are maintained in subunits separate from the active site containing catalytic
subunit. The radical must then be transferred over long distances into the active
site across a subunit interface. Class II enzymes use the B12 derived cofactor,
adenosyl-cobalamin, which undergoes homolytic cobalt-carbon bond cleavage,
generating a 5'-deoxyadenosine radical that directly abstracts a hydrogen from the
active site cysteine. Class III enzymes require an activase subunit that contains a
[4Fe-4S] cluster and S-adenosylmethionine to generate a 5'-deoxyadenosine radical
that abstracts a hydrogen from a glycine near the active site of the catalytic
subunit. This stable glycyl radical then abstracts a hydrogen from the active site
cysteine to initiate catalysis. The class III cofactor is oxygen sensitive while the
class I cofactors require 02 for their generation.
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Figure 1.4. Reaction mechanism for ribonucleotide reduction in class I and II
enzymes. Some class II enzymes use NTPs as substrates but the catalytic
mechanism is the same. For simplicity, only an NDP substrate is shown in this
scheme. B is any of the four canonical RNA bases. In the first step, substrate binds
to the enzyme causing a conformational change that allows for generation of a thiyl
radical in the active site. This radical abstracts a hydrogen from the 3' position of
the ribose to generate a substrate radical intermediate. Loss of water from the 2'
position is facilitated by deprotonation of a second active site cysteine residue.
Deprotonation of the 3'-OH by an active site glutamine allows formation of a ketone
at the 3' position, forming a second radical intermediate. This intermediate is
reduced upon formation of a disulfide by the deprotonated cysteine with a
neighboring cysteine to form a cystine radical anion. This radical species reduces
the ketone intermediate, generating a product radical that abstracts a hydrogen
atom to re-form the initial thiyl radical and generate the product. The thiyl radical
is then transferred back to the radical storage cofactor, and product can be released.
The resulting active site disulfide is reduced by a disulfide exchange with two
cysteine residues on the C-terminal tail of the catalytic subunit. This disulfide is
then reduced through the shuttling of reducing equivalents from NADPH through
thioredoxin reductase and thioredoxin.
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Figure 1.5. Proposed proton coupled electron transfer (PCET) pathway for
oxidation of the active site cysteine in a2 by the tyrosyl radical in P2. Residue
numbering is for the E. coli class Ia enzyme. The direction of electron transfer is
shown as a red line, with proton transfer steps shown as blue lines. The
involvement of W48 on the pathway has not been demonstrated experimentally.
Residues in the P2 subunit are colored black and residues in the a2 subunit are
colored blue.
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Figure 1.6. Scheme for allosteric control of RNRs that exhibit specificity and
activity regulation. This scheme is the same for RNRs that use NTP substrates;
NDP substrates are shown for simplicity. Specificity regulation is shown in blue
arrows and activity regulation in red and green arrows. At low concentrations dATP
stimulates reduction of pyrimidine substrates preferentially. When pyrimidine
dNTPs build up, TTP binding stimulates reduction of GDP. Build up of dGTP leads
to dGTP binding to the enzyme, stimulating ADP reduction. As dATP is produced, it
acts as an allosteric negative effector, binding to allosteric activity sites when
present at high concentrations (>50-75 pM) and inhibits the reaction for all
substrates. ATP competes for binding at this same allosteric site, and when present
at concentrations high enough to outcompete dATP binding, stimulates RNR
activity to provide the cell with more dNTPs.
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Figure 1.7. Allosteric activity regulation in the E. coli class Ia RNR is achieved by
changes in oligomeric state. The free a2 and P2 subunits are in equilibrium with the
active a2s2, which forms when ATP is bound at the allosteric activity site and
substrate is bound at the active site with its preferred effector bound to the
allosteric specificity site. An inhibited a4p4 forms when dATP binds to the activity
site.
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dATP
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from T. maritima
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from L. leichmannii from T4 bacteriophage
Figure 1.8. Structures of RNR catalytic subunits from all three classes reveal
evolutionarily conserved features. A) The overall fold is shown in cartoon
representation with a-helices colored red, P-strands colored yellow and loops colored
green. B) The central p/a barrel is shown with the conserved finger loop colored in
blue. C) Each monomer is colored either pink or blue to highlight the dimer
structure. The class II RNR from L. leichmannii is a monomer with an extra
domain, colored in light blue, that maintains the dimer interface seen in dimeric
class I and class II structures. Class I and II dimers are similar. The T. maritima a2
lacks the N-terminal ATP-cone domain, making it smaller than the class Ia a2 from
E. coli. The class III RNR has a distinct dimer structure.
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Figure 1.9. Nucleotide binding to the a2 subunit of the E. coli class Ia RNR shows the
location of the allosteric and active sites. One a chain is colored blue and the other in cyan.
The N-terminal 90 residues of both chains are colored green. Nucleotide binding sites are
highlighted with nucleotides shown as spheres, placed based on their location in in
previously solved structures (PDB ID 3R1R and 4R1R (73)). Substrate GDP, in yellow
spheres, is bound at the active site. Specificity effector TTP, in purple spheres, is bound at
the specificity site. The activity effector analog AMP-PNP, in and pink spheres, is bound at
the activity site. Labels indicate the location of the binding sites. The specificity site, located
at the dimer interface is approximately 15 A from the active site. The activity site, located in
the N-terminal domain, is approximately 35-40 A away from the active site.
51
Figure 1.10. The N-terminal ATP cone from the E. coli a2 subunit is depicted in
cartoon representation and colored in rainbow from N-terminus (blue) to C-
terminus (red). AMP-PNP bound at the activity site (modeled from PDB ID 3R1R
(73)) is shown as sticks with carbons in grey, oxygen in red, nitrogen in blue and
phosphorus in orange. This domain consists of four a-helices and a three-stranded
p-sheet that forms a cap above the nucleotide.
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(1SYY)
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M. musculus (1XSM)
P. vivax (201Z) S. typhimurium
class Ib (1R2F)
Figure 1.11. Structures of the radical generating subunit (32) from multiple
species reveal a conserved helical architecture. Structures are shown in cartoon
representation with a-helices colored red, p-strands colored yellow and loops colored
green. Organism and PDB IDs are given under each structure.
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Figure 1.12. Structure of the di-iron cluster in the E. coli P2 subunit. (PDB ID
1MXR (88)). Fe-coordinating residues are shown in sticks with carbons in grey and
the adjacent Tyr122 is shown in sticks with carbons in cyan. Oxygen is colored red
and nitrogen blue. The two irons are shown as brown spheres. The oxo bridge and
two waters are shown as red spheres. The iron ligands are provided by four a-
helices in the core of the protein.
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Figure 1.13. The C-terminus of P2 binds to the a subunit in an orientation
determined from structures of a2 cocrystallized with a 20-mer peptide of the P C-
terminus. This peptide, which has one helical turn but is mostly unstructured, is
shown in red cartoon, bound to the a subunit, shown in grey space filling
representation (PBD ID 3R1R (73)). The active site of the a subunit is facing into
the page.
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-Y122'
Figure 1.14. A compact a2P2 complex is proposed to be the active state of the E.
coli RNR. A docking model of the active a2p2 constructed from individual structures
of a2 (blue and cyan) and P2(red and orange) is show in cartoon representation on
the left (73). On the right, a space filling representation shows how residues on the
PCET pathway are aligned in this model. The precise location of Y356 is unknown
as it lies on the disordered C-terminus of 12 that has never been observed in crystal
structures of P2.
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Figure I.15. X-ray crystal structure of a complex between the a2 and P2 subunits
of the S. typhimurium class Ib RNR. Two possible complexes were observed in the
crystal lattice (PDB ID 2BQ1 (98)). a2 is colored red and orange, and p2 is colored
cyan and blue. The irons bound at the di-metal center are shown as green spheres.
A) In one of the two observed interactions, the subunit interface has a surface area
of 360 A2. This conformation arranges conserved residues of the P2 subunit nearest
to the active site of the one chain of the a2 subunit. According to the authors, this
represents an intermediate state moving towards the active a262. B) A second
interaction observed in the crystal packing has an interface with a surface area of
670 A2. The lack of interactions between conserved residues suggests this interface
is due to crystal packing.
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Figure 1.16. Small-molecule inhibitors of RNR. A) Hydroxyurea is a radical
quencher used to reduce the tyrosyl radical in P2. B) Triapine is a metal chelator
that may also quench the tyrosyl radical in P2. C) Gemcitabine is mechanism-based
inhibitor used clinically against multiple cancer types. D) 2'-azido- and E) 2'-halo-2'-
deoxynucleotides are mechanism-based inhibitors that have been used in
mechanistic studies of RNR chemistry. F) Clofarabine is a nucleoside analog that
does not require radical transfer chemistry to inhibit human RNR.
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Table I.1. Structures of catalytic subunits of RNR deposited in the RCSB protein
databank as of April 2013. Green lines distinguish organisms and/or classes. The
class of RNR is given for the first structure of the group. If the condition field is
blank, it is the same as the closest structure above it for which the condition is
given.
PDB organism space conditions effectors resolu
ID group bound/ -tion
mutations (A)
1R1R E. coli Class Ia R32 Li2SO4, MgSO4, Y730F 2.9
citrate pH 6.0, p-
peptide
2R1R E. coli R32 dTTP 3.0
3R1R E. coli R32 AMP-PNP 3.0
(activity site only)
4R1R E. coli R32 C292A mutant, 3.2
GDP, dTTP
5R1R E. coli R32 E441A 3.1
6R1R E. coli R32 E441D 3.1
7R1R E. coli R32 E441Q 3.1
1RLR E. coli R32 oxidized active 2.5
site
2XOX E. coli R32 2.3
2XAK E. coli R32 Y730N02Y 2.8
2XAP E. coli R32 Y731NO2Y 2.1
2XAV E. coli R32 Y731NO2Y/Y730 2.8
F
2XAW E. coli R32 Y730N02Y/Y731 3.1
F
2XAX E. coli R32 Y730N02Y/Y731 2.75
A
2XAY E. coli R32 Y730NO2Y/C439 2.65
A
2XAZ E. coli R32 Y730NO2Y/C439S 2.6
2X05 E. coli R32 Y731NH2Y 2.7
2XO4 E. coli R32 Y730NH2Y 2.5
3UUS E. coli C2 PEG 3350, dATP 5.65
Mg(CH3CO2) 2,
glycerol, DTT, MOPS
pH 7.5
4ERM E. coli C2 dATP/dADP 3.95
4ERP E. coli C2221 PEG 3350, ATP/F2CDP 4.45
NH 4(CH 3CO 2),
glycerol, DTT,
HEPES pH 7.5
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PDB organism space conditions effectors resolu
ID group bound/ -tion
mutations (A)
2ZLF Saccharomyces P21212 PEG 3350, NaCl, peptide bound 2.59
cerevisiae HEPES pH 7.5
Class Ia
2ZLG S. cerevisiae P21212 peptide mimic 2.52
bound
3K8T S. cerevisiae P21212 dGTP/ADP- 2.1
analog
1ZZD S. cerevisiae P21212 PEG3350, With peptide 2.6
Na(CH3CO2), RNR4
(NH4) 2 SO 4 pH 6.5
1ZYZ S. cerevisiae F4132 Na(CH3CO2), No peptide - 2.9
Na(HCO2) pH 4.6 reduced
2CVS S. cerevisiae P21212 no peptide - 2.6
oxidized
2CVT S. cerevisiae P21212 AMPPNP 3.2
2CVU S. cerevisiae P21212 AMPPNP/CDP 2.9
2CVV S. cerevisiae P21212 AMPPNP/UDP 2.9
2CVW S. cerevisiae P21212 TTP/GDP 2.4
2CVX S. cerevisiae P21212 dGTP/ADP 2.2
2CVY S. cerevisiae P21212 R2 peptide, TTP 2.4
2EUD S. cerevisiae P21212 AMP-PNP/F2CDP 2.3
3PAW S. cerevisiae P63 PEG MME 5000, dATP at A-site - 6.61
tacsimate pH 7.0, hexamer
HEPES pH 7.0
3S87 S. cerevisiae P21212 dGTP/ADP 2.25
3S8A S. cerevisiae P21212 R293A, dGTP 2.9
3S8B S. cerevisiae P21212 AMP-PNP/CDP 2.8
3S8C S. cerevisiae P21212 R293A, AMP- 2.8
PNP/CDP
3TB9 S. cerevisiae P21212 Q288A, AMP- 2.5
PNP/CDP
3TBA S. cerevisiae P21212 Q288A, 2.8
dGTP/ADP
3RSR S. cerevisiae P21212 Nucleotide analog 2.3
5'-NITP
2WGH Human Class P21 PEG3350, dATP 2.3
Ia NH4(CH 3CO 2),
BisTris pH 5.5
3HNC Human P21212i PEG3350, LiSO 4, TTP 2.41
TRIS pH 7.9
3HND Human P212i2i TTP/GDP 3.21
3HNE Human P212121 TTP/ATP 3.11
3HNF Human P212 12 1 TTP/dATP 3.16
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PDB organism space conditions effectors resolu
ID group bound/ -tion
mutations (A)
1PEM Salmonella P432 12 MgCl2, DTT, none 2.99
typhim urium NaMalonate pH 7.2
Class Ib
1PEO S. P432 12 dCTP 3.0
typhim urium
1PEQ S. P432 12 TTP 2.8
typhimurium
1PEU S. P432 12 dATP 3.2
typhimurium
2BQ1 S. P4132 Na(HCO2), HEPES "holocomplex" 3.99
typhimurium pH 7.5 with dGTP, ADP
not bound,
oxidized
1XJF Thermotoga C2 PEG 8000, NaCl, dATP 2.4
maritima - DTT, Na(CH3CO2)
class II pH 4.5
1XJG T. maritima C2 dATP/UDP 2.5
1XJJ T. maritima C2 dGTP 1.86
1XJM T. maritima C2 dTTP 2.4
1XJN T. maritima P21  dATP/CDP 2.25
1XJK T. maritima C2 dGTP/ADP 2.12
1XJE T. maritima C2 dTTP/GDP 1.9
300Q T. maritima C2 dTTP/GDP/adeno 1.8
sine
3000 T. maritima C2 dTTP/GDP/ado.co 1.9
balamin
300N T. maritima C2 dTTP/adenosylcob 1.95
alamin
1L1L Lactobacillus P21 (NH4)2SO 4, PEG 1.75
leichmannii 8000, glycerol,
Class II NaCitrate,
pH 5.6
1HK8 Enterobacteria P4 32 12 PEG 400, MgCl2, dGTP/Mn/Zn 2.45
phage T4 - HEPES pH 7.5, DTT
Class III
1H78 Enterobacteria P43212 dCTP 2.50
phage T4
1H79 Enterobacteria P4 3212 TTP 2.90
phage T4
1H7A Enterobacteria P4 3212 dATP 2.75
phage T4
1H7B Enterobacteria P43212 none 2.45
phage T4
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Table 1.2. Structures of class I p2 subunits of RNR deposited in the RCSB protein
databank as of April 2013. Green lines distinguish organisms and/or classes. The
class of RNR is given for the first structure of the group. If the condition field is
blank, it is the same as the closest structure above it for which the condition is
given.
PDB organism space conditions metal(s) bound/ resolu
ID group mutations -tion
S___ ____ _ 
__ ____ ____ (A)
1RIB E. coli Class Ia P212121 PEG 4000, NaCl, Fe 2.20
dioxane, Hg, MES
pH 6.0
1PIY E. coli P212121 Fe soaked 1.68
1PIZ E. coli P21212i D84E, Fe soaked 1.90
1PIM E. coli P212121 Fe, D84E, 2.00
dithionite reduced
1PIU E. coli P21i2i Fe, D84E 2.20
1PJO E. coli P212121 D84E/W48F, Fe 1.90
soaked
1RNR E. coli P21212i Fe, F208Y(Dopa) 2.50
1PJ1 E. coli P2i2i21 PEG 4000, NaCl, D84E/W48F, Fe 1.95
dioxane, Hg, MES soaked
pH 5.0
1PM2 E. coli P212 12 1 PEG 4000, NaCl, Hg, D84E, Mn soaked 1.80
MES pH 7.3
1XIK E. coli P212121 PEG 4000, NaCl, Hg, Fe 1.70
MES pH 6.0
1R65 E. coli P212121 Fe soaked 1.95
1MXR E. coli P212i2i Fe, Met 1.42
1PFR E. coli P21212i Fe, S211A 2.20
1YFD E. coli P212121 Fe, Y122H 1.90
1RSR E. coli P21212i Fe, F208A, N 3  2.00
1RSV E. coli P212121 Fe, E238A, N3 2.20
1BIQ E. coli P212121 Fe soaked, E238A 2.05
1MRR E. coli P21212i Mn substituted 2.50
1JQC E. coli P212121 Mn substituted, 1.61
H202 oxidized
1JPR E. coli P212121 Mn substituted, 1.88
NO oxidized
1AV8 E. coli P61 Saturated NaCl, pH Fe 2.80
7.6
2AV8 E. coli P61 Fe, Y122F 2.46
2XOF E. coli P61 Saturated NaCl, pH Fe, Y122NO2Y 2.20
7.9
2ALX E. coli P6122 (NH4)2SO 4, EPPS, Mn 2.60
MnCl, MgCl2, Hg,
MES pH 6.5 _ 1
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PDB organism space conditions metal(s) bound/ resolu
ID group mutations -tion
(A)
3N37 E. coli Class Ib P6322 PEG 4000, Li2SO4, Mn 1.65
HEPES pH 7.5
3N38 E. coli P6522 Fe soaked 1.90
3N39 E. coli P212i2i PEG 3000, Li2SO4, Mn, NrdI complex 2.50
HEPES pH 7.6
3N3A E. coli P212121 PEG 3000, Li2SO4, Mn, reduced NrdI 1.99
Na2S204, HEPES complex
pH 7.6
3N3B E. coli P212121 Mn, reduced NrdI 2.36
complex, H202
2VUX Human Class P21212i NaCl, (NH4)2SO4, Fe 2.80
la chymotrypsin,
NaCacodylate pH 6.5
30LJ Human P212121 NaH2PO4/KHPO4 pH No metal 2.10
5.6
2UW2 Human C2221 PEG 10,000, Fe 2.80
NH4(CH 3 CO 2),
BisTris pH 5.5
3VPM Human P4 3212 KCl, TRIS pH 7.5 Fe, E106A 2.70
3VPN Human P4 3212 Fe, E106D 2.25
3VPO Human P4 3212 Fe, E106Q 2.30
4DJN Human P21212i (NH4)2SO 4 , No metal 2.20
NaCacodylate pH 6.5
3HF1 Human p53R2 P212121 NaCitrate, Li2SO 4 , Fe 2.60
Class Ia (NH4)2SO4
1W68 Mus musculus C2221 NaCl, Na(CH3CO2) Fe soaked at pH 2.20
Class Ia pH 4.7 6.0
1W69 M. musculus C2221 Fe soaked with 2.20
dithionite at pH
6.0
1HON M. musculus C2221 Co soaked with 2.40
C0 2 + at pH 6.0
1HOO M. musculus C2 2 2 1 Co-crystallized 2.20
with C02+
1XSM M. musculus C2221 PEG 4000, NaCl, Fe 2.30
Na(CH3CO 2) pH 4.7
1SMS Saccharomyces P6i PEG 1000, EtOH, No metal, Rnr4 3.10
cerevisiae NaCl, Hg, HEPES homodimer
Class Ia pH 7.5
1SMQ S. cerevisiae P1 PEG3350, succinate, No metal, Rnr2 3.10
Li(CH3CO 2) pH 4.8 homodimer
1JKO S. cerevisiae P212121 PEG 4000, NaCl, Zn in Rnr2, 2.80
(CH 3CO 2) pH 4.9 Rnr2Rnr4
I _heterodimer
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PDB organism space conditions metal(s) bound/ resolu
ID group mutations -tion
-___(A)
1UZR Mycobacterium P42212 (NH4)2SO 4 , Na/K Fe, R2F-2 2.20
tuberculosis Tartrate,
Class Ib Na(CH3CO2) pH 5.6
1R2F Salmonella P21 PEG 8000, Fe, dithionite 2.10
typhimurium Na(CH3CO2), TRIS reduced, NO
Class Ib pH 8-8.5 soaked
2R2F S. P21 Fe 2.25
t yphim urium
4DRO Bacillus P212121 PEG 4000, Li2SO4, Mn 1.90
subtilis Class pH 6.5
Ib
3DHZ Corynebacteriu P2i PEG 4000, Apo 1.63
m NaCitrate,
ammoniagenes NH4(CH3CO2) pH 6.5
Class Ib
10QU C. P21 Fe soaked in MES 2.00
ammoniagenes pH 6.0-6.5
1KGN C. P21 Fe co-crystallized 1.85
ammoniagenes
1KGO C. P21 Fe soaked in MES 2.25
ammoniagenes pH 6.0-6.5 reduced
with dithionite
1KGP C. P21 Mn soaked in MES 2.00
ammoniagenes pH 6.0-6.5
3MJO C. C2 PEG 4000, Mn 1.36
ammoniagenes NaCitrate,
NH 4(CH3CO2), TRIS
pH 7.5
1SYY Chlamydia P4 32 12 PEG 20,000, Fe 1.70
trachoma tis Pb(CH3CO2)2, MES
Class Ic PH 6.5
2ANI C. trachomatis P4 3212 PEG 20,000, PbCl2, Fe, F127Y 2.00
MES pH 6.3
4D8F C. trachomatis P21  PEG 3000, Mn/Fe (high [Mn] 2.20
Na(CH3CO2) pH 7.6 reconsistution)
4D8G C. trachomatis P21 PEG 3000, Mn/Fe (low [Mn] 1.75
Na(CH3CO2) pH 7.4 reconsistution)
2RCC Bacillus C2 PEG 400, PEG 3000, Zn bound, SeMet 1.90
halodurans glycerol, HEPES pH substituted,
putative Class 7.5 structural
Sgenomics
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Chapter II
Structural interconversions modulate activity of E. coli
ribonucleotide reductase
The work presented in this chapter was published in similar form as Ando N,
Brignole EJ, Zimanyi CM, Funk MA, Yokoyama K, Asturias FJ, Stubbe J, &
Drennan CL. (2011) Structural interconversions modulate activity of Escherichia
coli ribonucleotide reductase. Proc Nat1Acad Sci USA 108:21046-21051.
Experiments described in this chapter were the result of a collaborative effort with
Dr. Nozomi Ando, Dr. Edward Brignole and Michael Funk whose contributions are
noted in the text.
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II.A. Summary
Essential for DNA biosynthesis and repair, ribonucleotide reductases (RNRs)
convert ribonucleotides to deoxyribonucleotides via radical-based chemistry.
Although long known that allosteric regulation of RNR activity is vital for cell
health, the molecular basis of this regulation has been enigmatic, largely due to a
lack of structural information about how the catalytic subunits (a2) and the radical-
generation subunits (P2) interact. Here we present the first structure of a complex
between a2 and P2 subunits for the prototypic RNR from E. coli. Using four
techniques (small-angle X-ray scattering, crystallography, electron microscopy, and
analytical ultracentrifugation), we describe an unprecedented a4p4 ring-like
structure in the presence of negative activity effector deoxyadenosine triphosphate
(dATP) and provide structural support for an active a2@2 configuration. We
demonstrate that under physiological conditions, E. coli RNR exists as a mixture of
transient a202 and a4p4 species whose distributions are modulated by allosteric
effectors. We further show that this interconversion between a2@2 and a4p4 entails
dramatic subunit rearrangements, providing a stunning molecular explanation for
the allosteric regulation of RNR activity in E coli.
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II.C. Introduction
Important targets of anti-cancer and anti-viral drugs, RNRs are classified by the
metallo-cofactor used to generate a thiyl radical (1) that initiates reduction of
nucleotides to deoxynucleotides (2, 3). Class Ia RNRs are found in all eukaryotes
and many aerobic bacteria, with the E. coli enzyme serving as the prototype. These
RNRs reduce ribonucleoside 5'-diphosphates (NDPs) and are composed of two
homodimeric subunits: a2 and P2 (Fig. II.1A). The a2 subunit contains the active
site, where nucleotide reduction occurs, and two types of allosteric effector binding
sites (4, 5). One effector site tunes the specificity for all four ribonucleotide
substrates in response to intracellular levels of deoxyribonucleoside 5'-triphosphates
(dATP, TTP, dGTP) and adenosine triphosphate (ATP) (6, 7) such that balanced
pools of deoxyribonucleotides are maintained (8). The second effector site controls
the rate of reduction, binding ATP to turn the enzyme on or dATP to turn it off (4,
6). This activity site is housed in an N-terminal cone domain (5, 9) and provides a
means for negative feedback regulation to safeguard against cytotoxic elevation of
deoxyribonucleotide levels (2, 3, 10). The P2 subunit harbors the essential diferric-
tyrosyl radical (Y122- in E. coh) cofactor (11) that initiates radical chemistry.
Active RNR has long been proposed to be a transient a2@2 complex (Fig. II.1B) with
enhanced subunit affinity upon binding of substrates and effectors (12-15). For each
turnover, a2, P2, substrate and effector must interact, triggering long-range proton-
coupled electron transfer (PCET) reducing Y122* in 12 and oxidizing C439 to a thiyl
radical in the active site of a2, over an unprecedented distance of >35 A (13, 15, 16)
(Fig. II.1C). Once the thiyl radical is generated in the active site of a2,
ribonucleotide reduction proceeds through a conserved mechanism (17). Allosteric
regulation of this activity is key to cell survival and involves conformational
changes as well as oligomeric state changes in both prokaryotic (12, 14, 18) and
eukaryotic systems (19-23). For E. coli (12, 14, 18), mouse (20-22), yeast (19), and
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human (19, 23), the negative effector dATP has been linked to increases in
oligomeric state with a recent gas-phase electrophoretic molecular mobility analysis
(GEMMA) study estimating a molecular weight of 510 kDa for the dATP-inhibited
E. coli RNR (most consistent with an a4p4 state) (18), whereas for human and yeast
RNR, dATP has been linked to a hexamerization (19, 22, 23).
To understand the role of oligomeric state in the activity regulation of this
prototypic class Ia RNR from E. coli, we have combined data from four
complementary structural techniques. Using small-angle X-ray scattering (SAXS)
and analytical ultracentrifugation (AUC), we provide evidence that supports a
compact a2p2 structure for the active complex that can be reversibly converted via a
dynamic conformational rearrangement to an inactive a4p4 state in the presence of
elevated dATP or protein concentrations. Additionally, using SAXS, single-particle
electron microscopy (EM), and X-ray crystallography we demonstrate that the a4p4
complex induced by the negative effector, dATP, is an unexpected ring-like
structure composed of alternating a2 and P2 subunits. Together, these results
explain how activity can be modulated by oligomerization, which is induced by
effector binding at an allosteric site that is -42 A from the active site.
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II.D. Results (Analytical ultracentrifugation experiments, data collection and
analysis were performed by Dr. Nozomi Ando and Michael Funk. Small-angle X-ray
scattering experiments, data collection and analysis were performed by Dr. Nozomi
Ando. Electron microscopy experiments, data collection and analysis were
performed by Dr. Edward Brignole).
II.D.1. ATP shifts oligomeric equilibrium
Sedimentation velocity AUC was employed to investigate the oligomeric
distributions of E. coli RNR at multiple protein concentrations and in the presence
of effectors at physiologically relevant concentrations (approximately 175 mM for
dATP, 3 mM for ATP, and 0.1 mM for TTP) (24-27). Using p2 that was pre-treated
with hydroxyurea to prevent turnover and thus oxidation of the catalytic site during
measurements, three different modes of RNR regulation were investigated: (a)
under negative feedback regulation with dATP in both specificity and activity sites
and CDP as the substrate; (b) under enhanced CDP reduction with ATP in both
specificity and activity sites and CDP as the substrate; and (c) under guanosine
diphosphate (GDP) reduction with thymidine triphosphate (TTP) in the specificity
site and no effector in the activity site.
In the presence of saturating dATP and CDP, a2 alone and P2 alone sediment at 5.2
and 8.4 S, respectively (Fig. II.2A). These sedimentation coefficients are in good
agreement with previously reported experimental values (12, 14) as well as
theoretical values calculated from their crystal structures (5, 28) of 5.8 and 8.4 S.
Similar results are obtained for the individual subunits with ATP/CDP and
TTP/GDP (Fig. 11.3). When a2 and P2 are combined in the presence of saturating
dATP/CDP, a distinct peak is observed at 15.6 S at a physiological RNR
concentration of 1 jiM (Fig. II.2A) (26, 27). Increasing the protein concentration does
not result in peak shifts, indicating that the 15.6 S peak can be attributed to a
single non-interacting species with a low dissociation constant (29). Gaussian fitting
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to the peak yields a molecular weight of 533 kDa by the Svedberg relation (Fig. II.4)
(30), similar to the 510 kDa estimate for the dATP-inhibited E. coli enzyme reported
by GEMMA (18), and consistent with an a404 complex. For a globular protein of this
molecular weight with a typical frictional ratio of 1.2, the expected sedimentation
coefficient is approximately 19 S (31), much larger than the observed value,
suggesting that the dATP-inhibited complex is highly non-globular.
In contrast, broad peaks with maxima near 10-11.5 S were observed in the presence
of saturating TTP/GDP or ATP/CDP at 1 pM protein concentration (Fig. II.2B).
Gaussian fitting of these peaks did not yield molecular weight estimates that were
consistent with any one single species of RNR, including the expected a2p2 active
complex. Furthermore, increasing the protein concentration by 10-fold shifted the
dominant peak toward 16 S (dashed line in Fig. II.2B), approaching the
sedimentation coefficient of the dATP-inhibited complex. The observation of broad
peaks that shift with increasing protein concentration are the hallmark of a mixture
of rapidly exchanging species rather than a single species (29). Contrary to our
previous understanding of E. coli class Ia RNR, the peak shifts observed here
indicate that a large complex dominates at high protein concentration in the
absence of dATP, with no effector in the activity site (Fig. II.2B, TTP/GDP) or even
with a positive activity regulator occupying the activity site (Fig. II.2B, ATP/CDP).
Significantly, the peak shifts suggest that under these conditions this large complex
is able to rapidly exchange with smaller species and is therefore in the equilibrium
mixture even at physiological protein concentrations.
II.D.2. dATP-inhibited complex contains both a2 and P2
To determine the subunit composition and stoichiometry of the dATP-inhibited
complex, we used SAXS, a structural technique that provides protein size and shape
information in solution. a2 was titrated into P2 under identical dATP/CDP
conditions investigated by AUC, leading to a rapid and dramatic increase in radius
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of gyration (Rg) up to the equimolar point, consistent with the formation of a large
complex with 1:1 subunit stoichiometry (Fig. 11.5). Given the 533 kDa molecular
weight determined by AUC, a 1:1 complex is most consistent with a 517 kDa a4p4
oligmerization state.
As a control, a2 was examined under identical conditions without P2. The Rg of a2
alone showed minimal concentration dependence with a value of 39.7 ± 0.3 A when
extrapolated to zero protein concentration to eliminate the effects of inter-particle
interactions (Fig. II.5B), in excellent agreement with the theoretical value of 39.3 A
calculated from the a2 crystal structure (5). The reverse titration and corresponding
control with P2 alone yielded similar results (Fig. 11.6), showing that both a2 and P2
must be present for the formation of higher order oligomers.
II.D.3. Structure of the dATP inhibited complex
EM and X-ray crystallography were used to investigate the architecture of the
dATP-induced a4p4 complex. EM images were acquired of 0.15 pM a2 and P2 in the
presence of 1 mM CDP and 0, 1, or 50 pM dATP (Fig. II.7A and Fig. 11.8). In the
absence of dATP, the subunits are largely dissociated, as expected from the
measured micromolar subunit affinity (32). The addition of dATP drives the
formation of distinct ring-like complexes approximately 200 A in outer diameter.
13,895 images of these ring-shaped particles were aligned and classified (Fig. 11.9)
and the resulting class averages are consistent with a2 and P2 subunits arranged in
an alternating pattern forming an a4P4 complex (Fig. II.7B, Average). Because the
EM images were collected as tilted-untilted pairs, we were able to generate a 3D
map of the a4p4 ring at -23 A resolution (Fig. II.7B and Fig. II.10). Crystal
structures of the individual dimeric subunits (5, 28) could be unambiguously fit to
the 3D map of the a4p4 ring, confirming the alternating subunit arrangement
suggested by the 2D class averages.
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To obtain a more detailed picture of the a4P4 complex, a 5.65 A resolution crystal
structure was obtained by co-crystallizing a2 and P2 with 10 mM dATP (Fig. II.7C
and Table 11.1). The structure, which was solved by molecular replacement, displays
electron density for dATP bound at both activity and specificity sites (Fig. II.11D-E)
and reveals the same a4P4 ring-shaped species in the asymmetric unit of the crystal
as that observed by EM (Fig. II.7B-C). The individual a2 and P2 subunits of the a4P4
structure align well with structures of uncomplexed a2 and P2 subunits, showing
only small variations in the a-cone domain, and sharing overall average root-mean-
square-derivations of 1.11 and 1.01 A for a2 and P2 subunits, respectively (Fig.
II.11B-C). In the a 4P4 structure, a2 and P2 contact each other at two points. In
addition to the previously identified (15) binding pocket on a2 for the C-terminus of
P2, we find a new interaction between the activity site, housed in the N-terminal
cone domain of a2 (Fig. II.7C-D, green), and each lobe of P2 (Fig. II.7C-D,
red/orange). This direct contact between the dATP-bound as activity site and the P2
subunits provides a molecular explanation for how the presence of activity effectors
can be sensed, leading to the regulation of activity. From these structural data, we
can also rationalize why a dATP-induced a 4p4 complex would be inactive. We find
that residues on the radical propagation pathway (Fig. II.1C) are not aligned
appropriately for electron transfer, instead facing a large central opening -100 A in
diameter (Fig. 1I.7C) such that W48 of P2 and Y731 of a2 are solvent exposed, and
Y356 on the flexible C-terminal tail of P2 remains disordered. Also, the distance
between W48 and Y731 is too long (-55-58 A) for PCET via only a single residue in
the middle (Y356). In contrast, for active E. coli RNR, expected W48-Y731 distances
are -23-25 A based on the proposed docking model (15), which has been supported
experimentally using distance restraints from pulsed electron-electron double
resonance (PELDOR) spectroscopy (13).
The unanticipated a 4p4 structure observed by EM and crystallography is supported
by SAXS and AUC. Importantly the use of these four methods allows for the
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interrogation of this RNR structure at a wide range of protein and dATP
concentrations. Protein concentrations of 0.15 mM (EM) to 25 mM (X-ray), and
dATP concentrations of 50 mM (EM) to 10 mM (X-ray) were examined. In addition,
physiological concentrations of protein (1-2 mM) and dATP (175 mM) were
investigated by AUC and SAXS in solution. Over this wide range of conditions, we
find a consistent view of the a4p4 structure. The theoretical sedimentation
coefficient calculated from the a4p4 structure is 15.6 S, in excellent agreement with
that observed experimentally by AUC (Fig. II.2A). The extrapolated Rg of 71.1+
1.1 A for a4p4 determined by SAXS (Fig. 11.12) is a larger value than expected for a
globular protein of this molecular weight, but consistent with an open ring
structure. Moreover, theoretical scattering curves calculated from the a4p4 X-ray
and EM structures agree well with the experimental scattering obtained by SAXS
(Fig. II.7E), demonstrating that the closed a4p4 ring is not only stable in solution,
but also the dominant form of the complex under negative feedback regulation by
dATP near physiological protein and effector concentrations.
II.D.4. dATP promotes subunit rearrangement
With the structures of free a2 and p2 determined previously (5, 28) and the structure
of the dATP-inhibited a4p4 complex now determined by both EM and
crystallography, SAXS was used to study the interconversion between different
oligomeric states in solution. SAXS is ideal for probing structural interconversions
as the relative fractions of individual states can be deconvoluted from mixtures (33).
Titration of dATP into RNR in the presence of CDP leads to a dramatic change in
the shape of the scattering curves and their corresponding Kratky curves, indicative
of a transition from a predominantly compact state to a non-globular state (Fig.
II.13A-B). Above 24 iM dATP, or 4 molar equivalents of dATP per a2, the scattering
curves are nearly superimposable and the Rg approaches that of the a4p4 ring (Fig.
11.14). This result is consistent with full dATP occupancy in the effector sites of a4p4,
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as expected from the reported dATP binding affinities for the specificity and activity
sites of 0.5 and 5 pM, respectively (4, 34).
Iso-intensity points in the scattering curves are observed, indicating that this
structural change can be explained by a two-state process (Fig. II.13A) (35).
Consistent with this interpretation, singular value decomposition shows that the
scattering curves can be fit to linear combinations of two independent states with
low residuals (Fig. 11.15). The two-state transition is accompanied by an increase in
the zero-angle scattering intensity (0), which is a function of protein concentration
and the electron density contrast between the hydrated protein and buffer (36).
Because the protein concentration was fixed and the micromolar dATP
concentration does not significantly affect the buffer density, the large increase in
1(0) can only be explained by an increase in protein mass. Using experimental 1(0)
values from the individual subunits as calibrants, the average molecular weight in
the dATP-driven transition was calculated to increase from 223 kDa in the absence
of dATP to 512 kDa at saturating dATP (Fig. 11.16). These values are in close
agreement with the 259 kDa a2p2 expected in the absence of dATP and the 517 kDa
a 4p4 expected under saturating dATP. The excellent molecular weight estimation of
a4p4 by this method suggests that the subunits have similar excluded volumes, and
hence similar hydration layers, as the free subunits (37). In contrast, the
underestimation in molecular weight of a2p2 can be at least in part explained by
diminished hydration around the individual subunits due to the compact
arrangement as determined by Kratky analysis (Fig. II.13B).
An ab initio shape reconstruction was performed on the scattering curve measured
in the absence of dATP, yielding a globular, three-lobed molecular envelope (Fig.
II.13D, middle). Consistent with the molecular weight estimation and compact
shape, this molecular envelope aligns well with the proposed a2p2 "docking" model
for active RNR (15). The fractions of this compact a2p2 and of a4p4 in the dATP
titration series were determined (Fig. II.13C) from a two-state fit to the scattering
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curves with low residuals (Fig. II.17B). By comparison, poor fits were obtained with
open configurations of a2P2, including an arrangement based on the previously
reported asymmetric structure of a class Ib RNR from Salmonella typhimurium (38)
(Fig. II.17C). Together, these results indicate that the addition of dATP drives a
two-state transition from a compact state, in which the subunits are closely
associated, to that in which the subunits form an open ring (Fig. II.13C-D and Fig.
11.14).
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I.E. Discussion
Allosteric regulation of activity in class Ia RNR provides a mechanism to prevent
the accumulation of cytotoxic levels deoxynucleotides. dATP is unique among
allosteric effectors in its ability to down-regulate RNR activity (4, 6). Here, using
SAXS, EM, and X-ray crystallography, we present the first structural model to
explain dATP inhibition of activity for the prototype class Ia RNR. We find that the
dATP-inhibited complex has an a4p4 stoichiometry as predicted by GEMMA (18),
but with an unprecedented arrangement of alternating subunits in an open ring
structure. Importantly, we have confirmed this surprising structure using four
different techniques and have shown that this state is the predominant species
stabilized by dATP under physiological solution conditions. Using the same
concentration of protein in the absence of dATP, the SAXS data agree well with the
predicted a262 docking model of the active RNR (15), providing the first structural
depiction of the elusive a2P2 oligomerization state.
In addition to high dATP concentrations driving the formation of the a4p4 state of E.
coli RNR, AUC results show that increasing protein concentrations also shifts the
conformational equilibrium toward the higher molecular weight a4p4 (Fig. II.2B).
At lower protein concentrations and in the absence of dATP, a4p4 is still present but
to a smaller degree, in rapid equilibrium with the active a262 state. Taken together,
the SAXS and AUC results suggest that the active RNR complex is an intermediate
between two inactive states, the dissociated a2 and P2 and the a4P4 ring (Fig.
II.13D), and that the equilibrium between these states is sensitive to both protein
and effector concentrations.
Although it has long been known that the a2 cone domain binds the activity
effectors ATP and dATP (5, 19), this a4p4 structure provides a molecular
explanation for how the cone domain regulates the activity of E. coli RNR. We find
that each a2 cone domain contacts a lobe of P2, burying a surface area (556 A2 at
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each of four interfaces; Fig. II.7D) that is large enough to stabilize the ring
structure as the dominant species under physiologically relevant protein (1-2 mM)
and dATP (175 mM) concentrations in the absence of ATP, while not so large as to
inhibit interconversion back to the active a 2 62 state in the presence of ATP and
other effectors. In the a4P4 state, the radical transfer pathway from P2 to a2 is
disrupted and solvent-exposed, unable to propagate radicals. In contrast, in a
compact a 2P2 state, these residues are expected to be closer together, buried and
shielded from bulk water (15). Thus the cone domain of a2 "communicates" the
nucleotide levels of the cell to P2, and the equilibrium of conformers can be shifted
toward the a 4p4 state, disrupting the radical pathway and inhibiting activity, or
toward a 2P2, restoring the radical pathway and enzyme activity, as nucleotide levels
dictate.
Interestingly, a recently published 6.6 A structure of yeast RNR also shows the a
cone domain to be present at a protein-protein interface. In this case, however, the
interface connects two a subunits in a dATP-induced a6 hexamer (19). Although it is
still early in terms of understanding structure/function for eukaryotic RNRs, this
recent structural work along with the results presented here provide compelling
support for the involvement of the cone domain in the formation of high-order RNR
oligomers, and pave the way for future studies.
Twenty-one years after the first structure of P2 was published (39), the first
structure of an a-p complex for this prototypic class Ia RNR is now available.
Through the power of multiple structural techniques and combined efforts of
multiple laboratories, the structures of all dominant forms of this enzyme can now
be described. From crystallography and SAXS, views of the dissociated subunits are
available (this work and (5, 28)), from SAXS and PELDOR, low resolution
structural data support an active a262 model (this work and (13)), and from
crystallography, EM, and SAXS, the structure of an allosterically inhibited a4P4 ring
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has been determined (this work). These structures have broad applications,
providing a molecular framework for considering the relationship between in vivo E.
coli nucleotide concentrations and RNR activity, as well as offering a basis for the
rational design of a new class of inhibitors that could act by stabilizing inactive
oligomeric states of the enzyme. This open ring structure of alternating subunits is
the latest surprise as this prototypic RNR enzyme, in all of its states, comes into
focus.
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II.F. Materials and Methods
II.F.1. Sample preparation
E. coli a2 and p2 were isolated as previously described (40, 41). To prevent substrate
turnover and active site oxidation during experiments, P2 was incubated with 30
mM HU (Sigma-Aldrich) at room temperature for 30 min to reduce the essential
Y122 radical. a2 was reduced by incubation with 30 mM 1,4-dithiothreitol (DTT,
USB Corporation) for 30 min at room temperature, followed by incubation with 15
mM HU to reduce any trace P2 that co-purifies with a2. Both protein solutions were
subsequently exchanged into assay buffer (50 mM HEPES pH 7.6 15 mM MgCl2 1
mM EDTA) by gel filtration with either a Superdex S-30 or Sephadex G-25 column
and stored at -80 *C in 10-100 pL concentrated aliquots. The elution buffer was
kept for the preparation of reference solutions for AUC and SAXS. The dimer
concentrations of a2 and p2 were determined using e28o of 189 and 131 mM-1cm-1,
respectively; unless noted otherwise, all molar concentrations are dimer
concentrations (i.e., a2 or P2). Pre-reduced a2 had a specific activity of 2500
nmol/min/mg, and retained 97% activity after 11 h at room temperature, as
determined by a coupled spectrophotometric assay (42). Prior to HU treatment, P2
had a specific activity of 7700 nmol/min/mg and was shown to retain 92% activity
after 11 h at room temperature. All of the experiments described here were
performed with HU-treated p2 and pre-reduced a2.
Nucleoside 5'-diphosphates (NDPs) from Sigma-Aldrich were dissolved into water or
assay buffer. The pH was slowly adjusted to 7-8 and the concentrations were
determined spectroscopically using e271 of 9.1 mM-1 cm-1 for cytidine and e253 13.7
mM-1 cm~1 for guanosine. High purity solutions of ATP, dATP, and TTP were
purchased from USB Corporation. Nucleotide solutions were stored frozen in small
aliquots and thawed immediately before experiments.
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II.F.2. Analytical ultracentrifugation (AUC) (Methods were performed by Michael
Funk and Dr. Nozomi Ando)
Sedimentation velocity AUC was performed using a Beckman XL-I analytical
ultracentrifuge at the MIT Biophysical Instrumentation Facility. Protein solutions
and reference solutions were prepared with 5 mM DTT and the indicated final
nucleotide concentrations, such that the buffer contents matched. Samples were
injected in meniscus-matching cells outfitted with sapphire windows and
interference window holders (Spin Analytical) and thermally equilibrated for
several hours at 20.0 0C after radial calibration and adjustment of laser settings.
Interference scans were collected at 40,000 rpm and 20 *C.
The apparent sedimentation coefficient distributions, g(s*), were generated using
the time-derivative method implemented in the program DCDT+ (30) using 15-80
scans. To resolve high molecular weight species, the ranges of scans were chosen
such that the peak broadening limit was at 540 kDa -1.3 MDa for complexes and
170 and 310 kDa, respectively for free subunits. In this method, differences in scan
pairs collected within short time intervals approximate the time-derivatives of the
sample concentration, dc/dt, from which g(s*) can be derived. The least-squared
apparent sedimentation coefficient distributions, 1s-g*(s), were obtained from the
same sets of scans with whole boundary least squares fitting in Sedfit (43). s-values
were corrected to standard values (s20,w) using a solvent viscosity of 1.042 cp,
solvent density of 1.00348 g/mL, and partial specific volumes as calculated in
Sednterp (44) of 0.7335 and 0.7346 mL/g for a2 and P2, respectively. Molecular
weights were determined by fitting Gaussians to isolated, concentration-
independent peaks in g(s*) using DCDT+. Theoretical s20,w values of a2, P2, and a4P4
were calculated with the program HYDROPRO (45) using the atomic coordinates
from crystallography (4R1R (5), 1RIB (28), and this work) and molecular weights
and partial specific volumes calculated from complete sequences in Sednterp (44).
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II.F.3 Small-angle X-ray scattering (SAXS) (Methods were performed by Dr. Nozomi
Ando)
SAXS was performed at the Cornell High Energy Synchrotron Source (CHESS) G1
station using a 10.5 keV 250 mm square X-ray beam with a flux of several 1012
photons/s. Data were collected on a custom 1024x1024 pixel CCD detector (46) with
a sample-to-detector distance of -1.1 m. The transmitted intensity was measured on
a PIN diode beamstop (47). Protein solutions and matching buffers were prepared
following the same protocol used for AUC sample preparation and kept on ice until
data collection. Samples were contained in 2 mm path length acrylic cells (ALine
Inc.) (47) with 7.5 [tm kapton windows (Chemplex). The same cell was used for
acquisition of protein solution and background scattering pairs. Several 1 and 2 s
exposures were taken per sample separated by 10 s pauses. The scattering images
were corrected and integrated about the beam center following previously described
image correction procedures (47). Exposures that did not display apparent
radiation-induced changes were averaged and normalized by the transmitted
intensities. Background scattering was subtracted from the protein solution
scattering to produce the one-dimensional protein scattering profile, 1(q), as a
function of q, where q = 4r/A sin 6; 26 is the scattering angle, and A is the X-ray
wavelength.
The pair distance distribution function, P(r), was calculated from the experimental
1(q) with the indirect Fourier transform method (36) implemented in the program
GNOM (48). The radius of gyration, Rg, and the forward scattering intensity, 1(0),
presented in this article were determined from P(r) by the relations:
fDmax
0
2 0' P(r)dr
and
1(0) = 4zfP(r)dr
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where the maximum electron pair distance (i.e. maximum protein dimension), Dmax,
was chosen where P(r) naturally approaches zero (36). Reasonable total estimate
scores, as indicated by GNOM (48), were obtained in all cases.
Low-resolution models of protein structures were generated from the GNOM
outputs (with a high-resolution limit of qRg ~ 8) using the ab initio reconstruction
programs DAMMIF (49), DAMMIN (50), and GASBOR (51). The program,
DAMAVER (52) was used to align ab initio models, reject outliers, and average the
probable models. Theoretical scattering curves were calculated from atomic
coordinates using CRYSOL (53). Singular value decomposition analysis and fitting
of theoretical and experimental scattering curves to dATP titration data were
performed using custom code written in MATLAB. Spline interpolation was used to
match q values of the experimental and theoretical scattering curves. The (0)
values of each species were scaled relative to each other by molecular weight and
then adjusted to reflect the fixed protein content in the experiment. Linear
combinations of scattering curves, Iritq), were fitted to SAXS data using least-
squares fitting in MATLAB:
N
where I/q) and £i are the scattering curve and molar fraction for the i-th species, N
is the number of species, and c is a constant scaling factor.
II.F.4. Electron Microscopy (Methods were performed by Dr. Edward Brignole)
1.5 iM a2 and p2 were combined with 1 mM CDP and 0, 1, or 50 pM dATP in assay
buffer. The mixture was incubated for 5 min at room temperature and then 5 p1 of a
10-fold dilution in assay buffer with nucleotides was applied to a carbon coated 300
mesh Cu/Rh grid (Ted Pella) that had been glow discharged before use. The grid
was immediately placed on a 45 pl drop of 2% uranyl acetate (Ted Pella) with 0.2%
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trehalose, then washed twice with 5 pl of the stain solution and a second carbon
layer was applied (54).
Eighty-nine pairs of images of the -55* tilted and untilted specimen were collected
at 50,000x magnification on a Tecnai F20 microscope (FEI) operated at 120 kV
equipped with a 4096x4096 pixel CCD camera (Gatan). CCD images were corrected
for background and gain during acquisition using Leginon (55) operated in manual
mode. CCD frames have a pixel size of 2.18 A at the specimen level.
CCD frames were binned 4-fold for particle selection. EMAN2's e2boxer.py (56) was
used in both Swarm and Manual modes to select ring- and C-shaped particles from
the untilted images. Then for each tilted-untilted image pair, TiltPicker (57) was
used to define the transform relating the images by selecting nine particles from the
corners, edges, and center of the overlapping field in the tilted and untilted images.
TiltPicker was modified to import the coordinates for the untilted particles and
merge these with the already selected particles. After importing the e2boxer.py
coordinates for the untilted image into TiltPicker, additional ring-like particles were
selected and false positives pruned manually and then the coordinates were
transferred to the tilted image.
A dataset of 14,055 tilt-pair particles were windowed from full-sized CCD images.
Untilted particles were initially partitioned into 128 classes using "reference-free"
alignment followed by rotationally invariant clustering (58) and used as references
for an iterative alignment and classification routine (59, 60). Redundant class
averages and those with poorly resolved features were then eliminated as references
and 160 particles were removed from the dataset as members of 4 poor quality
classes that emerged. Two classes that exhibited partial subunit occupancy were
divided using correspondence analysis and hierarchical clustering. Finally, the
iterative routine was used to refine the alignment and classification of the
84
remaining 13,895 particles into 33 classes, 14 of which reveal fully formed a4p4
rings (Fig. 11.9). Other averages indicate the presence of partially formed rings.
A 3D reconstruction was generated for the class of 1039 particles by back-projection
of the tilted particles using Euler angles defined by the alignment parameters of the
corresponding untilted particles (61). Prior to back-projection, the tilted particles
were CTF corrected as described by Radermacher (62) using scripts that were
generously provided by T. Shaikh (Wadsworth Institute, Albany, NY). Because the
3D reconstruction was generated from a relatively small number of particles, 103
untilted particles in the class were randomly selected and included in the class
reconstruction (19). Reconstructions were refined by four cycles of translational
search and backprojection followed by three additional cycles that included a
circumscribed optimization of in-plane (p) and projection angles (0 and <). Because
the a-P interactions appeared slightly asymmetric, no symmetry constraints were
applied during refinement of the EM structure. The 3D EM density map was
interpreted by rigid fitting crystal structures of a2 (4R1R (5)) and P2 (1RIB (28))
using UCSF Chimera (63). The individually fit a2 and P2 subunits and the a4P4
crystal structure correspond closely to the contours of the EM map (Fig. II.7B),
except for some compression in the direction perpendicular to the plane of the EM
specimen support. Compression is a well-documented artifact that often results
from partial flattening of particles preserved in stain (64-67).
II.F.5. Crystallization of a 4p4-dATP
Crystallization was performed by hanging drop vapor diffusion using a protein
sample that contained 25 [tM a2 (4.3 mg/mL) and 25 tM P2 (2.2 mg/mL) in assay
buffer supplemented with 5 mM DTT and 10 mM dATP. Protein solution (1 [LL) was
mixed with precipitant solution (1 gL) containing 100 mM MOPS pH 7.5, 12%
PEG 3350, 300 mM magnesium acetate, 5% glycerol and 10 mM FeCl3 and
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suspended over a 500 [tL reservoir of precipitant solution. Crystals grew within 3
days at room temperature (-24C). Crystals were cryo-protected by transferring
briefly (3-4 s) to a solution of 100 mM MOPS pH 7.5, 12% PEG 3350, 200 mM
magnesium acetate and 10% glycerol and then plunged directly into liquid N 2 .
II.F.6. Crystallographic data collection, structure solution, and refinement
Data were collected on beamline 8.2.2 at the Advanced Light Source at the
Lawrence Berkeley National Laboratory using an ADSC Quantum 315 CCD
detector. Data were indexed and integrated with HKL2000 and scaled with
Scalepack (68).
The structure was solved by molecular replacement using data to the full extent of
the resolution in Phaser (69) and search models consisting of previously solved
structures of a2 and P2 (2R1R chains A and B and 1MXR chains A and B,
respectively) with all waters, ligands and ions removed. A solution with two a2 and
two p2 molecules in the asymmetric unit was found.
Refinement was performed in CNS 1.3 (70) using all data with no sigma cutoff.
Limited model building was performed in Coot (71). Refinement included rigid body,
DEN assisted simulated annealing at 300 K (recently described for refinement of
low resolution structures (72)), and restrained group B-factor refinement with one
residue per group. Noncrystallographic symmetry (NCS) restraints were used, with
one NCS group containing a chains A and B, a second group containing a chains C
and D, and a third group containing all four P chains.
II.F.7. Model of a4p 4-dATP
The quality of the electron density map is shown in Fig. II.11. All side chains were
included in the model based on the high-resolution molecular replacement reference
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structures. Each of the four a chains contains residues 6-737 (of 761). Each of the
four P chains contains residues 1-339 (of 375), and each contains some density for
additional residues of the P C-terminal tail bound at the previously identified P tail
binding site on a (15). C-terminal residues of P have been modeled at this site based
on the previously solved structure of a2 with peptide bound (2R1R). These residues
include: 367-375 (P chains E, F), 363-375 (p chain G) and 365-375 (p chain H). Four
dATP molecules per a2 dimer were modeled at the known allosteric sites based on
the orientation of bound nucleotides seen in previous structures (2R1R and 3R1R)
and B-factors were refined (Fig. 11.11).
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active site
specificity site
a 2  IP2
B C
'Y731
Y356
8
Y122
a 2 2 docking model radical pathway
Figure II.1. Previously determined structures and proposed models for E. coli
class Ia RNR. A) Homodimeric a2 with nucleotides bound (spheres) and the cone
domains (residues 1-100) colored in green. Homodimeric P2 with diiron centers
(green) and disordered C-termini (gray lines) PDB: 4R1R, 3R1R, 1RIB (5, 15, 28) B)
Proposed a2p2 model in which the subunits are docked along their symmetry axis
(15). C) Radical pathway involving Y122-'3W48-+'.Y356 in p2 (Y122 and W48 shown
as orange spheres) and residues Y731-'>Y730->C439 in a2 (dark blue spheres). Y356
in 12 lies in the disordered C-termini (15).
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Figure 1I.2. Sedimentation coefficient distributions of E. coli class Ia RNR: dATP
and high protein concentrations shift the equilibrium toward a large complex.
Physiologically relevant effector and substrate concentrations were chosen to
saturate their respective sites, based on previously reported nucleotide-binding
affinities (4, 24, 25, 34, 51). A) In the presence of 175 iM dATP and 1 mM CDP, the
individual subunits (each at 2 mM) sediment at 5.2 and 8.4 S. When mixed, a single
slowly dissociating 15.6 S complex is observed with a molecular weight of 533 kDa.
B) In the presence of 3 mM ATP and 1 mM CDP (red curves) or 0.1 mM TTP and 1
mM GDP (blue curves), broad, protein concentration-dependent peaks are observed,
indicative of multiple species in rapid exchange. Raising the protein concentration
leads to a peak shift toward 16 S (position indicated by dashed line). Curves are
offset by a constant value for clarity.
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Figure II.3. Sedimentation coefficient distributions of individual subunits of E.
coli class Ia RNR. In the presence of 3 mM ATP and 1 mM CDP (red curves) or 0.1
mM TTP and 1 mM GDP (blue curves), the individual subunits (each at 2 mM)
sediment at approximately the theoretical values of 5.8 and 8.4 S determined from
crystal structures (8, 9).
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Figure II.4. Molecular weight determination of the dATP-inhibited complex by
AUC. The apparent sedimentation coefficient distribution g(s*) at a low protein
concentration of 2 iM (black) was chosen for Gaussian peak fitting to minimize the
effects of non-ideality on molecular weight determination. A single species fit
(magenta curve) was performed over the range 12.5 - 17.8 svedbergs in the program
DCDT+ (4); the residuals, Ag(s*), have an r. m. s. value corresponding to 0.0076
fringes. The fit yielded a molecular weight of 533.2 (529.7, 536.4) kDa and an s20,w
value of 15.632 (15.628, 15.635) svedbergs, where the 95% confidence intervals were
calculated by the Monte Carlo method implemented in DCDT+.
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Figure II.5. Subunit stoichiometry revealed by SAXS titration in the presence of
175 iM dATP and 1 mM CDP. A) Guinier representations of the scattering curves
for the titration of 0-30 mM a2 into a 6 mM P2 (red to violet). The linear regions at
low scattering angles (corresponding to length scales up to 630 A) demonstrate the
absence of non-specific aggregation in the samples. The change in slope as the
titration continues indicates a change in the average radius of gyration, Rg. B)
Complex formation between 0-30 mM a2 and a 6 mM P2 (red to violet), as measured
by Rg, is maximal at the equimolar point (dotted line), indicating a 1:1 subunit
stoichiometry. The decrease in average Rg above the equimolar point can be
attributed to the presence of excess a2. Increasing the concentration of a2 alone
(black) does not result in higher order association.
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Figure 11.6. Subunit stoichiometry revealed by SAXS titration in the presence of
175 pM dATP 1 mM CDP. A) Guinier representations of the scattering curves for
the titration of 0-30 mM P2 into 6 pM a2 (red to violet). The linearity at low
scattering angles (corresponding to length scales up to 630 A) demonstrates the
absence of non-specific aggregation in the samples. The change in slope as the
titration continues indicates a change in Rg. B) Complex formation between 0-30
mM p2 and 6 pM a2 (red to violet), as measured by Rg, is maximal at the equimolar
point (dotted line), indicating a 1:1 subunit stoichiometry. The decrease in average
Rg above the equimolar point can be attributed to the presence of excess P2.
Increasing the concentration of P2 alone (black) does not result in higher order
association and has an Rg of 27.4 +/- 1.9 A (SD) when extrapolated to zero protein
concentration, in good agreement to that calculated from the dimeric crystal
structure of 27.0 A (9).
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Figure 11.7. Structure of the dATP a4P4 complex by EM and X-ray
crystallography. A) EM images of RNR in the presence of 1 mM CDP and increasing
dATP concentrations show the formation of a4P4 rings. B) A class average with 1039
particles ("Average") is representative of the closed ring structures observed at 50
IiM dATP and is composed of alternating a2 and p2 subunits as indicated by its close
resemblance to the 2D projection of the a4P4 crystal structure ("Projection" in Panel
C). These insets are 314 A wide. Crystal structures of individual a2 and p2 subunits
(5, 39), colored as in Fig. II.1, fit to a 3D EM map of the a4p4 ring structure. C)
Crystal structure of dATP-bound RNR at 5.65 A resolution with the asymmetric
unit containing an a4p4 ring that agrees well with the EM model (5-9 A Ca rmsd). D)
Surface rendering of the crystal structure with half of the ring removed, revealing
the areas on a and P that are buried (yellow) upon formation of the a4P4 ring. E)
Experimental solution scattering (red) of 2 pM RNR in the presence of saturating
dATP/CDP superimposed with the theoretical scattering curves calculated from the
EM model (black solid) and crystal structure (cyan dashed).
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Figure 1I.8. Tilt pair EM images of negatively stained dATP-inhibited RNR. CCD
images were recorded of the 00 A) and -55* tilted B) specimen of a2 and 02 prepared
in the presence of 50 pM dATP and 1 mM CDP. Yellow trapezoids outline the
overlapping region between the images. Individual ring-shaped particles such as
those shown in the insets were selected for analysis. The scale bar in A) corresponds
to 1000 A in the CCD frames or 250 A in the insets.
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Figure 11.9. Class averages determined from EM images of RNR in the presence
of dATP. 13,895 particles were clustered into 33 classes that reveal differences in
subunit stoichiometry and conformation. 14 class averages (56% of the particles)
reveal fully formed a4p4 rings (shown above). The number of particles in each class
is indicated above its average.
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Figure II.10. Resolution of the a4p4 EM reconstruction. Resolution for the 3D
reconstruction of the class with 1039 particles (Fig. II.11B) was estimated to be 23 A
using the 0.5 correlation criterion.
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Figure II.11. Electron density and structure comparisons for the dATP-RNR
crystal. A) Electron density for one chain of a P2 dimer is shown with a 2Fo-Fc map
at 5.65 A resolution in blue mesh and contoured to 1.0 Y. Protein backbone is shown
in red ribbons and two Fe atoms are shown as orange spheres. B) An overlay of one
P chain from the a4p4 structure (in red) with P previously solved on its own (PDB ID
1PFR, in pink). The two chains overlay with no apparent differences. C) An overlay
of one a chain from the a4f4 structure (in blue) with a previously solved on its own
with AMP-PNP bound at the activity site (PDB ID 3R1R, in pink). The only
differences appear to be in the N-terminal domain that houses the activity site.
Because the structures being compared have different nucleotides bound we are
unable to tell if these differences are due to the nucleotide, the presence of P or the
error associated with low resolution data. D) Fo-Fc density calculated when dATP is
omitted at the activity site, contoured at +3.5 o (in green) and -3.5 o (in red).
Despite the low resolution, there is a substantial positive electron density peak for
dATP in this omit map. Protein backbone is shown as grey cartoons with
nucleotides shown where they are modeled in the final structure as sticks with
carbon in yellow, oxygen in red, nitrogen in blue, and phosphorus in orange. E) Fo-Fc
density calculated when dATP is omitted at the specificity site, contoured and
colored as in D).
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Figure II.12. Concentration independence of dATP-inhibited complex determined
by SAXS. The Rg of equimolar solutions of a2 and 12 (2-30 iM) in the presence of
175 iM dATP and 1 mM CDP is concentration-independent over a wide range,
indicating that the dATP-induced a4p4 complex is stable and that larger oligomers
do not form with increasing protein concentration. The Rg has a value of 71.1+/-
1.1 A (SD) when extrapolated to zero protein concentration to remove crowding and
other inter-particle interaction effects.
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Figure 11.13. SAXS investigation of the transition between lower and higher order
structures of E. coli class Ia RNR. A) Scattering curves measured as 0-175 mM
dATP was titrated into a 6 piM solution of a2 and P2 in the presence of 1 mM CDP
(red to violet) display iso-intensity points, suggesting a two-state transition. B)
Kratky representations of the scattering curves (Iq2 vs. q) at 0 mM (red), 12 mM
(green), and 40 mM (blue) dATP show a transition from a compact globular state, as
indicated by the monomodal peak, to a large non-globular state, indicated by a
bimodal curve (36). C) Fitting linear combinations of the a2p2 docking model (15)
and the a4p4 ring to the titration data provided relative fractions of the two states.
D) Ab initio SAXS reconstructions of free subunits aligned with deposited crystal
structures (5, 39), a compact c2p2 state aligned with the proposed docking model
(15), and the a 4 P4 ring aligned with the crystal structure (Tables 11.2 and 11.3 and
Fig. 11.14). The small additional density observed in the molecular envelope of a 2 P2
can be explained by the presence of -3% a4p4 (Fig. II.13C).
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Figure II.14. SAXS titration of dATP (0-175 pM) into 6 IM solutions of a2 and P2
in the presence of 1 mM CDP. Pair distance distributions, P(r), display the dATP-
induced change in shape from a globular species to a non-globular species with a
maximum dimension of 200 A. The change in average shape can be visualized by
three-dimensional ab initio shape reconstructions (statistics in Table 11.2).
Individual DAMMIF (14) and DAMMIN (15) models are aligned and shown as bead
models. The final averaged models generated by DAMAVER (17) are shown as blue
surfaces. In the absence of dATP, the molecular envelope is largely globular and
three-lobed, resembling the a2@2 docking model (39). As dATP is titrated, the three-
lobed mass reduces in size, and the additional density extends into a curved arm
until an entire ring is formed. These shapes resemble averages of the two states in
the dATP titration: the globular three-lobed a2 p2 and the dATP-inhibited a4P4 ring.
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Figure 11.15. SAXS titration of dATP (0-175 pM) into 6 pM solutions of a2 and P2
analyzed by singular value decomposition. A) Linear combinations of the two major
singular states (black curves) are nearly superimposable to the experimental data
(red to violet correspond to increasing dATP concentration). B) The residuals, AJ(q),
(same coloring as the scattering intensities) showed very little curvature, indicating
that two states are sufficient to describe the data. For clarity, both the scattering
intensities and residuals are plotted with constant offsets.
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Figure II. 16. Molecular weight determination by SAXS. At the dilute protein
concentrations used in this study, the zero-angle scattering intensity 1(0) (i.e., I(q)
at zero scattering angle, or q = 0) is a function of protein molar concentration c, the
electron density contrast between the hydrated protein and buffer Ap, and the
excluded volume of the protein V,, where the product Ap V is approximately
proportional to the molecular weight (12). Thus, 1(0) c c (Ap V)2 ~ c MW2 . A) The
experimental 1(0) of P2 alone (blue circles), a2 alone (magenta diamonds), and a4p4
(black triangles) in the presence of 175 pM dATP and 1 mM CDP were determined
at multiple protein concentrations. 1(0)/c was determined from the slope, and MW
was determined from the square root. B) 1(0)/c from a2 and P2 were used as
calibrants to convert 1(0)/c for a4P4 and a2P2 into molecular weights, where 1(0)/c of
a2@2was determined from 6 pM RNR in the presence of 1 mM CDP only. The
expected and calculated molecular weights show a good correlation.
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Figure II.17. Compact a2p2 model best fits the initial state in the SAXS titration
of dATP (0-175 pM) into 6 iM solutions of a2 and P2. Linear combinations of
experimental scattering of the a4p4 ring obtained at 175 iM dATP and theoretical
scattering of A) dissociated subunits (8, 9), B) the a4P2 docking model (39), C) an
asymmetric asp2 model generated by aligning E. coli subunit structures (8, 9) with
the S. typhimurium class Ib structure (41), and D) an open a262 model representing
half of the a4P4 crystal structure were fit to the SAXS titration data in MATLAB.
The residuals shown below each model (offset by a constant, with red to violet
correspond to increasing dATP concentration) show the least curvature with the
docking model; the residuals at 175 iM dATP (violet) are zero because the
corresponding scattering curve was used to represent a4P4 in the fitting.
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Table 11.1. Data collection and refinement statistics for crystal structure
Data collection
Beamline
Space group
Cell dimensions
a, b, c (A)
a, p3, y (*)
Wavelength (A)
Resolution (A)a
Number of unique
Rsym
<I/oI>
Completeness (%)
Redundancy
reflections
Advanced Light SourceAdvanced Light Source
Beamline 8.2.2
C2
287.39, 153.46, 169.42
90.0, 119.91, 90.0
0.9794
50.0 - 5.65 (5.85-5.65)
19134
0.074 (0.599)
9.3 (2.0)
99.4 (99.4)
3.1 (3.1)
Refinement
Resolution
Number of unique reflections
Rwork/Rree (%)b
Number of atoms
Protein
dATP
Fe
Average B-factors (A2)
Protein
dATP
Fe
R.m.s. deviations
Bond lengths (A)
Bond angles (*)
Ramachandran plot (%)
Most favored (%)
Additionally allowed (%)
Generously allowed (%)
Disallowed (%)
50.0 - 5.65
19096
25.7/30.3
34781
240
8
242.2
290.5
120.0
0.004
0.820
90.3
9.5
0.2
0.0
aHighest resolution shell is shown in parentheses. bRree was calculated using 5% of
the data.
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Table 11.2. SAXS shape reconstruction statistics from dATP titration experiment.
All samples contained 1 mM CDP and were in 50 mM HEPES pH 7.6, 15 mM
MgCl 2, 1 mM EDTA, 5 mM DTT. Experimental scattering profiles were converted
into inputs for shape reconstructions in GNOM with reasonable total estimate
scores (13). Ring-like states were reconstructed in DAMMIN with a cylindrical
search space with the outer radius, inner radius, and height specified in
parentheses; the averaged damstart model was used as
refinement (40).
a search space in a round of
[dATP] (pM)
q range (A-')
6 pMRNR
0
0.009-0.123
6 pMRNR
5
0.012-0.122
6 pMRNR
8
0.014-0.109
6 pMRNR
12
0.012-0.105
Real space range (A)
Shape reconstruction
Symmetry
Search space
sqrt(x2)
# Models averaged/total
DAMAVER NSD (var)
[dATP] (iM)
q range (A-1)
Real space range (A)
Shape reconstruction
Symmetry
Search space (A)
sqrt(x2)
# Models averaged/total
DAMAVER NSD (var)
Shape reconstruction
Symmetry
Refined search space
sqrt(x2)
# Models averaged/total
DAMAVER NSD (var)
0-164
dammif 1.1.0
P1
sphere
1.794-1.796
9/10
0.570 (0.046)
6 pMRNR
16
0.012-0.091
0-205
dammin53/
fast
P1
cyl(i10,0,100)
1.391-1.394
9/10
0.589 (0.025)
dammin53/
slow
P1
damstart
1.392-1.394
10/10
0.450 (0.016)
0-192
dammif 1.1.0
P1
sphere
1.913-1.916
9/10
0.518 (0.014)
6 pMRNR
24
0.012-0.091
0-186
dammin53/
fast
P1
cyl(110,0,100)
1.371-1.376
10/10
0.589 (0.013)
dammin53/
slow
P1
damstart
1.369-1.371
9/10
0.421 (0.037)
0-200
dammif 1.1.0
P1
sphere
1.721-1.723
9/10
0.625 (0.025)
6pIiMRNR
40
0.014-0.091
0-200
dammin53/
fast
P1
cyl(1 10,0,100)
1.303-1.309
9/10
0.665 (0.033)
dammin53/
slow
P1
damstart
1.304-1.305
10/10
0.537 (0.027)
0-200
dammif 1.1.0
P1
sphere
1.757-1.760
9/10
0.780 (0.045)
3 pMRNR
175
0.012-0.107
0-198
dammin53/
fast
P2
cyl(1 10,20,100)
1.900-1.904
10/10
0.796 (0.038)
dammin53/
slow
P1
Damstart
1.899-1.901
9/10
0.471 (0.017)
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Table 11.3. SAXS shape reconstruction statistics for the free subunits and the
dATP-inhibited C4p4 complex. All samples contained 1 mM CDP and were in 50 mM
HEPES pH 7.6, 15 mM MgCl2, 1 mM EDTA, 5 mM DTT. Experimental scattering
profiles were converted into inputs for shape reconstructions in GNOM with
reasonable total estimate scores (13). The a4p4 ring was reconstructed in DAMMIN
with a cylindrical search space with the outer radius, inner radius, and height
specified in parentheses; the averaged damstart model was used as a search space
in a round of refinement (40). Shape reconstruction of c2 was performed in
GASBOR with 1522 total residues.
[dATP] (pM)
q range (A-')
Real space range (A)
Shape reconstruction
Symmetry
Search space
sqrt(x2)
#Models averaged/total
DAMAVER NSD (var)
15 pM P2
175
0.014-0.172
0-81
dammif 1.1.0
P1
prolate
1.841-1.841
10/10
0.607 (0.032)
15 pM a2
175
0.012-0.164
0-121
gasbor22i
P2
sphere
1.89-1.91
9/10
1.279 (0.222)
[dATPI (pM)
q range (A-1)
Real space range (A)
Shape reconstruction
Symmetry
Search space (A)
sqrt(x2)
# Models averaged/total
DAMAVER NSD (var)
Shape reconstruction
Symmetry
Refined search space
sqrt(X2)
# Models averaged/total
DAMAVER NSD (var)
1.5 pM a4p4
175
0.012-0.107
0-198
dammin53/fast
P2
cyl(1 10,20,100)
1.900-1.904
10/10
0.796 (0.038)
dammin53/slow
P1
Damstart
1.899-1.901
9/10
0.471 (0.017)
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Chapter III
Structures of inactivated forms of E. coli class Ia
ribonucleotide reductase
The work presented in this chapter was published in similar form as Zimanyi CM,
Ando N, Brignole EJ, Asturias FJ, Stubbe J, Drennan CL. (2012) Tangled Up in
Knots: Structures of Inactivated Forms of E. coli Class Ia Ribonucleotide Reductase.
Structure 20(8), 1374-1383.
Experiments described in this chapter were the result of a collaborative effort with
Dr. Edward Bridgnole and Dr. Nozomi Ando, whose contributions are noted in the
text.
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III.A. Summary
Ribonucleotide reductases (RNRs) provide the precursors for DNA biosynthesis and
repair and as such are successful targets for anti-cancer drugs such as clofarabine
and gemcitabine. Recently, we reported that dATP inhibits E. coli class Ia RNR by
driving formation of RNR subunits into a4p4 rings. Here, we present the first X-ray
structure of gemcitabine-inhibited E. coli RNR and show that the previously
described a4p4 rings can interlock to form an unprecedented (a4P4)2 megacomplex.
This complex is also seen in a higher-resolution dATP-inhibited RNR structure
presented here, which employs a distinct crystal lattice from that observed in the
gemcitabine-inhibited case. With few reported examples of protein catenanes, we
use data from small-angle X-ray scattering and electron microscopy to both
understand the solution conditions that contribute to concatenation in RNR as well
as present a mechanism for the formation of these unusual structures.
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III.C. Introduction
Essential for DNA biosynthesis and repair, the prototyptic class Ia ribonucleotide
reductase (RNR) from E. coli employs two subunits a2 and P2 that perform radical-
based chemistry to convert ribonucleotides to deoxyribonucleotides. The P2 subunit
houses the diferric-tyrosyl radical cofactor used to initiate radical chemistry; a2
contains catalytic and regulatory sites (Fig. 111.1). Prior to each round of catalysis, a
radical transfer occurs in which the radical moves an unprecedented 35 A from P2 to
the catalytic site in the a2 subunit, generating the essential catalytic thiyl radical
(1-3). Although RNRs are successful targets for anti-cancer drugs such as
clofarabine and gemcitabine (4-9), there is surprisingly little structural information
depicting holoRNRs (containing both subunits) with or without these anti-cancer
drugs. Here we present two crystal structures of inhibited forms of holoRNR from E.
coli: the first structure of a gemcitabine-diphosphate (F2CDP) inactivated
holocomplex to 4.45 A resolution and the highest resolution structure of a dATP-
inhibited RNR, improving the resolution from 5.65 A(10) to 3.95 A.
Gemcitabine-diphosphate (F2CDP) is a mechanism-based inhibitor of both E. coli
and human RNR that binds and reacts at the catalytic site and irreversibly inhibits
a2 using only one equivalent of F2CDP per dimer. After reaction with the inhibitor,
one a per a2 dimer becomes covalently modified by the sugar of F2CDP (11, 12). Size
exclusion experiments indicated that reaction with the drug results in a stabilized
complex of the two subunits not seen in the presence of other substrates or effectors
(12), motivating our use of this inhibitor in crystallization experiments. In contrast
to the chemotherapeutic agent F2CDP, dATP is a physiological and reversible
inhibitor of RNR, responsible for down-regulating activity in the presence of excess
deoxynucleotides (13-15). dATP exerts its effect by binding to the activity site on a2
and shifting the conformational equilibrium away from an active a2P2 state toward
an inactive a4P4 state (10, 16) (Fig. III.1). Accompanying this oligomeric state
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change is a dramatic movement of the P2 subunit which swings from a position
docked with a2 to a position almost 40 A away, forming connections with another a2
subunit and leading to formation of a ring-like a4P4 structure (Fig. III.1). In the
resulting a4P4 structure, the radical transfer pathway is completely abrogated (Fig.
111.1) (10).
Amazingly, we find that for both the F2CDP and dATP inhibited RNR structures,
two a4P4 rings interlock to form concatenated (a4p4)2 rings. The observation of
concatenated rings was completely unexpected - the structure is literally tied in
knots. Although concatenated enzyme structures have been reported in the
literature (17, 18), previously it was not clear if these structures were more than
crystallographic space group artifacts. To address this question, we compare RNR
X-ray structures solved in different space groups, and use small angle X-ray
scattering (SAXS) to explore whether concatenated rings can form in solution. We
also examine what role, if any, F2CDP plays in the formation of RNR interlocked
rings. Finally, using electron microscopy (EM), we obtain snapshots of partially
formed RNR rings, providing a glimpse into the ring assembly process. With so little
known about the structures of holoRNRs and about enzyme concatenation, these
data are of broad interest.
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III.D. Results
III.D.1. F2CDP-inhibited and dATP-inhibited Structures of E. coli Class Ia RNR
Crystallization using F2CDP treated a2 and P2 subunits in the presence of ATP, has
yielded a 4.45 A resolution structure of this complex with Rwork/Rfree values of
23.3/26.7 (Table III.1). In this C222 1 crystal form, the asymmetric unit contains two
a2 dimers and four p monomers (Fig. III.2A). Applying crystallographic symmetry
operations generates four physiological p2 dimers and results in a (a 4 p 4) 2 complex
comprising two asymmetric units (Fig. III.2C). The a2 dimers are packed near one
another, burying a total surface area of 1200 A2 between the two dimers (Fig.
III.2E). Each a monomer also makes contacts to two distinct p2 molecules, one from
its own ring, burying -1500 A2 total, and one from the interlocked ring, burying an
additional 160 A2 (Fig. 111.3).
The concatenation of two a4p4 rings to make an (a 4 p4 )2 complex is also seen in the
3.95 A resolution structure of dATP-inhibited E. coli class Ia RNR (Rwork/Rfree of
25.9/28.4). In this C2 crystal form (Table 111.1), one a4P4 complex is present in the
asymmetric unit (Fig. III.2B), however, if two asymmetric units are shown, a second
ring is found to be interlocked with the first (Fig. III.2C). Both the F2CDP/ATP
structures and dATP-inhibited structures show two concatenated a4p4 rings, but the
relative orientation of the rings with respect to each other is different (Fig. III.2C,
D). As a consequence, the packing of the two a2 subunits is not as close in the dATP-
inhibited structure with only 230 A2 of total buried surface area between the two a2
dimers (Fig. III.2F compared to 2E), and each ring is slightly more asymmetric (Fig.
111.3).
Again, each a monomer makes contacts to two distinct P2 molecules, one from its
own ring (Fig. III.4), burying ~1500 A2 total, and one from an interlocked ring,
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burying an additional 400 A 2 . Overall, the (a4p4)2 structures are strikingly similar
given the different space groups and inhibitor/effector combinations used, indicating
that these concatenated rings are formed reproducibly under a variety of conditions.
To test the necessity of a small molecule inhibitor such as F2CDP or dATP on the
formation of the interlocked ring structure, crystallization was attempted under the
same conditions as the F 2CDP/ATP-RNR structure, but with CDP in place of F2CDP
and with an inactive form of P2 (met-P2). When nucleated with F2CDP/ATP-RNR
microcrystals, these crystallization conditions yield the same C2221 crystal form,
suggesting that small molecule inhibitors are not essential for this arrangement of
molecules in the crystal lattice (data not shown).
III.D.2. Solution Studies of Concatenated Ring Formation (Small-angle X-ray
scattering experiments, data processing and analysis were performed by Dr. Nozomi
Ando)
Previously, we showed that dATP drives the formation of an a 4@4 ring that is stable
over a wide range of protein concentrations (2 - 30 [M) in solution (10). Here, we
used SAXS to investigate the effect of F2CDP on the solution conformation of E. coli
RNR. Scattering profiles were obtained from RNR in the presence of 4 molar
equivalents of F2CDP per a2 and are shown in Kratky representation (Iq2 vs. q) in
Fig. III.5A. At 10 tM a2 and P2, the Kratky plot is multimodal with a significant
peak observed at q-0.06 A-1 (Fig. III.5A, red), a signature feature of the non-
globular a 4@4 ring (10). Decreasing the protein concentration to 3 [M a2 and P2 leads
to a monomodal Kratky plot, indicative of a globular shape (Fig. III.5A, dark grey).
A 270 kDa molecular weight estimation obtained by a Porod invariant method (19),
suggests that this 3 [M sample can be described as a globular a 202 consistent with
the model in Fig. III.1, a species previously observed by SAXS in the absence of
dATP (10). Linear combinations of theoretical profiles calculated from the a2@2 and
a4P4 models shown in Fig. III.1 yield good fits to the experimental profiles (Fig.
III.5A, black curves). Consistent with our previous observations (10), these data
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indicate that an increase in protein concentration favors a shift in equilibrium from
predominantly a2P2 to predominantly a4p4.
In a second SAXS experiment, the crystallization precipitant for the F 2CDP/ATP
RNR structure (25% PEG 3350, 100 mM HEPES pH 7.5, 200 mM NH 4 (CH 3 COO),
5% glycerol) was titrated into 10 jxM F2CDP-treated RNR. Upon addition of
precipitant, the shape of the Kratky plot alters dramatically (Fig. III.5B). The
signature peak of the a4p4 ring at q-0.06 A:' decreases relative to the first peak at
lower q, indicative of increasing globularity with increasing precipitant. This
change in shape is concomitant with an increase in overall radius of gyration from
69 to 77 A, exceeding the previously determined value for the a4p4 ring (71.1 A) (10).
Unsurprisingly, two-component linear combinations of a 2p2 and a4p4 species
described above were insufficient to describe the data. Good fits were obtained by
the inclusion of an (a4p4)2 species in the linear combinations (Fig. III.5B, black
curves) yielding the fractions of each species (Fig. II.5C). Here, the relative
orientations of the rings seen in the dATP-inhibited structure provide a better fit to
the solution data than those observed in the F2CDP/ATP structure.
Because experimental scattering profiles are obtained at finite protein
concentrations and therefore are not devoid of excluded volume effects, molar
fractions extracted from fitting theoretical profiles are not precise quantities. Thus,
the observation of a trend across the titration series is essential. The trends
observed in Fig. III.5C provide strong support that the a4p4 species are used to form
the (a4p4)2 species. Together, these data are consistent with the addition of
crystallization precipitant facilitating the conversion of non-globular ring species to
interlocked rings that are larger in size and more globular.
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III.D.3. EM Analysis Shows Population of Partial Ring Intermediates (Electron
microscopy experiments, data collection and analysis were performed by Dr.
Edward Brignole)
The formation of (a4p4)2 species from a4p4 rings, suggests that these RNR rings must
be flexible or come apart. To explore this issue, we analyzed electron microscopy
images of a2 and p2(150 nM) in the presence of inhibitor dATP (50 mM). At these
low protein concentrations, no (a4p4)2 species are expected and we find that the
complexes are a mixture of completely closed a4p4 rings and partially formed
species. Previously, we focused our analysis of these EM images on investigating
the structure of the dominant species, the fully assembled dATP-inhibited a4P4 RNR
ring (10), whereas here we were interested in extending the analysis to include the
partially assembled rings. EM images of RNR oligomers were aligned and clustered
by similarity, resulting in 33 classes of RNR complexes with different composition
and structure. Approximately 56% of particles (in 14 of 33 classes) form completely
closed a4p4 rings in the presence of 50 mM dATP whereas other class averages
reveal broken rings in which one connection between adjacent a2 and P2 dimers has
been severed (19% of particles) and partial rings with a missing P2 subunit (19% of
particles) (Fig. 111.6 and Fig. 111.7). The open and partial rings may represent
assembly or disassembly intermediates and, together with the asymmetry observed
in many of the closed rings, suggest that the connections between a2 and P2 can be
readily formed and broken.
Comparison between the class averages suggests a hinge motion in the a-p
interaction. By overlaying the class variance images and the class averages,
additional heterogeneity is apparent within each class, particularly those classes
with severed a-P connections (Fig. 111.7). Thus the conformations captured by EM
class averages appear to represent samples along a continuum of motion in the a-P
interface. To assess the degree of flexibility in the a-P interaction, atomic models of
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a2 and p2 were fitted into 3D maps of the structures represented by the severed-ring
EM classes. Each interacting a-p pair from both the EM reconstructions (Fig.
III.6B) and from the two crystal structures (Fig. 111.2) was aligned and compared.
This analysis reveals that the a-p orientation within the closed a4p4 rings varies by
up to 70, and that a-p interfaces in the less constrained open conformations can
readily accommodate motions of 10-25* (Fig. III.6D-E). Such elasticity of the a4p4
ring would seem to be required both for conversion of an a4p4 inactive state into an
active a2p2 species of RNR as well as for the formation of the (a4p4)2 interlocked
rings.
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III.E. Discussion
Despite the significant interest in RNRs due to their sophisticated allosteric
regulation and success as drug targets, the interactions between the a2 and 12
subunits of the class Ia enzymes have been challenging to visualize. Here we
present two X-ray structures of the prototypic E. coli RNR enzyme that display
interactions between both subunits. These structures represent inhibited forms of
RNR, one inhibited with chemotherapeutic agent gemcitabine-diphosphate (F2CDP)
and the other bound with the negative allosteric regulator dATP. Unexpectedly,
structure data show that the subunits are arranged into two interlocked a4p4 rings.
Although rare, two concatenated protein structures have been previously described
(17, 18). In particular, RecR, an enzyme involved in homologous recombinational
DNA repair, forms interlocked tetrameric-ring structures in its crystal lattice (Fig.
111.8). Because DNA is proposed to bind in the center of one RecR tetrameric ring,
the presence of the second interlocked ring is not thought to be physiologically
relevant (17). However, the ability of RecR tetramers to interlock may indicate a
propensity of these rings to open and close, an important aspect of its DNA binding
function. Thus two of the three concatenated protein structures involve tetrameric
ring structures that are either known or proposed to open and close as part of their
cellular activities.
The other example of interlocked protein rings is found with bovine mitochondrial
peroxiredoxin III, which forms magnificent concatenated dodecameric structures
(18) (Fig. 111.8). Here it is not known which state of the enzyme is active or why
such a multimeric complex might form. For both RecR and peroxiredoxin III, data
are not available to firmly establish if these interlocked structures form in solution,
although the authors of the peroxiredoxin studies (18) mention preliminary
analytical ultracentrifugation data that suggest some formation of concatenated
rings in solution. Also, although mechanisms of protein ring concatenation have
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been considered for both RecR and peroxiredoxin III, experimental support is
unavailable (17, 18).
To address the conditions under which interlocked protein rings can form in a
crystal lattice, we investigated whether F2CDP was required in the E. coli RNR
crystallization solution for the formation of the C2221 crystal arrangement of
concatenated rings. We find that it is not required, consistent with the mode of
F2CDP inhibition necessitating active enzyme (the a2p2 state). Instead, the requisite
high protein concentrations for crystallization can explain the formation of a4p4
rings in the C222 1 cell. Structural data also show that the (a4p4)2 state can form in a
C2 crystal form in the presence of inhibitor dATP, known to form the a4p4 ring.
Thus despite the different crystallization conditions and inhibitors used, E. coli
RNR preferentially forms interlocked rings in the crystalline state.
The solution-based technique, SAXS, was employed to examine whether interlocked
rings form in solution. Consistent with the above observations from crystallography,
the presence of F2CDP is not the determinant for concatenation of E. coli RNR
rings. Instead, the primary determinant is the presence of ingredients from the
crystallization precipitant (25% PEG 3350, 100 mM HEPES pH 7.5, 200 mM
NH 4(CH 3COO), 5% glycerol). Interestingly, one ingredient, PEG, is a well-known
molecular crowding agent (20-22) that often favors high order oligomerization (23).
A dramatic shift from a4P4 to (a4p4)2 is observed upon addition of precipitant (Fig.
III.5B), providing the first unambiguous experimental support that concatenated
rings can form in solution.
It is intriguing that the subunits of the a4p4 ring do not rearrange into compact
assemblies in the presence of a crowding agent such as PEG, but rather the ring
retains its hole (with a diameter of -80 A) and that hole is filled with a second
doughnut-like ring. The preference to respond to 'crowding' with concatenation of
individual a4p4 rings rather than by subunit rearrangement is surprising in that
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RNRs from other species, such as yeast, will form larger complexes (a 6p2) (24).
Despite the similarity in the structure of the yeast and E. col a2 subunits (1, 25),
the E. coli enzyme does not form a-hexamers. The only complexes larger than the
active a2p2 state that E. coli RNR appears to form are a4p4 or when 'crowded' (a4p4)2.
A significant remaining question is how concatenated rings form. Three
mechanisms can be considered (17, 18). In the first, one ring is formed and the
second ring is assembled around the first ring. In the second mechanism, two rings
simultaneously become interlocked due to association of monomers from distinct
rings before the assembly process is complete. In the third, a ring would open,
embrace a second ring, and reclose. Our SAXS data favors the third mechanism. In
particular, the SAXS data show that in the presence of precipitant, the fraction of
a2p2 remains fairly constant but the fraction of a4p4 decreases significantly as the
(a4p4)2 species develops (Fig. III.5C). This observation indicates that interlocked
rings form from a2 and p2 subunits that were previously part of single rings. Rings
could come apart completely, with subunits reassembling around an intact ring or
assembling simultaneously to form interlocked rings, however, it is hard to explain
why the amount of a2p2 species would not be more dramatically affected in such a
case. Thus, this SAXS result is more consistent with mechanism three in which
rings open and reclose. In addition, EM images of E. coli RNR with inhibitor dATP
show that -19% of the particles are a4p4 rings that have opened to varying degrees
(Fig. III.6), depicting the flexibility necessary for this mechanism of concatenation.
The production of deoxynucleotides by RNR is essential for DNA biosynthesis and
repair, but overproduction can be detrimental (26), requiring all organisms,
including E. coli, to adopt cellular processes to both up and down regulate RNR
activity (27). The modulation of E. coli RNR activity by ATP and dATP levels, which
involves the binding of ATP/dATP to the activity sites on a2 and the subsequent
equilibrium shift between active a2p2 and inactive a4p4 states, provides a sensitive
and efficient method for both up and down regulation of RNR function (10, 15, 16).
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The higher resolution structure of dATP-inhibited RNR presented here allows us to
identify residues at this key a-P interface near the activity site within the a4p4
complex (Fig. III.4). Although polar residues such as Trp, Ser, Glu and His line
these surfaces, providing some potential for hydrogen bonding interactions, the
overall contact area is small (Fig. III.4), consistent with the ability of E. coli RNR to
efficiently sever these interactions and convert to an active state in response to
ATP.
Finally, with a recent 6.6 A resolution X-ray data for yeast RNR revealing
hexameric a-subunit ring-like structures in the presence of dATP (24), it is
apparent that attention must be paid to the propensity of multiple RNRs to form
rings. Although the contributions of particular residues to the stability of the
protein-protein interfaces within these rings remains to be determined, it is
interesting to note that the residues on the E. coli a nearest the a-P interface (Fig.
III.4) are not conserved, even within bacterial species. Exploiting differences in ring
structures may offer new strategies to inhibit RNRs in a species-specific manner.
Clearly the ability of RNR subunits to form and break interactions at interfaces is
key to allosteric regulation of activity, and we now find that this subunit flexibility
can even lead to the formation of interlocked rings. In particular, the work
presented here demonstrates that the a4p4 rings formed by the E. coli enzyme have
the proclivity to concatenate in the presence of crowding agents. With conclusive
evidence for formation of these interlocked rings in solution, our SAXS and EM data
also provide some of the first experimental data to address the mechanism of
protein ring concatenation. While beautiful to observe, these concatenated rings
appear to be more than a crystallization magic trick. We now understand the
relationship between the previously determined a4p4 dATP-inhibited state of E. coli
RNR and this interlocked ring system, with information about when and how these
concatenated rings can form.
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III.F. Materials and Methods
III.F.1. Reagent preparation
Cytidine 5'-diphosphate was purchased from Sigma-Aldrich and dissolved into
assay buffer (50 mM HEPES, pH 7.6, 15 mM MgCl2, 1 mM EDTA). The pH was
slowly adjusted to 7-8 with NaOH and the concentration was determined
spectroscopically using C2 7 1 of 9.1 mM-1 cm1. High purity solutions of ATP, and
dATP were purchased from USB Corporation. F 2 C was a gift to the group of J.S.
from Eli Lilly. F2CDP was prepared as described (28).
III.F.2. Protein Preparation
The a2 and P2 proteins were prepared as described (29, 30). The concentrations of a2
and p2 were determined using C280 of 189 and 131 mM-1cm-1, respectively; all molar
concentrations are dimer concentrations (i.e., a2 or P2).
III.F.3. Crystallization of F2CDP-inactivated RNR
The F2CDP-inactivation reaction was carried out immediately before crystallization
by supplementing a protein mixture (31 [LM a2 and 62 [tM P2 in 50 mM HEPES, 15
mM MgCl21 mM EDTA, pH 7.6) with 3 mM ATP, 5 mM DTT and 120 [tM F2CDP,
and incubating in a 25*C water bath for ten minutes prior to crystallization. The
F2CDP inactivated complex was crystallized by adding 2 [tL of the protein mixture
to 4 [tL of precipitant solution (25% PEG 3350, 100 mM HEPES pH 7.5, 200 mM
NH4(CH 3COO), 5% glycerol) and equilibrating over a 500 [tL reservoir of precipitant
solution at room temperature. To grow crystals large enough for data collection,
drops were streak seeded from crushed crystals grown in similar conditions.
Crystals appeared after one week and continued to grow for several weeks. Crystals
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were cryo-cooled by adding 5 [tL of solution containing 25% PEG 3350, 100 mM
HEPES pH 7.5, 200 mM NH 4(CH 3COO), and 20% glycerol to the drop containing
crystals then looping out of this drop after 1-3 minutes and plunging directly in
liquid N 2. Diffraction data were collected at the Cornell High Energy Synchrotron
Source (CHESS) beamline Al at 100 K and processed using HKL2000 (31) (Table
III.1).
III.F.4. Crystallization of dATP-inactivated RNR
For the dATP structure, hydroxyurea-inactivated P2(met-32) was used in place of
active P2. Met-p2 was prepared from purified active P2 as described (10). Crystals
were grown by adding 1 [tL of protein (25 [LM a2 and 50 [tM met-P2 in 50 mM
HEPES, 15 mM MgCl21 mM EDTA pH 7.6 supplemented with 10 mM dATP and 5
mM DTT) to 1 ptL of precipitant solution (10% PEG 3350, 100 mM MOPS pH 7.5,
200 mM Mg(CH 3COO)2, 25 mM MgCl2, 6 mM n-Nonyl-p-D-maltopyranoside
(Hampton Research) and 5% glycerol) and equilibrating over a 500 [tL reservoir of
precipitant without n-Nonyl-p-D-maltopyranoside at room temperature. Crystals
were cryo-cooled after one week by looping thorough solutions of 13% PEG 3350,
100 mM MOPS pH 7.5, 200 mM Mg(CH 3COO) 2, 40 mM MgCl2, 5 mM DTT, 10 mM
dATP and successive concentrations of 10, 15, and 20% glycerol and plunged
directly in liquid N 2. Diffraction data were collected at the Advanced Photon Source
at Argonne National Labs on beamline 241D-C at 100 K and processed using
HKL2000 (31) (Table 111.1).
III.F.5. Structure Solution and Refinement
The initial F 2CDP-RNR structure was solved with a lower resolution data set by
molecular replacement in the program PHASER (32) using previously solved
structures of a and P monomers with no ligands included as search models (PDB ID
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1RLR (1) and 1PFR (33) respectively). After higher resolution data was obtained,
initial refinement of the F2CDP structure was done using Fourier synthesis
methods. The dATP-RNR structure was solved using Fourier synthesis methods
from the previously published 5.65 A structure (10). For both structures, iterative
rounds of data refinement and model building were performed in CNS 1.3 (34) and
COOT (35) respectively. Refinement consisted of rigid body, low temperature (300
K) simulated annealing using deformable elastic network restraints (36) and group
B-factor refinement with two B-factors per residue, one for main-chain atoms and
one for sidechain atoms. During all rounds of refinement, loose non-crystallographic
symmetry (NCS) restraints were used.
III.F.6. Final Model of F 2CDP/ATP-RNR
At 4.45 A resolution, secondary structure can be unambiguously assigned whereas
side chain positions are not well defined. Side chains are included in the model
based on their positions in previously solved high resolution structures however
their high B-factors (average of 147.8 A2) indicate the positions are not precisely
determined. In the F 2CDP-RNR structure, there is some positive density in all four
catalytic sites where the inhibitor would be expected to bind and react (Fig. 111.9).
Because we do not know the identity of the reaction product and the resolution of
the data is too poor to distinguish possible products, nothing has been modeled in
these sites. The catalytic site of the a subunit contains two redox active cysteine
residues that are oxidized to a disulfide during the reaction (1, 37). All four catalytic
site disulfide pairs appear to be reduced. All residues present in the model are listed
in Table 111.2 with refinement statistics in Table III.1. In addition the model
contains ATP at all four activity sites as well as two Fe3+ atoms with a bridging
oxygen and two Fe ligated H20s in each P chain. Positive difference density at the
di-iron center could be accounted for by modeling the bridging oxygen and iron
ligated water molecules based on their location in previously solved high resolution
structures of the P subunit. After including them in the model all difference density
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was accounted for showing that even at this relatively low resolution we can detect
water bound at the di-iron center. In the Ramachandran plot, 90.3%, 9.6%, 0.1%
and 0.0% of residues are in favored, allowed, generously allowed, and disallowed
regions respectively.
III.F.7. Final Model of dATP-RNR
All residues present in the 3.95 A resolution dATP model are listed in Table 111.2
with refinement statistics in Table 1II.1. The model contains dATP at all four
specificity sites and all four activity sites (Fig. 111.9). In addition, density was seen
in all four catalytic sites. Only diphosphates bind at the catalytic site but no
diphosphates were added to the crystallization so dADP, a likely contaminant of
dATP and product of RNR, was modeled in this site (Fig. 111.9). In addition 2 Fe3 +
atoms with a bridging oxygen and 2 Fe ligated H20s are present in each P chain,
modeled as described for the F 2CDP-RNR structure. In the Ramachandran plot,
90.2%, 9.8%, 0.0% and 0.0% of residues are in favored, allowed, generously allowed,
and disallowed regions respectively.
III.F.8. Small-angle X-ray Scattering of F2CDP-inactivated RNR (methods were
performed by Dr. Nozomi Ando)
The F2CDP-inactivation reaction was carried out immediately prior to SAXS data
collection. A protein mixture (30 [LM a2 and 30 [LM P2 in assay buffer (50 mM
HEPES, 15 mM MgCl21 mM EDTA pH 7.6)) was supplemented with 3 mM ATP, 5
mM DTT, 120 sLM F2CDP (final concentrations), and incubated in a 25*C water bath
for ten minutes. In the precipitant titration experiment, in order to mimic
crystallization conditions, the 30 [tM inactivated mixture was diluted 3-fold with
precipitant mixtures (25% PEG 3350, 100 mM HEPES pH 7.5, 200 mM
NH 4(CH 3COO), 5% glycerol) that were diluted with water to give the total v/v
precipitant concentration indicated. To obtain data at 3 mM RNR, the 30 mM stock
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solution was diluted 10-fold with assay buffer containing 3 mM ATP and 5 mM
DTT.
SAXS was performed at the Cornell High Energy Synchrotron Source (CHESS) G1
station using a 9.5 keV 250 mm square X-ray beam with a flux of several 1012
photons/s/mm 2 . Data were collected on a custom 1024x1024 pixel CCD detector (38)
with a sample-to-detector distance of -2 m. The transmitted intensity was
measured on a PIN diode beamstop (39). Protein solutions and reference solutions
were prepared such that the buffer contents matched.
Samples were contained in 2 mm path length acrylic cells (ALine Inc.) (39) with 7.5
[tm kapton windows (Chemplex). The same cell was used for acquisition of protein
solution and background scattering pairs. Several 1 and 2 s exposures were taken
per sample separated by 10 s pauses. The scattering images were corrected and
integrated about the beam center following previously described image correction
procedures (39). Exposures that did not display apparent radiation-induced changes
were averaged and normalized by the transmitted intensities. Background
scattering was subtracted from the protein solution scattering to produce the one-
dimensional protein scattering profile, 1(q), as a function of q, where q = 4r/A sin 6;
26 is the scattering angle, and A is the X-ray wavelength.
Theoretical scattering curves were calculated from atomic coordinates using
CRYSOL (40). Here, the resulting forward scattering intensities (1(q) at q=0) are
proportional to the square of the molecular weights. Linear combinations of
theoretical scattering curves, Ifit(q), were fitted to SAXS data using least-squares
fitting in MATLAB:
N
Ifi,(q) =c fI,(q)
where I(q) and 1£ are the scattering curve and molar fraction for the i-th species, N
is the number of species, and c is a constant scaling factor.
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The average globularity of the species in solution was investigated by Kratky
analysis (41). Here, the scattering profile is plotted as Iq 2 vs. q to emphasize the
power-law dependence in the mid-q range. I(q) of globular, folded species display a
q 4 dependence in this range, giving rise to a single prominent peak in the Kratky
plot. Multiple distinct peaks in a Kratky plot are observed in the case of proteins
with multiple domains in a non-globular arrangement (42) as in the inhibited a4p4
RNR structure (10).
III.F.9. Electron Microscopy (EM) of dATP-inhibited RNR (methods were performed
by Dr. Edward Brignole)
For EM studies, met-p2 was used in place of active P2. 150 nM a2 and met-@2 were
combined with 1 mM CDP and 50 pM dATP in assay buffer. 5 pl of the mixture was
applied to a carbon coated EM grid that had been glow discharged immediately
before use. The grid was washed 3 times with a stain solution containing 2% uranyl
acetate (Ted Pella) and 0.2% trehalose and then a second carbon layer was applied
(43). Eighty-nine pairs of CCD images were collected of the -55* tilted and untilted
specimen at 50,000x magnification and 120 kV on a Tecnai F20 microscope (FEI)
operated manually using Leginon (44) to store the images. CCD frames have a pixel
size of 2.18 A at the specimen level.
Ring and C-shaped particles were selected from the untilted images using EMAN2's
e2boxer.py (45) and TiltPicker (46) was modified to import and transform the
coordinates onto the tilted images. 14,055 pairs of particles were windowed and 160
particles were removed from the dataset after an initial reference-free alignment
and classification as members of 4 poor quality classes. An iterative alignment and
supervised classification routine was then repeated on the remaining 13,895
particles using SPIDER as described previously (47) resulting in 33 classes. 3D
density maps were reconstructed for each class using CTF-corrected tilted particles
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(48, 49) supplemented with a random selection of 10% of the untilted particles (24).
Each reconstruction was low-pass filtered at its resolution as determined by the
Fourier shell correlation at 0.5.
The reconstructions were interpreted by iterative rigid fitting crystal structures of
a2 (4R1R) (50) and p2 (iRIB) (51) using UCSF Chimera's "fitmap" command (52).
When compared with the fit structures and our a4p4 crystal structures, the EM
density maps appeared compressed in the dimension perpendicular to the carbon
support film by a factor of -1/3, a well-documented artifact of specimen preservation
in negative stain (53, 54). Despite the flattening, contours of the crystal structures
could be clearly recognized on the upper and lower surfaces of the EM
reconstructions, indicating that the features had been merely compressed in the z-
dimension. To compensate for the compression artifact, density maps were
stretched to voxel dimensions of 4.36 x 4.36 x 6.54 A and the fitting of individual
subunits was refined. Interacting a-p pairs were extracted from the fitted models
and from the a4P4 crystal structures and then the a-subunits of each pair were
superimposed in Chimera. Relative motions of the P subunits were calculated with
Chimera's "measure rotation" command (52). Chain E of the dATP crystal structure
was chosen as the frame of reference because this chain has an intermediate
conformation among the P subunits extracted from the a4p4 crystal structures.
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III.H. Figures and Tables
Catalytic site Activity site
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T a - C439
a - C439
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Figure 111.1. Structures of E. coli class Ia RNR. Left, a pseudo atomic model of the
active a2P2 state of E. coli RNR based on SAXS (10). Right, crystal structure of the
dATP-inactivated a4P4 form of RNR (10). a2 subunits are in cyan/blue with N-
terminal domain in green and P2 in red/orange. Residues along the proposed radical
path between the di-iron center (green spheres) and Y122 in P and C439 in a are
shown as black spheres, and highlight how the proposed radical transfer pathway in
the active enzyme is disrupted in the a4p4 ring. Also labeled are the two types of
allosteric effector binding sites: a specificity site and an activity site. The specificity
site, found at the a dimer interface, responds to intracellular levels of
deoxyribonucleoside 5'-triphosphates (dATP, TTP, dGTP) and ATP such that
balanced pools of deoxyribonucleotides are maintained (15). The activity site, found
at the N-terminal domain controls the overall enzymatic rate, binding ATP to
activate the enzyme or dATP to turn it off (13-15).
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F2CDP/ATP complex (C222,) dATP complex (C2)
Figure 111.2. Multiple crystal forms display interlocked a4p4 rings for E. coli RNR.
Each a4p4 ring is colored separately with F2CDP/ATP-RNR complex in blue/yellow
and dATP-RNR complex in green/purple. A,B) One asymmetric unit for each
complex is shown as ribbons with transparent surface and with full surface, for
F2CDP/ATP- and dATP-RNR complexes, respectively. C,D) The full (a4p4)2 RNR
complex is shown from front and side orientations for each complex. E,F) A top
down view of each RNR complex shows the packing of two a2-dimers (left) and close-
up of interactions of just the a2 dimers in an identical orientation (right). Other
known structures with interlocked rings are shown in Fig. 111.8.
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BdATP complex (C2) one ring per ASU
C
F2CDP/ATP complex (C222,) two half rings per ASU
Figure 111.3. Close-up views and distances describing interactions of a2 and P2
within interlocked rings. A) A full ring (a2 in blue/cyan, P2 in red/orange, and N-
terminal domain of a in green) with the interacting P2 from a second ring
(tan/purple). B) Close-up of interaction between a2 of one ring and p2 from second
ring. The buried surface area of this interaction is minimal (160 A2 in F 2CDP-RNR
complex or 400 A2 in dATP-RNR complex). C) Close-up of interaction between the a2
of one ring (blue/cyan) and its activity site in the N-terminal domain (green) with p
of the same ring (orange). This interaction buries 700 A 2 . The C-terminus of this p
(orange) is also bound to the peptide-binding site of a (cyan), burying an additional
800 A2 . D) Asymmetry in the a4p4 ring is seen in the dATP complex. The as dimers
are shown in blue/cyan with N-terminal domains in green and the p2 dimers are
shown in red/orange. Distances reported are measured in A from the C. of C439 in a
to the C. of Y122 in P for each pair. The structure appears to be rectangle like (two
sides measure -66 A and the opposing two measure -68 A). The F2CDP complex
however is more square-like in structure. The space group symmetry of this crystal
form restrains the opposing sides to be of the same length (- 65 A). The less
symmetrical model (dATP complex) fits better to the previously reported EM
structure of the dATP complex (10). These differences also highlight a flexibility
that is available within the ring structure.
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ly2 Ser295
Figure 111.4. Detailed view of the a-P interface within an a4p4 ring. Protein is
shown in ribbons with residues found near the interface shown in sticks. Residue
names and numbers are labeled. a is colored in green and P in orange (carbons same
color as ribbon, oxygen in red, nitrogen in blue) with dATP bound at the activity site
in sticks (carbon in yellow, oxygen in red, nitrogen in blue, phosphorus in orange).
Additional close-up views of interfaces and distances between a2 and P2 subunits are
shown in Fig. 111.3.
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Figure 111.5. SAXS studies on F2CDP-treated E. coli RNR reveal conditions
important for oligomeric state changes. A) The Kratky plots of 3 [tM (dark grey) and
10 [tM (red) F2CDP-treated E. coli RNR. The presence of one large peak at 3 JIM
RNR indicates a globular species, such as a2p2, whereas the presence of two peaks
at 10 tM RNR indicates a non-globular species, such as the a4p4-ring. A two-
component fit to the data (black line) indicates that the solution at 3 [tM RNR is
94% a2@2 and 6% a4p4, while the solution at 10 tM RNR is 43% a2p2 and 57% a4p4.
B) The Kratky representation of 10 mM F2CDP-treated RNR over the course of a
titration with 0-50% v/v crystallization precipitant indicates a shift from a less
globular species, such as a a4I4 ring, to a more globular species, such as (a4p4)2. The
movement of the first peak from the dotted line to lower q is consistent with an
increase in overall radius of gyration. A three-component fit to the data (black
curves) yields C) the fractions of a262, a4p4, and (a4p4)2 species present at the
indicated percentages of precipitant. Data suggest that precipitant favors the
formation of (a4p4)2 from a4p4.
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Figure 111.6. Electron microscopy analysis of dATP-inhibited RNR reveals
flexibility in the a4p4 ring. A) Class averages of a closed a4p4 ring (right) and a4p4 in
opened-ring conformations with severed interaction between the a2 and p2 subunits.
B) 3D reconstructions for each class with fit atomic structures (PDB ID 4R1R and
IRIB) illustrate the flexibility in the a2-p2 interface. C) The conformational
distribution of particles based on the entire set of 33 class averages (Fig. 111.7). D)
Interacting a-p pairs from the fitted models in B) and from dATP and F2CDP crystal
structures, aligned using the a subunits (blue with N-terminal domain in green).
Rotations of the P subunits from the crystal structures (red) or from the EM
structures (orange) were measured relative to chain E from the dATP crystal
structure (arrows). E) Red lines indicate the rotation measured for each a-p pair
from the crystal structures. The histogram (orange bars) presents the angular
distribution of a-p interactions observed in the EM reconstructions.
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Figure 111.7. EM class averages and variances reveal malleability of the a-p
interaction. Classes are grouped according to subunit stoichiometry and
organization into categories of A) closed a4p4 rings, B) opened a 4p4, C) a4p2, and D)
a2p4 & others. Boxes around the categories of class averages are colored according to
the pie chart in Figure III.6C. Class averages (cyan density) were overlaid with the
class variances (red density) indicating the presence of additional conformational
variation within each class. The number of particles in each class is indicated.
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Figure 111.8. Known structures of concatenated proteins. The crystal structures
of A) bovine mitrochondiral peroxiredoxin III (PDB ID 1ZYE) (18) and D) the DNA
repair protein RecR from Deinococcus radiodurans (PDB ID 1VDD) (17) contain one
ring in the asymmetric unit, shown in ribbons. B) The homododecamer of the
peroxiredoxin is shown in surface representation in red. E) The homotetramer or
RecR is shown in surface representation in orange. C,F) The ring of a second
asymmetric unit (shown in blue or teal) is found to be interlocked with the first in
both structures.
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A
dATP-RNR
complex
activity site
B
F2CDP/ATP-
RNR complex
activity site
dATP-RNR
complex
catalytic site
D
F2CDP/ATP- Chain A Chain 
D
RNR complex
catalytic site
Figure 111.9. Electron density at activity sites and catalytic sites. In all panels,
protein is modeled as ribbons with nucleotides in sticks, (carbon in cyan, yellow, or
magenta, oxygen in red, nitrogen in blue, phosphorus in orange). 2F-Fc electron
density contoured at 1.0 o is shown in blue mesh. F-Fc electron density contoured
at +3.0 (1 is shown in green mesh and contoured at -3.0 o is shown in red mesh. A)
Activity site from chain A of the dATP-RNR complex. 2F-F and F-F electron
density maps are made with dATP omitted from calculation (left) and included in
calculation (right). B) Activity site from chain A of the F2CDP/ATP-RNR complex
shown as in A) but with ATP modeled. C) Catalytic site from chain A of the dATP-
RNR complex with an F-Fc electron density difference map made without
including the dADP in calculation (left) and 2F-F electron density map with
modeled dADP (right). D) Catalytic site of the F2CDP/ATP-RNR complex shown for
two chains (chain A on left and chain D on right) with uninterpretable F-Fc
electron density. 2Fo-F electron density is not shown.
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Table 111.1. X-ray data collection and refinement statistics
Data collection
Space group
Cell dimensions
a, b, c (A)
a, P, y (0)
Wavelength (A)
Resolution (A) a
Rsym a
<I/cIl> a
Completeness (%)a
Redundancy a
Refinement
Resolution (A)
Number of reflections
Rwork/Rree (%)
Number of atoms
Proteinb
Nucleotides
Fe
Water
Average B-factors
(A2)
Protein
Nucleotidesc
Fe
Water
r.m.s deviations
Bond lengths (A)
Bond angles (0)
PDB ID
F 2CDP/ATP-RNR
C222 1
128.7, 398.9, 319.4
90.0, 90.0, 90.0
0.9769
50.0 - 4.45 (4.61-4.45)
11.5 (35.7)
8.5 (2.2)
91.1 (70.6)
3.8 (2.0)
49.0-4.45
41827
23.3/26.7
35053
124
8
8
147.8
171.4
121.6
109.3
0.008
1.01
4ERP
dATP-RNR
C2
280.5, 155.7, 166.9
90.0, 119.1, 90.0
0.9794
30.0 - 3.95 (4.09-3.95)
16.1 (45.7)
5.0 (2.3)
96.5 (96.5)
2.9 (2.9)
30.0 - 3.95
52934
25.9/28.4
34976
348
8
8
109.0
130.0
74.8
89.3
0.02
0.74
4ERM
aValues in parentheses are for the highest-resolution shell.
bA list of residues included in the models is given in Table 111.2.
cElectron density for modeled nucleotides is shown in Fig. 111.9.
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structures of the two RNR complexes.
Chain
Chain A (a)
Residues modeled
4-737 (of 761)
Chain B (c) 4-738
Chain C (c) 4-736
Chain D (a) 3-738
Chain E (p) 1-340, 362-375 (of 375)
Chain F (p) 1-345, 363-375
Chain G (p) 1-342, 361-375
E-
Chain A (a)
1-344, 363-375
4-736 (of 761)
Chain B (a) 4-737
Chain C (a) 7-737
Chain D (a) 5-737
Chain E (p) 1-339, 363-375 (of 375)
Chain F (p) 1-340, 360-375
Chain G (p) 1-340, 360-375
Chain H (P) 1-341, 360-375
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Chain H (P)
F-
Table III.2. Residues modeled in the
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Chapter IV
Revised rules for allosteric regulation of E. coli class Ia
ribonucleotide reductase by ATP and dATP
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IV.A. Summary
Ribonucleotide reductases (RNRs) are subject to allosteric regulation in order to
maintain dNTP levels for accurate DNA biosynthesis and repair. In E. coli, the
overall NTP to dNTP ratio is modulated through the binding of effectors (ATP or
dATP) to an activity site on the enzyme, which in turn up- and downregulates
catalytic activity, respectively. Likewise, the ratio of one dNTP to another is
modulated through the binding of effectors (ATP, dATP, dTTP, dGTP) to a
specificity site, which in turn adjusts the preference of RNR for its substrates CDP,
UDP, GDP, and ADP. To investigate the molecular basis for this allosteric
regulation by ATP and dATP in the prototypic class Ia RNR from E. coli, we have
determined structures of the a2 subunit co-crystallized with dATP or ATP. Two
molecules of ATP are observed at the activity site, whereas one dATP binds at this
site. Binding of ATP and dATP at the specificity sites is also observed.
Ultrafiltration techniques confirm that, as in the crystal, three ATPs bind per a
subunit in solution, and provide estimated Ks for ATP binding (120 [M for the two
ATPs at the activity site and >158 [tM for the one ATP at the specificity site). The
weak binding of ATP to the specificity site is consistent with the crystal structure,
and suggests that ATP is not a specificity effector for E. coli RNR in vivo because it
cannot outcompete dNTP binding at the same site in the cell. In terms of allosteric
regulation of activity, comparisons of these structures with the previously reported
structure of the inactive dATP-a4p4 complex reveal the juxtaposition of the second
ATP site to the a-p interface, illustrating how the binding of two ATP molecules
could shift the equilibrium between inactive and active states of RNR.
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IV.C. Introduction
Ribonucleotide reductase (RNR) is an essential enzyme in all organisms that
provides the cell with deoxyribonucleotides (dNTPs). Due to this key function, it is
highly regulated via allosteric mechanisms to maintain dNTP levels for accurate
DNA biosynthesis and repair. All RNRs are categorized into one of three classes
based on what cofactor they use to generate a protein radical required for catalysis.
The class Ia RNR from E. coli uses a di-iron cofactor for radical generation and has
served as the prototype for understanding RNR chemistry and regulation. When
allosteric regulation of RNR is disrupted in vivo, increased rates of mutagenesis are
observed (1, 2). In 1969 the "rules" for allosteric regulation of the E. coli class Ia
RNR were first described (3). ATP, dATP, dGTP, and TTP bind to the allosteric
specificity site on the catalytic subunit, a2, to influence the substrate specificity
(Fig. IV.1). The substrates for this enzyme are ribonucleoside diphosphates, and
ATP or dATP binding at the specificity site favors CDP or UDP reduction, TTP
binding favors GDP reduction, and dGTP binding favors ADP reduction (3). By the
use of specificity regulation, a single enzyme can provide all four dNTPs in the
proper ratios required for DNA replication fidelity. In addition, the a2 subunit has a
second allosteric site, termed the activity site, where ATP and dATP bind to
activate or inhibit the catalytic activity, respectively (3). As a result, the optimal
concentrations of dNTPs are maintained. In this chapter we investigate the
molecular mechanisms by which allosteric activity and specificity regulation are
achieved. Co-crystalllization of the E. coli a2 subunit with ATP or dATP, in newly
described conditions, has allowed for the determination of structures that reveal
molecular details of ATP and dATP binding to the allosteric activity and specificity
sites.
Prior to this work, a single crystallization condition for the E. col a2 had been
reported and nucleotide soaking experiments had been performed using this crystal
form to yield structures with either TTP at the allosteric specificity site and no
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nucleotides bound at the activity or active sites, TTP at the specificity site and GDP
at the active site (modeled at half occupancy), or AMP-PNP, a non-hydrolyzable
analog of ATP, at the allosteric activity site (4). These structures helped to identify
the allosteric activity site that is located in the N-terminal region of the protein
(colored yellow in Fig. IV.1) in a four-helix bundle that is covered on one end by a
three-stranded 0-cap (4). The activity site is separated by -40 A from the active site
which is housed in a ten-stranded p/a barrel. The allosteric specificity site is located
at the a2 dimer interface on either end of a four-helix bundle. It consists of residues
from both chains and is proximal to the active site (Fig. IV.1). Although these
structures highlighted the locations of the active site and allosteric sites, in all cases
the nucleotides were not well ordered as indicated by low occupancy and low
correlation with electron density (4). In addition, AMP-PNP does not have the same
allosteric effects as ATP in activity assays leaving the interpretation of the AMP-
PNP-bound structure unclear (5). Additional structures of substrates and effectors
bound to E. coli RNR are needed to explain the mechanisms that control the
complex allostery used by this enzyme.
The active site and allosteric effector binding sites are located in the as subunit, but
formation of a complex between a2 and the radical generating subunit, P2, is
required for catalytic activity (6). A radical, required to initiate the reduction
reaction, must be transferred from P2, into a2, traversing a distance of -35 A to
reach the active site (7). After turnover, the radical is delivered back to 12 before the
complex dissociates and another round of catalysis can occur (8). Formation of an
active a2P2 complex is facilitated when substrate and the correct allosteric
specificity effector and ATP are bound to a2 (9). Low-resolution structural
techniques (10, 11) have supported a compact model for the a2@2 that was first
proposed based on the structures of the individual subunits (Fig. IV.1) (12). The
molecular landscape of the a-p interface and the mechanism by which substrate and
effector binding play a role in its formation, however, remain unclear.
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The active a2p2 interconverts with a catalytically inhibited a4p4 oligomeric form of
the enzyme. Binding of dATP to the allosteric activity site shifts the equilibrium
between the two species towards formation of this a4P4 species (10, 13). Recent
structural characterization of this dATP inhibited a4p4 revealed that the relative
orientation of the a2 and P2 subunits in this complex prevents formation of a
productive electron transfer pathway and thus the enzyme cannot perform
chemistry (Fig. IV.1). These structures also revealed that a key interaction between
a and P in the a4p4 complex occurs via the N-terminal region of a that houses the
allosteric activity site (Fig. IV.1)(10, 14). This observation suggests how dATP and
ATP modulate activity, as their binding site is at the interface of the inactive a 4 p4 .
The exact mechanism by which dATP and ATP influence this a-p interface,
however, was unclear. If the difference is merely the presence or absence of a 2'-OH
group, how is such a dramatic rearrangement caused? To address this question, we
have determined structures of the E. coli a2 subunit with ATP or dATP bound at the
allosteric activity site. We compare these structures with the dATP-bound E. coli
a 4p4 as well as recently reported structures of the human class Ia a2 with ATP and
dATP bound (15). An analysis of these structures provides molecular level
information about the mechanism by which dATP and ATP binding are
distinguished and allows us to propose how these differences affect activity
regulation.
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IV.D. Results
IV.D.1. Crystallization of E. coli a2-dATP and a 2-ATP
Using high-throughput sparse matrix screening, a new crystallization condition was
found for of the E. coli RNR a2 subunit in the presence of effector nucleotides. The
space group of this crystal form is P4 32 12 with two chains of a in the asymmetric
unit forming the physiological a2 dimer (Fig. IV.2). The packing is distinct from the
only previously reported crystal form for E. coli a in the space group R32. This R32
crystal form contains three a chains in the asymmetric unit, comprising one
physiological a2 dimer and one a monomer that forms a physiological dimer with a
crystallographic symmetry related molecule. These R32 crystals only formed when
the protein solution contained a 20-residue peptide corresponding to the C-terminus
of the P subunit. The last 15 residues of this peptide were visible in the electron
density and are essential to the lattice contacts in this crystal form (12). In contrast,
this peptide is not necessary for formation of the P4 3212 lattice. Using this new
crystallization condition, co-crystal structures of a2 with dATP and ATP were
obtained, allowing for the first characterization of the differences in binding of these
allosteric effectors. The overall folds of both a2-dATP and a2-ATP are similar to that
previously observed (Fig. IV.3).
IV.D.2. Binding of dATP and ATP at the allosteric specificity site
In the a 2-dATP structure, all dATP molecules are ordered with easily interpretable
electron density (Fig. IV.4A and IV.7A). Binding of dATP at the allosteric specificity
site involves multiple contacts between the nucleotide and protein main chain and
side chain atoms (Fig. IV.4). N6 of the adenine makes a hydrogen bond with the
backbone carbonyl of Ser249 and there is a van der Waals interaction between the
base and Cys292 from one a chain. All other interactions are with the second a
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chain of the a2 dimer. 04' of the ribose hydrogen bonds to His275 and 03' hydrogen
bonds to Asp232. The phosphate oxygens make hydrogen bonds to Arg262 and
Arg269 as well as to the backbone amides of Arg269 and Lys234. There is one Mg 2 +
coordinating three phosphate oxygens and three water molecules in octahedral
geometry. There are no interactions between the Mg 2+ and protein.
In the a 2-ATP structure, all ATP molecules are ordered with easily interpretable
electron density (Fig. IV.5A and IV.8A). At the allosteric specificity site, ATP makes
identical interactions as dATP, described above. The 2'-OH makes no hydrogen
bonding interactions and is in close proximity (-3 A) to the hydrophobic side chain
of Phe281 (Fig. IV.5).
There are differences in the specificity site of the E. coli and eukaryotic RNRs (Fig.
IV.6). Although our E. coli a2-ATP structure is the first reported structure with ATP
bound at the allosteric specificity site, there are 4 structures of the class Ia RNR
from Saccharomyces cerevisiae with AMP-PNP bound at this site (16, 17). These
structures reveal that the 2'-OH of AMP-PNP points towards a tyrosine residue
(Tyr285 in S. cerevisiae), making a hydrogen bonding interaction that could
stabilize ATP at this site (Fig. IV.6D). There is a structure of dATP bound at the
allosteric specificity site of the human RNR that reveals this tyrosine is also present
in human a (Fig. IV.6C). If an ATP is modeled here, the 2'-OH could make a
hydrogen bonding interaction with this residue. Thus, ATP binding may be more
favorable in the S. cerevisiae and human class Ia RNRs than in E. coli. To verify
this, more biochemical studies are needed, as nucleotide binding has not been fully
characterized for the S. cerevisiae or human a2.
IV.D.3. Binding of dATP and ATP at the allosteric activity site
Binding of dATP at the allosteric activity site involves multiple contacts between
the nucleotide and protein main chain and side chain atoms (Fig. IV.7). N6 of the
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adenine base hydrogen bonds to Glu15, N1 hydrogen bonds to the backbone amide
of Asn18, and N7 hydrogen bonds to Lys9. 04' of the ribose hydrogen bonds to
Thr55 and 03' hydrogen bonds to His59 (Fig. IV.7B). The phosphates interact with
Lys9, ArglO, and Lys9l. There is one Mg 2+ coordinating three phosphate oxygens
and three water molecules. There are no interactions between the Mg 2+ and protein.
In contrast to the one dATP molecule bound at the allosteric activity site, in the
case of ATP we observe two molecules bound (Fig. IV.8). The first ATP is bound in
the same site occupied by dATP. N6 of the base hydrogen bonds to Glu15 and N1
hydrogen bonds to the backbone amide of Asn18 (Fig. IV.8B). 04' of the ribose
hydrogen bonds to Thr55 and there is a weak hydrogen bond between 02' and the
backbone carbonyl of Lys21. The phosphates are stabilized by Lys9, Arg1O, and
Lys91. There is one Mg 2+ coordinating three phosphate oxygens of this molecule of
ATP and three phosphate oxygens of the second ATP, which occupies a previously
undescribed binding site. The base of this second ATP (shown in yellow in Fig.
IV.8A, C) forms r-r stacking interactions with Trp28 and Phe97. 02' of the ribose
makes a weak hydrogen bond to the backbone carbonyl of Phe87, and 03' forms a
hydrogen bond to an ordered water molecule that is within hydrogen bonding
distance of His59 and the a-phosphate of the other ATP. Lys21 and Arg24 are in
close proximity to the phosphate groups of this second ATP and can provide
electrostatic stabilization.
The phosphates of the first ATP and dATP have a similar conformation and in both
cases one Mg 2 + is bound, coordinated to an oxygen from each of the three
phosphates. In the case of dATP, this Mg 2 + also coordinates three water molecules
whereas in the ATP case, it is coordinating phosphate oxygens from the second
ATP. The coordination of both ATPs to one Mg 2 + is consistent with the observation
that ATP binding appears to be cooperative (3, 18).
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The unexpected observation of two ATP molecules bound at the allosteric activity
site is the most dramatic difference between the complexed structures of dATP and
ATP (Fig. IV.9.A, B). As described above, the first ATP is bound in a position nearly
equivalent to the position of dATP, whereas a second ATP binds in a unique site. An
overlay of the ATP and dATP-bound structures shows a slight shift in the position
of the ribose of the first ATP relative to dATP (Fig. IV.9C). Despite this shift, the
interactions between the adenine ring and Lys9, Glu15, Asn18 and Thr55 are
maintained (Fig. IV.7B and IV.8B). Interactions with the ribose, however, are
different. The 3'-OH of dATP forms a hydrogen bond with His59 but the
corresponding 3'-OH of the first ATP is positioned further from His59 and does not
form a hydrogen bond with this residue (Fig. IV.7B, IV.8C and IV.9C). Instead the
imidazole ring of His59 is flipped about 900 in the ATP bound structure, and now
makes a water-mediated hydrogen bond to the ribose of the second ATP (Fig.
IV.9C). This water, found only in the a 2-ATP structure, also hydrogen bonds to
His88 (Fig. IV.9B).
The movement of His59 is correlated with a set of distinct side chain
rearrangements that must occur for the second ATP binding site to be formed (Fig.
IV.9D). The position of His59 in the a2-ATP structure would be unfavorably close to
Phe87 in the position observed in the a 2-dATP structure and we observe a change in
the position of Phe87 in the a 2-ATP structure moving it away from His59 (Fig.
IV.9D). This new position of Phe87 in a 2-ATP would clash with Trp28 in the
position it is found in in the a2-dATP structure and we observe a movement of
Trp28 in the a2-ATP structure to avoid steric clash with Phe87 (Fig. IV.9D). Thus
the rearrangement of His59, Phe87, and Trp28 appear concerted, and their
arrangement in the a2-ATP structure together with Phe97, forms the second ATP
binding pocket. In this pocket, the aromatic ring of Trp28 sits parallel to the
adenine ring forming a r-n interaction. The ring of Phe87 is perpendicular to the
adenine ring (~3.6 A away) and occupies a position that would be blocked by Trp28
160
if it did not flip to make its ri-stacking interaction with the adenine ring. The
position of Phe87 in the a 2-dATP structure occupies the same space as the ribose of
the second ATP making the movement of both Phe87 and Trp28 required for
binding the second ATP in this mode. The phenyl ring of Phe97 is parallel to the
adenine ring on the face opposite Trp28. There is no change observed in the position
of Phe97 between the two structures.
IV.D.4. Comparison of E. col a2-dATP and a 2-ATP structures with human a 2-dATP
and a 2-ATP structures
Crystal structures of the human class Ia RNR bound to either dATP or ATP were
recently reported (Fig. IV.10A) (15). These structures were obtained by soaking
nucleotides into crystals of a2 grown in conditions with a pH of 7.9. The dATP bound
a2 was solved to 3.16 A resolution and the ATP bound a2 was solved to 3.11 A
resolution (15). In comparing our E. col a 2-dATP co-crystal structure to the human
a 2-dATP soaked structure, we note differences in nucleotide binding (Fig. IV.7B and
IV.10B). In the E. coli structure, there are hydrogen bonds between the adenine and
Lys9 and Glu15, residues that are conserved in class Ia RNRs (these residues
correspond to Lys5 and Glull in human). These hydrogen bonds are not observed
for dATP bound to the human RNR, instead the adenine hydrogen bonds to
backbone atoms only (Fig. IV.10B). In addition, whereas the E. coli RNR forms a
hydrogen bond between the 3'-OH of the dATP ribose and His59, the 3'-OH of the
dATP ribose in the human RNR makes no hydrogen bonding contacts to the
equivalent residue, Asp57 (Fig. IV.7.B and IV.10.B), despite the fact that mutation
of this residue abolishes enzyme inhibition by dATP. The closest polar atom is the
backbone carbonyl of Leu56, which is 3.7 A away, and the side chain of Asp57 is not
modeled in this structure because there is no electron density for it. Also, in E. coli
a2-dATP we observe an Mg 2 + coordinated to the phosphates of dATP, but this Mg
2+
was not seen in the structure of human a 2-dATP.
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We also observe differences in binding of ATP to E. coli RNR compared to human
RNR (Figs. IV.8B, IV10C). The first ATP in E. coli is bound in the same site as the
ATP in the human RNR structure. The hydrogen bonding interactions with the
adenine are the same for the two structures, but there are differences in binding of
the ribose. In the E. coli a 2-ATP the 2'-OH is 3.3 A from the backbone carbonyl of
Lys2l. The distance between the 2'-OH of ribose and the same backbone carbonyl in
the human a 2-ATP is 3.7 A (Fig. IV.8C and IV.10C). The 3'-OH of the ribose in the
E. col a 2-ATP does not make any hydrogen bonding interactions with protein, but
in the human a 2-ATP the 3'-OH of the ribose is hydrogen bonding with Asp57
(equivalent to His59 in E. coh). In the E. col a2-ATP structure, there is one Mg 2+
coordinating the phosphates and the second ATP, whereas in the human as2-ATP
structure, two Mg 2+ ions were modeled, coordinating the phosphates of ATP.
At the allosteric activity site of the human RNR, the authors note a 2.4 A shift in
the position of the 3'-OH of the ribose of ATP and dATP, which the authors
attribute to a steric clash between the 2'-OH of ATP and the side chain Ile18 of the
human a2 (Ile22 in E. coli numbering) (Fig. IV.10A). In contrast, when the N-
terminal 90 residues of the E. coli a2-dATP and E. col a 2-ATP are aligned by their
C. positions, the difference in the position of the 3'-OH is less than 1 A (Fig. IV.9C).
In the E. col a 2-dATP structure, the 2' carbon of dATP is 4.3 A away from the
closest carbon of Ile22, so the addition of a hydroxyl group at this position would not
require a significant shift in the position of the ribose. In fact, the E. col a2-ATP X-
ray data indicate only a slight shift in the position of the ribose such that the 2'-OH
is about 3.3 A away from the backbone carbonyl of Lys2l, potentially forming a
weak hydrogen bond with a main chain atom. The distance between the 2'-OH and
the corresponding backbone carbonyl in the human structure is 3.7 A, too long for a
hydrogen bond.
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To examine whether these variations in hydrogen bonding are due to significant
differences in the overall structure of the activity site, we superimposed the human
and E. col a2 structures (Fig. IV.11). We find that overall the structures are similar.
To better analyze the binding of nucleotides in the human a2 structures, the
deposited structure factors for this data set were obtained from the RCSB protein
data bank (www.pdb.org, PDB ID 3HNE). Likelihood-weighted bulk solvent-
corrected electron density maps were calculated using model phases in the Phenix
software package (19). Electron density maps of human a2 show large regions of
positive difference electron density for the human a 2-ATP structure and weak
2F-Fc density for nucleotide in the a2-dATP structure (Fig. IV.12).
To explore whether the large amount of positive electron density could represent a
second ATP bound to the human RNR (Fig. IV.12), we re-refined the structure with
a second molecule of ATP bound as it is in the E. coli structure using simulated
annealing, positional and B-factor refinement in the program Phenix (19). The
resulting 2FK-F electron density fits the phosphates and ribose of a second ATP
surprisingly well but there is no density for the adenine indicating it is flexible (Fig.
IV.12). Interestingly, the aromatic residues that make r-n interactions with the
adenine of the second ATP are not present in human a (Fig. IV.13). Trp28
corresponds to Lys24, Phe87 corresponds to Ser84 and Phe97 is on a loop in the E.
col a2 that is not present in the human structure. Lys24 could replace a r-r
interaction with a n-cation interaction, but the interactions with Phe87 and Phe97
are completely lost. Overall, the refinement of two ATPs in the human a2 -ATP
structure suggests that although this site is not as good for binding a second ATP as
observed for the E. col a2 activity site, at the concentrations used in the soaking
experiment (10 mM), ATP does bind here as evidenced by the better fit to the
electron density of two ATPs as opposed to one. The stoichiometry and affinity of
ATP binding to the human a2, which have not been reported, could help to clarify
the function, if any, of this second ATP.
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IV.D.5. Binding parameters for ATP
To support the crystallographic observation of two ATP binding sites at the
allosteric activity site of each E. coli a, we revisited the ultrafiltration binding assay
described by Orm5 and Sj6berg that was previously successful for measuring the
Ks of nucleotide binding to a2 (18). In this assay, radioactive nucleotides are used
to measure free and bound ligand concentrations after separation by centrifugation
in a spin filter, allowing for the measurement of binding constants in a short period
of time. Studying ATP binding to a2 has been challenging for multiple reasons.
There are few techniques that can characterize weak binding affinities, nucleotides
become hydrolyzed over time making techniques such as equilibrium dialysis non-
ideal, and there appear to be multiple binding sites exhibiting cooperativity that
cannot be properly modeled with the limited amount of data obtainable (3, 18).
Previously published binding studies reported a K for ATP binding to the a2
subunit of 80 pM at 25 *C with a maximum of 4 binding sites (18). This result was
attributed to binding of one ATP at each allosteric activity site and one at each
allosteric specificity site per monomer, yielding 4 ATPs per a2 dimer. However, the
highest concentration of ATP used was 300 pM, only about 3-4 times the K, which
is insufficient for saturation. We now consider that due to low occupancy of binding
to the specificity site, the 4 ATPs reported to bind to a2 were those binding to the
allosteric activity site. Also, these studies were analyzed by Scatchard linearization,
which distorts experimental error (20) possibly contributing to under-estimation of
binding stoichiometry.
Here, we used the ultrafiltration method previously reported (18), but now with
higher concentrations of ATP and using non-linear regression to analyze the data.
The resulting binding curves were calculated using data collected from multiple
experimental runs using non-linear regression in the software package Prism. A
one-state binding model was used that assumes all binding sites are equivalent.
This assumption is inaccurate but higher-order binding models have too many
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parameters for the amount of data available. Using this approximation, the Ka for
ATP binding at 25 *C was measured to be 158 ± 37 pM with the maximum number
of binding sites being 6.8 + 0.6 (Figure IV.14A). The experiment was repeated in the
presence of 100 or 500 pM dGTP, which should bind at full occupancy to the
specificity site (the K for dGTP at the allosteric specificity site is 0.77 PM (18)), and
thus reports only on binding of ATP to the activity site. In the presence of dGTP, the
Ka for ATP at the allosteric activity site was measured to be 120 ± 52 PM with a
maximum number of binding sites of 3.8 ± 0.5. These data are consistent with the
binding of two ATP molecules at each activity site.
As a further control of our method, we repeated the experiment with a different,
tighter binding nucleotide, TTP. The reported K for TTP at 25 *C is 2 PM with a
maximum number of binding sites of 1.8 (associated errors were not reported) (18).
Here, using an identical protocol to that for ATP binding, the resulting binding
curve for TTP yielded a K of 4.2 + 1.3 pM with a maximum number of binding sites
of 2.1 ± 0.2 (Fig. IV.14B), which is consistent, within error, with the previously
reported values.
IV.D.6. Comparison of dATP binding at the activity site in free a2 and a4p4
structures
One remaining question is how dATP binding at the activity site influences
formation and/or stabilization of the a4P4 state. There are no significant differences
between dATP binding in free a2 and the a4p4 complex (Fig. IV.7B, C). The largest
observable difference is a free P04 2 coordinated to the Mg 2+ in the a 4p4-dATP
structure in place of three waters in the a 2-dATP structure. The modeling of this
phosphate, however, is uncertain. Positive difference density appears above the
Mg 2+-coordinated waters in the a4p 4-dATP model (described in chapter V) and this
difference is accounted for when P04 2 is modeled in place of waters (Fig. IV.7D).
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The data quality for this structure is not sufficient to be confident in this
assignment so we will not interpret this difference here.
The residues of the a subunit that are involved in the a-P interface in a4p4 are
located on the first and second helix of the N-terminal four helix bundle. These
helices, called a-helix 1 (residues 19-23) and a-helix 2 (residues 36-46), are found in
the same conformation in the a2-dATP and a2-ATP structures (Fig. IV.15A) but
there is a rearrangement that must occur for a4p4 formation. These changes are not
crystallization artifacts; in all of these structures, helix 1 and 2 are not involved in
crystal contacts. In the a4p4 complex, the last turn of helix 2 unwinds, His46 shifts
from a largely hydrophobic environment on the a subunit toward the a-p interface
and Asp222 of P2. In addition, Ile47 moves from a solvent exposed position in free a2
into a hydrophobic pocket formed by Ile58, Phe49 and Ile53 of the a subunit (Fig.
IV.15B). This newly formed pocket interacts with Ile297 of the P2 subunit (Fig.
IV.15C). The residues of helix 2 that unwind do not directly interact with dATP or
either of the two ATPs (Fig. IV. 15B, C), but there is a network of polar residues that
could mediate a signal from His46 of helix 2 to Asp27 of helix 1 (Fig. IV.16A). In the
a2-ATP structure, Asp27 (adjacent to Trp28 which flips conformations upon ATP
binding) is 3.6 A from His23. His23 is 3.0 A away from Glu42, which is 4.5 A from
His46. Also, Arg24 moves closer to the phosphates of the second ATP in the a2-ATP
structure. In the a 2-dATP structure, these- interactions are also observed, but the
conformation of Asp27 is slightly altered such that it is now 4.5 A away from H23.
The other distances vary slightly but are within the same range as observed for a2-
ATP (Fig IV.16B). In contrast, in the E. coli a 4p4-dATP structure, His23 and Glu42
are involved in contacts with the P2 subunit and His23 is observed in a distinct
rotamer conformation that requires disruption of this proposed network of polar
residues (Fig. IV.16C). Although this network consists of weak hydrogen bonds, it
does link the activity effector binding site with residues that contact P2 in the a4p4-
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dATP complex and thus could be important for complex formation and activity
regulation.
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IV.E. Discussion
ATP and dATP bind to the same allosteric site in the a2 subunit of RNR to cause
drastic changes in enzyme activity. Despite knowing the structure of E. col a2 and
the architecture of this allosteric site, it remained a mystery as to how one hydroxyl
group affected such a change in activity. Structures of the E. coli RNR a2 subunit
co-crystallized with ATP and dATP suggest a novel mechanism for distinguishing
between these effectors, namely the presence of two ATPs versus one dATP at the
allosteric activity site. Solution binding data support the observation that two
molecules of ATP bind at this site. Together, these data allow us to propose a model
for the E. coli class Ia RNR where the binding of two ATPs to the allosteric activity
site can either promote formation of the active a22complex or destabilize the a4p4
complex formed in the presence of dATP or both. A comparison of dATP bound in
the free a2 subunit and dATP bound at this same site in the inhibited a4p4 structure
show that formation of the inactive a4p4 involves conformational changes in the a2-
N-terminal domain. In particular, a turn of a-helix 2 unwinds, repositioning side
chains to create the observed a-p interface. Based on the observation that the a2-
dATP structure resembles the a2-ATP structure in this region, we find these
changes are not solely due to dATP binding. Instead, these structures suggest
rearrangements in hydrogen bonding between helix 1 and helix 2 are important for
a-p interaction and the binding of a second ATP affects movements in helix 1
through secondary contacts, in particular through interactions with Trp28 and
Arg24.
The binding of the first ATP is markedly similar to the binding of dATP at this site,
the only differences being the rearrangement of His59 such that dATP forms a
hydrogen bond between the 3'-OH and His59 whereas ATP does not, and an
additional hydrogen bond between the 2'-OH of ATP and the backbone carbonyl of
Lys2l. His59 has previously been implicated as a player in allosteric activity
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regulation, as mutation of this residue to Ala increases the Ki for dATP from 1.7 to
49 [tM (21). The decreased affinity for dATP at the activity site is explained by the
structure of a 2-dATP. His59 makes a direct hydrogen bond to the 3'-OH of dATP
and loss of this interaction could be sufficient to cause the reported effects especially
because it is the only hydrogen bond to dATP that is not shared by the first ATP. In
contrast to His59, when an adjacent residue, His88 was mutated to Ala the Kiwas
increased from 1.7 to 13 [tM. This smaller affect is consistent with the observation
that His88 does not directly contact dATP or ATP.
His59 in E. coli corresponds to Asp57 in human RNR. Mutation of Asp57 to Asn in
the mouse or human RNR diminishes dATP binding at the allosteric activity site
and this mutant is insensitive to inhibiting concentrations of dATP (22-24). This
observation is analogous to that made for the H59A mutant in E. coli (21).
However, in the structures of human a2-ATP and a2-dATP, ATP hydrogen bonds to
Asp57 whereas when dATP is bound, Asp57 is disordered and cannot be modeled
(15). This human RNR structural data is inconsistent with the human RNR
biochemical and binding data that show the D57A mutant has a greater affect on
dATP binding. The human RNR structural data is also the opposite of what we
observe for the E. coli enzyme where His59 interacts with dATP directly. Better
quality structures of the human enzyme with better ordered N-terminal domains
are important for resolving this discrepancy between the structures and biochemical
data.
Remarkably, despite a lack of conservation of aromatic residues that bind the
second ATP between the E. coli and human RNR, modeling of 2 ATPs at the
allosteric activity site of the human a2 RNR results in a better fit to the electron
density than modeling only one ATP. This result indicates multiple ATPs can also
bind in a similar way in the human a2. A number of differences in activity
regulation between the enzymes, however, make the comparison complicated. There
are no structural changes or side chain rearrangements that need to occur for a
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second ATP to bind at the human activity site, making it less clear how differential
binding is communicated. A low-resolution crystal structure of an as hexamer of the
yeast RNR showed the N-terminal domain is involved in a2-a2 contacts but the
resolution was not sufficient to determine what residues were involved in the
contacts (15). Because these contacts are between two a2 subunits as opposed to a2
and P2 subunits, the interactions made by the N-terminus are likely different and
the role of a putative second ATP binding site remains to be determined. At this
point, it is not known what the active and inactive forms of eukaryotic RNRs are. It
is possible that, unlike in E. coli RNR, the oligomeric state of human RNR may not
change between active and inactive states. Further characterization of the
oligomerization states of human RNRs under active and inactive conditions, their
interconversions, as well as the residues involved in subunit-subunit interfaces will
help reveal the possible role for a second ATP binding at the allosteric activity site
of the human RNR.
A third allosteric effector binding site has been proposed for RNR from mouse (25).
Oligomeric changes monitored by light scattering or analytical ultracentrifugation
were correlated with enzymatic activity in the presence of increasing concentrations
of ATP. CDP reductase activity increases with increasing concentrations of ATP up
to 0.2 pM after which activity decreases with increasing concentrations of ATP up to
1 mM. Above concentrations of 1 mM, activity increases again. This triphasic
dependence on ATP concentration was attributed to the presence of three ATP
binding sites, and at the highest ATP concentrations the protein was found to be an
as hexamer. The proposed third ATP binding site was thus termed the
"hexamerization site". No binding data were presented to support this proposal.
Based on the structure of the human a2, it appears that three ATPs can bind to the
catalytic subunit of a mammalian RNR (one at the allosteric specificity site and two
at the allosteric activity site). It has been proposed that different a6 oligomers can
form under different conditions (15, 26) and with only one low-resolution structure
of the as hexamer from yeast RNR in the presence of dATP, we cannot yet propose
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how binding of a second ATP to the activity site affects RNR activity, but there may
be a common mechanism of distinguishing dATP from ATP binding at the allosteric
activity site, namely binding stoichiometry.
One final difference in ATP binding between the E. coli and human RNRs involves
the allosteric specificity site. Both ATP and dATP can bind to the specificity site
with the same affect of promoting CDP and UDP reduction over GDP or ADP
reduction (3, 6). The two nucleotides, however, have very different affinities for this
site. The K for dATP at the E. coli allosteric specificity site is 0.43 PM (18) but the
Ka for ATP at this site is greater than 100 pM (17). For E. coli, we have measured
the binding constant for ATP to be 120 pM when only the allosteric activity site is
available for binding and 158 pM as the average for all six sites per dimer. Thus,
the affinity for ATP at the specificity site must be > 158 pM. The molecular
underpinnings of this difference are clear from the structure of a 2-ATP. The binding
of dATP and ATP are nearly identical at this site. The dominant difference is the
presence of the 2'-OH of ATP. This hydroxyl group points directly into a
hydrophobic pocket and is 3.1 A from Phe281 (Fig. IV.5). All other interactions with
the adenine, the phosphates, and 03' and 04' of the (deoxy)ribose are the same for
ATP and dATP thus the difference in affinity must come from the unfavorable
interaction with the 2'-OH.
This result calls into question the role of ATP as a specificity effector in vivo. ATP
does bind to the specificity site in vitro, in the absence of competing nucleotides, as
we know from our binding studies and from the crystal structure of a 2-ATP, which
was obtained with a2 in the presence of 5 mM ATP. Although the physiological
concentration of ATP is not far from this (-3 mM), the other dNTP effectors are
present in the cell at concentrations of -100 pM (27), around 100-fold higher than
their Ks for the specificity site (0.5 - 2 pM (18)), while ATP is present at only 10-20
times its a, making it less competitive for binding. ATP binding studies have been
carried out for the class Ib RNR from Salmonella typhimurium, and because class
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Ib RNRs do not contain an allosteric activity site, affinities for the specificity site
can be measured directly. These binding studies were unable to measure the Ka for
ATP precisely because it was too high but was estimated to be around 500 P.M (28,
29). The new structures of E. coli RNR a2 presented here suggest that S.
typhimurium RNR should bind ATP at the specificity site with tighter affinity than
the E. coli because the hydrophobic pocket that makes close contact with the 2'-OH
of ATP in E. coli is replaced in S. typhimurium RNR by a polar tyrosine residue.
However, the K estimate of 500 pM indicates that, like in E. coli, binding of ATP at
the allosteric specificity site is weak. Further, the human a2 specificity site
resembles the specificity site of S. typhimurium more than that of E. coli, thus, we
expect that human a2 will bind ATP with a similar affinity (-500 PM). Such low
affinity for ATP at the allosteric specificity site supports a change in the common
rules for allosteric specificity regulation in RNR whereby ATP is not a relevant
specificity effector in vivo. ATP and dATP have a redundant role in specificity
regulation, so ATP is not needed to maintain specificity regulation for all NDPs. In
fact, if specificity regulation is intended to maintain dNTP pools, regulation should
not be controlled with NTPs. The removal of ATP from the list of specificity effectors
does not change the trends of specificity regulation but simply removes the
redundancy of ATP and dATP promoting binding of the same substrates. Thus, in
our proposed new model, dATP, dGTP and TTP are responsible for regulating
substrate specificity by binding to the allosteric specificity site in vivo and binding
of one dATP at the allosteric activity site inhibits RNR activity whereas binding of
two ATPs at this site increases RNR activity.
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IV.F. Materials and Methods
IV.F.1. Reagent preparation
Cytidine 5'-diphosphate was purchased from Sigma-Aldrich and dissolved into
assay buffer (50 mM HEPES pH 7.6, 15 mM MgCl2, 1 mM EDTA). The pH was
slowly adjusted to 7-8 with NaOH and the concentration was determined
spectroscopically using C271 of 9.1 mM-1 cm-1. High purity solutions of ATP, dATP
and dGTP were purchased from USB Corporation or Invitrogen. [2,8-3H]-Adenosine
5'-triphosphate, tetraammonium salt with a specific activity of 9.3x107 cpm/nmol
and [methyl-3H]-Thymidine 5'-triphosphate, tetraammonium salt with a specific
activity of 1.4x108 cpm/nmol were obtained from Moravek Biochemicals and added
to freshly prepared unlabeled ATP or TTP obtained from Sigma, lyophilized, and
resuspended in 50 mM HEPES pH 7.6, to give a final activity of 690 or 3090
cpm/nmol for [3H]-ATP and 470 cpm/nmol for [3H]-TTP. Pall Nanosep 30K Omega
filters were used for ultrafiltration assays.
IV.F.2. Protein preparation
The a2 protein was prepared as described (30, 31). The concentration of a2 was
determined spectroscopically using C28 0 of 189 mM-1cm-l; all molar concentrations
are dimer concentrations. a2 had a specific activity of 3800 nmol/min/mg as
determined by a coupled spectrophotometric assay (8).
IV.F.3. Crystallization of a 2-dATP and a 2-ATP
a 2-dATP was crystallized by the hanging drop vapor diffusion method. A protein
solution containing 116 [IM C2 in 50 mM HEPES pH 7.6, 15 mM MgSO4, 1 mM
EDTA, 5 mM DTT, and 10 mM dATP was mixed in a 1:1 ratio with a precipitant
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solution containing 6.8% PEG 3350, 80 mM HEPES pH 7.3, 280 mM MgCl 2 , 4%
glycerol, and 1.0% cyclohexyl-methyl-p-D-maltoside (CYMAL@-1) detergent
(Hampton Research) and equilibrated over a reservoir of 500 [L of precipitant
solution at 4 0C. After one week of growth, crystals were cryo-protected by looping
through a solution of 10.5% PEG 3350, 100 mM HEPES pH 7.3, 380 mM MgCl2,
13% glycerol and plunged directly in liquid N 2. Diffraction data were collected at the
Advanced Light Source at Lawerence Berkeley National Labs on beamline 8.2.2 at
100 K and processed using HKL2000 (32).
a 2-ATP was crystallized by the hanging drop vapor diffusion method. A protein
solution containing 88 [M a2 in 50 mM HEPES pH 7.6, 15 mM MgSO4, 1 mM
EDTA, 5 mM DTT, and 5 mM ATP, 1.0% CYMAL@-1 was mixed in a 1:1 ratio with
a precipitant solution containing 8.0% PEG 3350, 100 mM HEPES pH 7.3, 275 mM
MgCl2, and 5% glycerol and equilibrated over a reservoir of 500 pLL of precipitant
solution at room temperature (~25*C). After two days of growth crystals were cryo-
protected by looping through a solution of 8.5% PEG 3350, 100 mM HEPES pH 7.3,
300 mM MgCl2, 5 mM DTT, 5 mM ATP and successive concentrations of 10, 15, and
20% glycerol and plunged directly into liquid N2. Diffraction data were collected at
the Advanced Photon Source at Argonne National Labs on beamline 241D-C on a
Quantum 315 CCD detector at 100 K and processed using HKL2000 (32) (Table
IV. 1).
IV.F.4. Structure Solution and Refinement
The a 2-dATP co-crystal structure was solved by molecular replacement in Phaser
(33) to 3.6 A resolution, using as the search model, a single a monomer from the
previously solved structure of a2 in the presence of the ATP analog AMP-PNP (PDB
ID 3R1R, chain A) with all ligands and waters removed. The structure was refined
to 2.70 A resolution with Rwork/Rfree values of 19.8/24.3 (Table IV.1). The a 2-dATP
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model consists of two a chains, both including residues 4-737 (of 761). The C-
terminus is disordered and cannot be seen in the experimental electron density.
One Mg-dATP is bound at each specificity site (two per dimer) and one Mg-dATP is
bound at each activity site (two per dimer). 116 waters, 6 non-nucleotide associated
Mg 2+ atoms, 5 Cl- atoms, and 4 SO42- ions have been modeled. Refinement statistics
are given in Table IV.1.
The a 2-ATP co-crystal structure was solved using Fourier synthesis methods to 2.7
A resolution from the a 2-dATP co-crystal structure with all ligands and waters
removed. The structure was refined to 2.70 A resolution with Rwork/Rree values of
19.8/24.4 (Table IV.1). The Rfree was chosen to be identical to that for the a 2-dATP
data set. The a 2-ATP model consists of two chains of a, both including residues 4-
737 (of 761). The C-terminus is disordered and cannot be seen in the experimental
electron density. One Mg-ATP is bound at each specificity site (two per dimer) and
two ATPs are bound at each activity site (four per dimer) with one Mg 2+ coordinated
between the two molecules. 131 waters, 10 non-nucleotide associated Mg 2+ atoms, 5
Cl- atoms, and 2 SO 42- ions have been modeled. Refinement statistics are given in
Table IV.1.
For all structures, iterative rounds of refinement and model building were
performed in CNS 1.3 (34) and COOT (35) respectively. Simulated annealing
composite omit maps generated using CNS 1.3 were used to validate modeling of
bound ligands. Refinement consisted of rigid body, simulated annealing, positional
and individual B-factor refinement with no sigma cutoff. Loose non-crystallographic
symmetry (NCS) restraints were used throughout refinement and then removed
during the final rounds.
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IV.F.5. Determination of nucleotide binding parameters by ultrafiltration
The ultrafiltration method described by Orm6 and Sjoberg (18) was used with
modifications to carry out determination of ATP binding parameters. In place of
Millipore Ultrafree-MC filter units with polysulfone PTTK membranes, which are
no longer available, we used Pall Nanosep 30 kDa molecular weight cutoff filters
with polyethersulfone membranes. When these filters were washed with buffer
containing 0.5 mM ATP, they showed no detectable binding of radio-nucleotides.
For ATP binding parameter determination, filters were washed twice by adding 200
pL equilibration buffer (50 mM HEPES pH 7.6, 15 mM MgCl2, 1 mM EDTA, 5 mM
DTT, 0.5 mM cold ATP) to the filter unit, equilibrating in a 25 *C water bath for 5
min., then spinning in a table top centrifuge at 12,000 x g for 30 s. Excess
equilibration buffer was removed by pipetting.
After the second wash the sample consisting of 7-20 pM a2, 50 mM HEPES pH 7.6,
15 mM MgCl2, 1 mM EDTA, 5 mM DTT, and 50-1000 jiM [3H]-ATP with a specific
activity of either 690 cpm/nmol or 3090 cpm/nmol in a total volume of 150 PL was
added to the filter. The solution was equilibrated in a 25 0C water bath for 5 min.
and a 25 pL aliquot was taken for determination of total nucleotide concentration.
The sample was then centrifuged at 12,000 x g for 1 min. 25 iL of the filtrate was
then taken to determine free nucleotide concentration by scintillation counting. For
activity-site-only binding parameter determination, 100 or 500 IM dGTP was
included in the sample before equilibration. The amount of bound nucleotide was
found by subtracting the amount of free nucleotide from the total nucleotide. When
no protein was included in the solution the count of radioactivity was the same in
both the pre-spin sample and the filtrate. Data were plotted as a saturation binding
curve and analyzed using non-linear regression and a one-site specific binding
model in the program Prism (www.graphpad.com).
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IV.H. Figures and Tables
Activity site (ATP, dATP)
Specificity site (TTP, dGTP, dATP, ATP)
Active site (NDPs)
ATP
Q2 + 2 C2 P2 a44
Figure IV. 1. Structures of the E. coli class Ia RNR. The individual a and p
subunits each form homodimers, shown in cartoon representation. The a2 subunit
(in cyan and blue) binds NDP substrates in the active site and ATP and dNTP
effectors at the allosteric sites (shown as spheres). The N-terminal domain
containing the allosteric activity site is colored in yellow. A compact asp2 structure
is required for catalytic activity. This complex is in equilibrium with the free
subunits and an a4p4 complex which is formed when dATP binds to the allosteric
activity site (10). The presence of ATP promotes formation of the active complex (3).
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Figure IV.2. Packing of E. coli a2 crystal forms. A) Packing of subunits for all
previously reported crystal structures in space group R32 is shown with dimers
colored in blue, green, or pink (12). B) R32 packing is shown along a second unit cell
axis. C) The new P4 3212 packing is shown with dimers colored in pink and blue.
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Figure IV. 3. Overall structures of E. col a2-dATP and a 2-ATP agree with that of
the previously reported E. col a2 structure. Overlay of a2 with AMP-PNP bound at
the allosteric activity site (PDB ID 3R1R (4)) colored in cyan, a2-dATP colored in tan
and a2-ATP colored in gray with nucleotides shown as spheres.
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Figure IV.4. dATP binding at the E. coli RNR specificity site in the a 2-dATP
structure shown in stereo. A) 2Fo-Fc density contoured at 1.0 o is shown in blue
mesh with F-Fc density contoured at +3.0 o in green mesh and F-Fc density
contoured at -3.0 o in red mesh. dATP is shown in stick representation with
carbons colored in light blue, oxygen in red, nitrogen in blue, phosphorus in orange,
sulfur in yellow and magnesium in gray. Mg 2 + and waters are shown as spheres. B)
Interactions with surrounding residues are shown with carbons from chain A in tan
and from chain B in light yellow. Distances are given in A.
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Figure IV. 5. ATP binding at the E. coli RNR allosteric specificity site in the a2-
ATP structure shown in stereo. A) 2F-Fc density contoured at 1.0 o is shown in
blue mesh with F-Fc density contoured at +3.0 o in green mesh and F-Fc density
contoured at -3.0 o in red mesh. ATP is shown in stick representation with carbons
colored in blue, oxygen in red, nitrogen in dark blue, phosphorous in orange, sulfur
in yellow and magnesium in gray. Mg 2+ and waters are shown as spheres. B)
Interactions with surrounding residues are shown with carbons from chain A in
gray and from chain B in light purple. Distances are given in A.
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Figure IV.6. Surface representation of the allosteric specificity sites of selected
class Ia RNRs. A) E. coli a 2-dATP and B) E. coli a 2-ATP (Carbon colored in gray,
oxygen in red, nitrogen in blue, phosphorus in orange, and sulfur in yellow with
nucleotides shown as sticks with carbon in purple and Mg2 + as a green sphere). The
2'-OH of ATP points directly into a hydrophobic pocket. C) Human a 2-dATP (PDB
ID 2WGH, (15)) shown in the same representation. If ATP is bound here, the 2'-OH
would not be in a hydrophobic pocket but could form a hydrogen bond with the polar
tyrosine at this position. D) S. cerevisiae a 2-AMP-PNP (PDB ID 2CVT (16)) shown
with AMP-PNP carbons in cyan. The 2'-OH of AMP-PNP points towards the polar
residue, Y285.
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Figure IV.7. dATP binding to the E. coli RNR allosteric activity site in the a2-
dATP and a4P4-dATP structures shown in stereo. A) Binding of dATP at the activity
site in a2 is shown with 2F-F electron density contoured at 1.0 (Y shown in blue
mesh, F-Fc density contoured at +3.0 a in green mesh and F-F density contoured
at -3.0 o in red mesh. dATP is shown in stick representation with carbons colored in
pink, oxygen in red, nitrogen in blue, phosphorus in orange, sulfur in yellow and
magnesium in gray. Mg 2+ and waters are shown as spheres. B) Binding of dATP at
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the activity site in a2. Interactions with surrounding residues are shown with
protein carbons colored in tan. Distances are given in A. C) Binding of dATP at the
allosteric activity site in the a4P4 complex. dATP is shown in stick representation
with carbons colored in pink. Protein backbone is shown in cartoon representation
and interactions with surrounding residues are highlighted with carbons in yellow.
Distances are given in A. D) Density for dATP at the activity site of a4p4 -dATP,
maps as in panel (A) (structure from Chapter V).
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Figure IV.8. ATP binding at the E. coli RNR allosteric activity site shown in
stereo. A) 2F-F electron density contoured at 1.0 o is shown in blue mesh with
F-F density contoured at +3.0 Y in green mesh and F-Fc density contoured at
-3.0 a in red mesh. ATP is shown in stick representation with carbons colored in
cyan or yellow, oxygen in red, nitrogen in blue, phosphorus in orange, sulfur in
yellow and magnesium in gray. Mg2+ and waters are shown as spheres. B) Residues
that interact with the first ATP are shown with protein carbons in gray. Distances
are given in A. C) Interactions with both ATPs are shown with distances in A.
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AFigure IV.9. Conformational rearrangement is necessary for binding two ATPs at
the allosteric activity site. The activity site of a2 is shown with protein backbone in
cartoon representation and residues important for ATP binding labeled and shown
as sticks. A) a 2-dATP with side chain carbons colored in pink and nitrogen in blue.
dATP is shown as red sticks with Mg 2+ in gray and coordinating waters in red
spheres. B) a 2-ATP with protein carbons colored in green and nitrogen in blue.
ATPs are shown as cyan and yellow sticks with Mg 2+ in gray and the water that
hydrogen bonds to the yellow ATP as a green sphere. C) Stereoview of an overlay of
the two structures highlights the movement of W28, F87 and H59 that occurs to
allow for the binding of the second nucleotide. D) Stereoview of a2-ATP in a
different orientation, colored as in C) but only the yellow ATP is shown in
transparent sticks. The conformation of H59 in the ATP structure clashes with F87
when it is in the orientaion found in the a 2-dATP structure.
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Figure IV. 10. Comparison of ATP and dATP binding in human a2. A) An overlay
of human a 2-ATP (backbone in purple ribbon, ATP in cyan sticks, solved to 3.11 A)
and human a-dATP (backbone in tan ribbon, dATP in red sticks, solved to 3.16 A),
shown in stereo, reveals a significant shift in the position of the ribose (15). The side
chain of 118 is shown as sticks. B) Interactions between dATP and the human RNR
activity site are shown in stereo. dATP carbons are colored in pink and interacting
residue sidechains are shown as sticks and with carbons colored tan. C) Interactions
between ATP and the human RNR activity site are shown in stereo. ATP carbons
are colored in cyan and interacting residue sidechains are shown as sticks with
carbons colored purple. Distances are given in A.
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1Figure IV. 11. Stereoview of differences in dATP and ATP binding to the E. coli
and human class Ia RNR a2. Nucleotides and residues that have different binding
interactions in the E. coli and human structures are shown as sticks. Numbering is
given as E. coli/human. A) E. col a2-dATP structure is shown in orange and human
a 2-dATP structure is shown in pink. In the human a-dATP structure, D57 is not
modeled, and K5 and Eli do not interact with the adenine of dATP. B) E. coli a2-
ATP structure is shown in gray and human a 2-ATP structure is shown in blue. D57
interacts with ATP in the human a 2-ATP structure whereas H59 does not interact
with the first ATP in the E. col a2-ATP structure. In the E. col a2-ATP structure,
ATP is closer to the backbone of K21 allowing for stabilization of the 2'-OH of ATP.
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Figure IV. 12. Electron density for different refinements of ATP and dATP in
human a2 structures. A) Electron density calculated for the human a2-ATP
structure based on published coordinates. 2F0-Fc electron density contoured at 1.0 o
is shown as blue mesh, Fo-K density contoured at +3.0 o as green mesh and at -3.0
o as red mesh. B) F0-F, density for human a 2-ATP is shown on its own for clarity. C)
Electron density calculated for the human a2-ATP structure after modeling a second
ATP and refining in Phenix (19). 2F-K density contoured at 1.0 o is shown as blue
mesh, Fo-F, density contoured at +3.0 o as green mesh and at -3.0 o as red mesh.
The second ATP accounts for all positive density. D) Fo-F density is shown on its
own and indicates the adenine is not ordered. E) Electron density calculated for the
human a 2-dATP structure based on published coordinates. 2Fo-F density contoured
at 1.0 o is shown as blue mesh, Fo-F, density contoured at +3.0 u as green mesh and
at -3.0 o as red mesh. F) Fo-F, density is shown on its own. There is little F-F'
density in the human a 2-dATP compared to the human a2-ATP.
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AFigure IV. 13. Location of ATP binding residues in the E. col a2 that are not
conserved in human RNR. A) The E. coli a 2-ATP is shown with both ATPs modeled.
Interacting residues are colored yellow and shown as sticks. The aromatic side
chains W28, F87, and F97 stabilize the adenine and H59 stabilizes the ribose. B) A
second ATP modeled into the human a2-ATP structure, based on its position in the
in E. col a2-ATP, reveals species-specific residue differences. The human a2 lacks
the aromatic side chains that stabilize the binding of a second ATP in E. col a2.
Unlike the E. coli activity site, no side chain rearrangements are required for this
second ATP to bind. Residues at corresponding positions are colored green and
shown as sticks. F97 of E. coli is located on a structural element not present in
human a2.
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Figure IV. 14. Effector nucleotide binding curves measured by the ultrafiltration
method for E. coli class Ia RNR. Each dot is an independent measurement. A) [3H]-
ATP binding to a2 alone is in green circles, [3H]-ATP binding to a2 in the presence of
100 or 500 jiM dGTP in blue squares. B) [3H]-TTP binding to a2 alone is shown with
blue circles. Solid lines are fits to the data using non-linear regression with the
resulting K and n values given.
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Figure IV. 15. Comparison of residues on a-helix 2 in the free a2 and a4p4 states,
shown in stereo. (A) The structures of a 2-dATP and a 2-ATP are overlayed (coloring
as in Fig. IV.9). Residues of helix 1 and helix 2 that interact with p in the a4p4
complex are colored green. B) a2-dATP (tan) is overlayed with a 4p4-dATP (backbone
in green with dATP in purple sticks). The last turn of helix 2 unwinds in the a4p4
complex but not in a2 in isolation. This helical turn is not in direct contact with
dATP or ATP but changes the positions of H46 and 147 substantially. C) a4p4-dATP
structure is shown highlighting that 147 of the a2 subunit (green) is repositioned to
sit in a hydrophobic pocket that forms a binding site for 1297 of the P2 subunit
(orange). H46 of the a2 subunit is repositioned towards the interface with the P2
subunit.
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Figure IV. 16. Comparison of E. coli a2 hydrogen bonding networks involving helix
1 and helix 2 in free a2 and a4p4 states. A) E. col a 2-ATP structure is shown with
backbone colored in gray and ATP in sticks with carbons colored pink. Residues
comprising a network that undergo rearrangement to form a4f4-dATP are shown
with side chains in sticks. Distances are given in A. B) E. col a 2-dATP structure is
shown with backbone colored tan and dATP in sticks with carbons colored pink. The
residues shown in panel A) are also shown here in sticks with distances given in A.
C) E. col a 2-ATP structure overlayed with E. col a 4P4-dATP structure (in green
with dATP carbons in yellow). H23 and E42 interact with S295 and G298 of P2
respectively (shown with black dashed lines). The movement of H23 significantly
disrupts the interactions shown in panel A).
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Table IV. 1. X-ray data collection and refinement statistics for E. coli RNR a 2-ATP
and a 2-dATP
a2-dATP
Data collection
Space group
Cell dimensions
a, b, c (A)
Wavelength (A)
Resolution (A)a
Rsyma,b
<I/oI> a
Completeness (%)a
Redundancy a
Refinement
Resolution (A)
Number of reflections
Rwork/Rreec (%)
Number of atoms
Protein
Nucleotides
Mg 2+/Cl-/SO 4 2-
Water
Average B-factors (A2)
Protein
Nucleotides
Mg 2+/Cl-/SO 4 2-
Water
R.m.s deviations
Bond lengths (A)
Bond angles (0)
Ramachandran plot (%)
Favored
Allowed
Generously allowed
Disallowed
P4 3212
118.5, 118.5, 290.3
0.9793
50.0 - 2.70
(2.80 - 2.70)
7.9 (51.5)
10.3 (3.5)
99.9 (100.0)
6.0 (6.2)
50.0-2.70
55180
19.8/24.3
11699
120
10/5/20
116
47.3
56.3
49.0/60.0/140.4
39.4
0.007
1.44
90.1
9.7
0.2
0.0
a2-ATP
P4 3212
119.1, 119.1, 290.6
0.9794
50.0 - 2.70
(2.80 - 2.70)
9.0 (48.7)
8.9 (3.2)
99.2 (100.0)
4.8 (4.9)
50.0 - 2.70
55416
19.8/24.4
11682
186
14/5/10
131
41.2
57.7
41.1/55.1/122.8
32.7
0.007
1.35
90.6
9.2
0.2
0.0
a) Value in parentheses is for highest resolution bin
b) Rym=(i Zi cI (hkl)-< I(hkl) > |)/(thttli ion (hkl))
C) Rree was calculated from 5% of the total reflections
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Chapter V
Substrate and effector bound structures of the E. coli
class Ia ribonucleotide reductase reveal molecular
rules for allosteric specificity regulation
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V.A. Summary
Ribonucleotide reductase (RNR) produces deoxyribonucleotides from ribonucleotide
precursors for DNA replication and repair. A single enzyme converts all four
required building blocks and controls substrate specificity through an allosteric
mechanism to provide balanced concentrations required for DNA replication
fidelity. In the E. coli class Ia RNR, deoxyribonucleoside-triphosphate (dNTP)
effectors bind to an allosteric specificity site to alter the preference between the four
substrates: CDP, UDP, GDP, and ADP. Specifically, dATP binding leads to
preferential CDP and UDP reduction, TTP binding leads to preferential GDP
reduction and dGTP binding leads to preferential ADP reduction. Previous
structural studies revealed that the specificity site can communicate with the
substrate-binding site using a flexible loop (termed loop 2), but these structures did
not show how loop 2 could make unique base-specific contacts with different
effectors that translate into differential substrate binding affinities. To address this
question, we have determined structures of E. coli class Ia RNR with all four
substrate/specificity-effector pairs (dATP/CDP, dATP/UDP, dGTP/ADP, TTP/GDP).
Importantly, we have used an a4p4 form of this protein that crystallizes such that
lattice contacts do not impede conformational rearrangements necessary for
allosteric specificity regulation. Here, we find that the backbone of Ser293 in loop 2
is responsible for recognition of the base of effector dATP, communicating its signal
to the substrate-binding site through Gln294, whose sidechain specifically stabilizes
the base of pyrimidine substrates. In contrast, Gln294 specifically interacts with the
base of effector dGTP, communicating its signal through Ser293, which stabilizes
loop 2 residues Gly299 and Gly300 that then interact with the base of preferred
substrate ADP. Finally, there are no strong interactions between loop 2 and the
base of TTP. The major influence of TTP on GDP binding can be explained by the
sterics of this bulky substrate, which is preferentially bound when loop 2 is
unrestrained, leading to a more open substrate-binding site.
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V.C. Introduction
The fidelity of DNA replication is vital to the conservation of genetic information
between generations. Its importance is revealed in the multitude of regulatory
mechanisms used by the cell to insure accurate copies are made (1-4).
Deoxyribonucleotides, the building blocks for DNA synthesis, are produced from
ribonucleotide precursors by the enzyme ribonucleotide reductase (RNR). As a
central controller of deoxyribonucleotide triphosphate (dNTP) synthesis, RNR uses
multiple modes of allostery to maintain dNTP pools. Three classes of RNR are
known and classified by the cofactor they use to generate a protein radical required
for catalysis. The best characterized of all RNRs is the class Ia enzyme from
Escherichia coli that employs a di-iron-tyrosyl radical cofactor to initiate chemistry.
The substrates for this enzyme are nucleoside diphosphates (NDPs), and this single
enzyme is responsible for conversion of all four available NDPs to their
corresponding dNDPs. dNDPs are subsequently phosphorylated to dNTPs for use in
DNA biosynthesis and repair. Although one enzyme produces all de novo dNTPs,
their abundance in the cell is not stoichiometric (5, 6). In an allosteric feedback
cycle, binding of dATP (or ATP), to the allosteric specificity site of RNR promotes
CDP or UDP reduction. Reduction of CDP and UDP leads to a buildup of TTP, and
TTP binding promotes GDP reduction. Similarly buildup of dGTP levels and
subsequent binding of dGTP to the allosteric specificity site promotes ADP
reduction (Fig. V.1) (7-9). Through this cycle, dNTP ratios are maintained. To
explore the molecular basis of this specificity regulation, we have solved the first
full set of substrate/specificity effector pairs bound to the catalytic subunit of the E.
coli class Ia RNR. The quality of these structures is sufficient to fully describe, for
the first time, how binding of dNTPs at the allosteric specificity site promotes
binding of the preferred substrate.
Along with specificity regulation, RNR uses allosteric regulation to control the
overall size of dNTP pools by sensing dATP/ATP ratios. Binding of ATP or dATP at
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an allosteric activity site leads to up- or down-regulation of enzyme activity
respectively (Fig. V.1) (10). In the E. coliclass Ia RNR, it has been established that
this allosteric activity regulation is achieved by changes in the oligomeric state of
its two subunits, a2 and P2 (9-11). The catalytic as subunit houses the substrate-
binding site and both allosteric sites (7, 12, 13), and the P2 subunit houses the di-
iron-tyrosyl radical cofactor that is required for substrate turnover (14). When ATP
is bound at the allosteric activity site, the additional binding of specificity effectors
and substrates to the a2 subunit results in the formation of an a2@2 complex that is
capable of radical propagation (Fig. V.2A). In particular, within this active a2@2
state of E. coli RNR, a long-range proton coupled electron transfer pathway is
established. This pathway, which involves residues from both subunits, allows the
radical to move from Tyr122 of P2 to Cys439 at the active site of a2, the latter
residue being located on the so-called 'finger loop' in a 10-stranded p/a barrel within
the a2 subunit (Fig. V.2B,C). The resulting transient cysteine radical initiates the
catalytic transformation by abstracting a hydrogen from the 3' position of the
substrate ribose (15, 16). The affinity between the subunits in the a2@2 complex is
weak (~0.4 iM in the absence of effectors) but is increased up to 5-fold in the
presence of complementary substrate/specificity effector pairs (17, 18). Based on
these results, it appears that substrate/effector binding may be involved in forming
a stable active a2@2complex.
When dATP binds at the allosteric activity site of the E. coli class Ia RNR,
formation of an a4p4 complex is promoted. The structure of this complex was
recently solved (11) revealing a ring of alternating a2 and p2units that cannot form
a productive electron transfer path, leaving the enzyme inactive (Fig. V.2A). dATP-
driven negative regulation is common in class Ia RNRs (10, 19, 20), but the
structural basis of this inhibition is not believed to be conserved (21, 22). In
contrast, substrate specificity regulation is believed to be common for class I and II
RNRs but the structural mechanisms are not yet clear despite the availability of
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several structures of both class I and class II RNRs with effectors and substrates
bound (23, 24). Class II RNRs differ from class I in that they do not use a second
protein subunit for radical generation, instead using an adenosylcobalamin cofactor,
but the allosteric specificity site is structurally homologous for both classes. This
site is found at either end of a four-helix bundle that comprises the dimer interface
of the a2 subunit and employs residues from both chains of the dimer to bind
nucleotides (Fig. V.2B). Although obtaining structures of RNRs with substrates and
effectors bound has been challenging, some do exist (12, 23, 24). From structures of
TTP bound to the E. col a2 (12), structures of substrate and effector pairs bound to
the class Ia a2 from Saccharomyces cerevisiae (24), and the class II a2 from
Thermatoga maritima (23) some of the critical determinants of specificity binding
and communication to the active site have been identified. Two flexible loop regions,
termed loop 1 (residues 263-277 in E. col) and loop 2 (residues 292-301 in E. coli)
(Fig. V.2B), become better ordered upon substrate binding with residues in loop 1
stabilizing the specificity effector phosphates and ribose, and loop 2 bridging the
nucleotide bases of the effector and substrate (12). Loop 2 rearrangements appear to
confer the substrate specificity in the structures of substrate/effector pairs bound to
the catalytic subunit of RNR from S. cerevisiae and T. maritima, but few close
contacts between loop 2 and substrate and effector nucleotides were observed,
leaving the structural basis for specificity regulation uncertain.
Only one substrate/specificity effector bound structure is available for the class Ia
RNR from E. coli, and the nucleotides were not ordered well enough to model them
with a high level of confidence (12). The observation that the catalytic subunit of the
E. coli enzyme readily binds nucleoside diphosphates in the a 4P4-dATP crystal form
led us to perform soaking experiments that provided structures of all four
substrate/specificity effector pairs (dATP/CDP, dATP/UDP, TTP/GDP, or
dGTP/ADP) bound to the catalytic subunit. Our analysis reveals interactions
common to all substrate/effector pairs as well as effector-specific interactions with
loop 2 that dictate substrate preference.
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V.D. Results
V.D.1. Obtaining structures of a4p4-dATP with substrates and allosteric effectors
bound
In the previously reported structure of a4 p4 -dATP, electron density indicated that a
nucleoside diphosphate was bound in the active site of the a subunit even though no
nucleoside diphosphates were used in the crystallization (25). This density was
attributed to dADP because hydrolysis of the y-phosphate from dATP, the only
nucleotide used in the experiment, is not unlikely over the course of the
crystallization (2-3 days at 250C). Multiple attempts to solve substrate-bound
structures of c2 in isolation have been unsuccessful, making the observation of a
dNDP bound in the active site of this a 4p4-dATP structure encouraging. Soaking
experiments with NDP substrates and their appropriate dNTP effectors were
carried out using the a4p4-dATP crystal form as described in the methods. In all
cases, substrates and effectors were found ordered at their respective binding sites
(electron density is shown in Fig. V.8).
In all four substrate/effector soaked structures, the model consists of four a chains,
comprising two a2 dimers and four P chains comprising two P2 dimers arranged in
an alternating pattern to form an open ring structure as described previously (Fig.
V.2A, right) (11, 25). The residues modeled for each chain of each structure are
given in Table 1. In all four structures, the following regions are disordered and
cannot be seen in the experimental electron density: the last -24 C-terminal
residues of a that contain the redox active cysteines Cys754 and Cys759 and the
-20 residues of P that connect the first 330 residues of the subunit to the last -15 C-
terminal residues that bind to the a subunit (including the radical pathway residue
Tyr365).
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V.D.2. Conformational changes associated with tighter substrate binding
The previously reported crystal form of E. col a2 did not bind substrates at full
occupancy (12). Also, in the crystal form of a2-dATP (described in chapter IV), the
specificity site loops are involved in crystal contacts and thus cannot move into the
conformation needed to stabilize effector and substrate binding once the crystal
lattice is formed. The a4p4 form of the enzyme cannot turn over substrates due to
abrogation of the radical transfer pathway, but substrate binding is not impeded,
and the packing of the ring-shaped molecule keeps the C2 subunits further from
each other relative to a lattice consisting of only c2. This difference in the crystal
lattice may be the reason that substrate soaks using the a4p4 form were highly
successful as compared to the use of a2 crystalline states. An initial alignment of
one c chain from the free c2-dATP and the a4p4-dATP complex crystal structures
was performed using only the conserved active site finger loop (residues 430-450).
This finger loop, that contains Cys439, where a transient thiyl radical is formed to
initiate catalysis, is in the center of a ten stranded p/a barrel that contains the
substrate binding site (Fig. V.2B,C). In this alignment, one half of the active site
barrel overlays exactly, while the second half of the barrel and the N-terminal
portion of the structure undergoes a change in relative position (Fig. V.3). To better
characterize this movement, a difference distance matrix was calculated using the
program DDMP (26). This program generates a pairwise difference distance matrix
plot for two structures and reveals relative movements in a reference-independent
manner. Briefly, the distance between every possible pair of atoms in one chain of c
from the a4p 4-dATP structure is measured then subtracted from the same distance
measured in the a 2-dATP structure, giving a representation of how much the
distances between pairs of atoms change between the two structures. The resulting
plot is shown in Fig. V.4. Areas of dark blue indicate a shortening of the distances
between sets of atoms whereas red indicates a relative lengthening (scale is
+/- 3 A). The pattern of movements seen in the plot indicates that the N-terminal
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220 residues (region 1 of Fig. V.4) shift significantly, bringing them closer to the
first half of the active site barrel (residues -224-439, region 2 of Fig. V.4). We also
observe that loop 2 (region 3 or Fig. V.4) and a flexible loop that sits adjacent to the
N-terminus (residues 646-651, region 5 of Fig. V.4) also undergo large motions. It is
clear that there is a significant movement of -224 N-terminal residues towards the
core of a2, and in a crystal form where this region of the protein is involved in
crystal contacts, this rearrangement is not likely to be possible.
The overlay of these structures, aligned again by active site finger loop residues
430-450, reveals local movements that occur at the active site concomitant with
substrate binding (Fig. V.5). Residues Ser622, Ser625 and Thr209 form hydrogen-
bonds with the substrate diphosphate, whereas in the non-bound state (pink ribbon
in Fig. V.5A), these residues are shifted about 1.5 A away from the center of the
barrel. Thr209 is part of the N-terminal region that is shown to move in the DDMP
plot. The inability of the molecule to rearrange to form these hydrogen-bonds, due to
restricted movement in the crystal lattice could be sufficient to prevent substrate
binding in the crystal. In the previously reported E. coli a2 structure with GDP and
TTP bound (12), movements of the N-terminal region are similarly restricted as
observed in DDMP plots (not shown) and these hydrogen-bonding residues are
again further from the weakly bound substrate (Fig. V.5B).
V.D.3. Interactions between the ribose and phosphates of specificity effectors and
RNR
Regardless of the identity of the dNTP base, the ribose and phosphates of the three
specificity effectors (dATP, dGTP and TTP) form identical contacts with RNR. These
interactions are made with only one chain of the a2 dimer. Asp232 is within
hydrogen-bonding distance of 03' of the ribose (Fig. V.6B). Two conformations of
His275 are observed giving rise to a hydrogen-bond to either 04' or 03' of the ribose.
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In each case, the most dominant conformation, based on distances measured
between His275 and 04' and 03', is modeled.
One Mg 2+ coordinates three phosphate oxygens of the specificity effector and three
water molecules (Fig. V.6B). The Mg 2+ has been modeled with an octahedral
geometry. There are no interactions between the Mg 2+ and protein. There are also
electrostatic interactions between the phosphates and Arg269 and Arg262 as well as
hydrogen-bonds between phosphate oxygens and the backbone amide of Arg269 and
Lys234. In the CDP/dATP, model there is some negative difference density at the y-
phosphate of dATP indicating some flexibility of the phosphates or partial
occupancy of a diphosphate at this site (Fig. V.8). One possible reason for this
observation could be that dATP was co-crystallized with the protein but not
included during the soak with CDP, performed two days later.
V.D.4. Interactions between the ribose and phosphates of substrates and RNR
Similar to the nucleotide specificity effectors, the ribose and phosphates all four
substrates (ADP, GDP, CDP and UDP) form identical contacts with RNR,
regardless off the identity of the base. The p-phosphate of the substrate makes four
interactions with RNR. There is an electrostatic interaction with the guanidinium
group of Arg298, a loop 2 residue, which is stacked against the substrates base (Fig.
V.7B). There are also hydrogen-bonds between the P-phosphate and the sidechains
of Thr209 and Ser625 and the backbone amide of either Thr209 or Ser625
depending on the position of the phosphates. The a-phosphate makes hydrogen-
bonds with the backbone amides of Ser622 and Glu623. There is no Mg 2+ associated
with the substrate. Instead of using a metal ion, the enzyme appears to stabilize the
negative charge chiefly through an interaction with Arg298 of loop 2 in addition to
hydrogen bonds to backbone atoms of N-terminal residues and residues from the p/a
barrel.
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The substrate ribose also makes conserved interactions. 03' forms hydrogen-bonds
to the side chains of Asn437 and Glu441 (Fig. V.7B). This observation is consistent
with the proposed role of Glu441 as a general base to deprotonate 03' in the
reaction mechanism (5, 27). 02' is within hydrogen-bonding distance of the
backbone carbonyl of Ser224, and in the CDP/dATP structure, 02' forms a
hydrogen-bond with a water molecule that is further stabilized through interactions
with the backbone carbonyl of Gly253 and backbone amide of Leu438 (Fig. V.7B).
This water was also observed in structures of substrate-bound a2 in S. cerevisiae,
and the authors propose it may be relevant to the catalytic mechanism (24). In the
other three structures, there is positive difference density at this site but when a
water molecule is refined, there is no 2F-F density supporting its presence. With
the given resolution of these structures (3.2-3.4 A), it is not conclusive whether a
water is present and thus, it has not been modeled. In the catalytic mechanism,
Cys225 is the proposed proton donor for the 2'-OH that is lost as H 2 0. Cys225 is 3.4-
3.6 A from the 02' in our structures. The distance between the sulfur atom of
Cys439, where the thiyl radical is formed and C3' of the ribose, where a hydrogen
atom is abstracted to initiate catalysis, is 3.5-3.7 A.
V.D.5. Loop 2 interactions with specificity effectors and substrates
Loop 2 is ordered in all four structures as indicated by 2F-F electron density (Fig.
V.8). As noted above, Arg298 of loop 2 forms a conserved interaction with all four
substrates. The side chain is stretched over the substrate base, forming a n-cation
interaction with the base and providing hydrogen-bonds to the p-phosphate as well
as charge stabilization (Fig. V.7 and Fig. V.9). On the effector side of loop 2, Cys292
packs against the base of all three effectors (Fig. V.9).
The remaining interactions with loop 2 are distinct for each substrate/effector pair
(Fig. V.9). dATP, which preferentially increases RNR activity for CDP and UDP
substrates, makes two hydrogen-bonds with loop 2 residues. N1 of the adenine
209
forms a hydrogen-bond with the backbone amide and sidechain of Ser293, and N6
forms a hydrogen-bond to the backbone carbonyl of Ser293. These hydrogen-bonds
hold Ser293 in place, and position the adjacent Gln294 into a conformation that
points into the substrate binding site (Fig. V.9A, B). In this conformation, Gln294
forms a hydrogen-bond with 02 of both CDP and UDP. There is no difference in
substrate binding between CDP and UDP, as the unique positions of the pyrimidine
ring (N2 and N4/04) are not involved in any contacts with the protein.
Furthermore, this positioning of Gln294 by dATP selects for pyrimidine binding, as
binding of a purine base is not favored because of steric occlusion by Gln294.
dGTP, which preferentially increases RNR activity for substrate ADP, forms one
hydrogen-bond with loop 1 residue Thr276 (Fig. V.9C). It is the only effector for
which a hydrogen-bond is formed between the base and loop 1. In contrast to dATP,
dGTP forms only one or two hydrogen-bonds to loop 2 instead of three. Because the
6-position of the effector is 0 in dGTP instead of NH 2 as in dATP, interaction with
the carbonyl of Ser293 is now unfavorable. Likewise, N1 is protonated in guanine
and unprotonated in adenine, making the interaction with the backbone amide and
sidechain hydroxyl of Ser293 unfavorable for dGTP. The net loss of all three
hydrogen-bonds between Ser293 and effector in the dGTP structure, results in the
movement of this residue -3 A away from the effector binding site. Instead of
binding the effector, the carbonyl of Ser293 now hydrogen-bonds to the backbone
amide of the loop 2 residue Gly300 and the sidechain hydroxyl of Ser293 now
hydrogen-bonds to the Gly300 carbonyl. Stabilization of Gly300 in this position in
turn allows for a hydrogen-bond between the carbonyl of Gly299 with the N6
position of dGTP's preferred substrate ADP. dGTP, instead of interacting with the
backbone atoms of Ser293, now hydrogen-bonds with the backbone carbonyl of
Gln294, stabilizing a conformation in which Gln294 is swung away from the
substrate-binding site. This movement of Gln294 allows room for the larger ADP to
bind (Fig. V.9C). Thus, Ser293 and Gln294 are responsible for both differentiating
adenine from guanine at the effector binding site and for differentiating pyrimidines
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from purines at the substrate site, either directly (in the case of Gln294) or
indirectly through stabilization of Gly299 and Gly300. For the dATP/UDP or CDP
pairs, Ser293 plays a role in effector recognition and Gln294 in substrate
recognition. These roles are reversed for dGTP/ADP.
When TTP, which preferentially increases RNR activity for substrate GDP, binds to
the specificity site, there are no strong interactions between the thymine base and
loop 1 or loop 2, and Gln294 is found in a position swung away from the substrate-
binding site (Fig. V.9D). On the substrate side of loop 2, N1 and N2 of GDP are both
within hydrogen-bonding distance of the backbone carbonyl of Gly299. This is the
only interaction between loop 2 and the substrate. N2 of GDP is also within
hydrogen-bonding distance of the backbone carbonyl of Ala252. This additional
interaction with a non-loop 2 residue gives GDP one more hydrogen-bond than the
other substrates, consistent with the observation that it has the highest affinity of
the four substrates (8).
The preference between ADP and GDP appears to rely on a shift of Gly299 and
Gly300. When dGTP is bound, Gly299 is positioned closer to the substrate, allowing
a hydrogen-bond to N6 of ADP. If GDP were bound here instead, a carbonyl oxygen
would be in the place of N6, making an unfavorable interaction with the carbonyl
oxygen of Gly299, and Gly299 would need to shift to a new position. Such an altered
position of Gly299 is seen in the GDP/TTP structure where the backbone carbonyl of
Gly299 now interacts with N1 of GDP. This movement of Gly299 in the dGTP bound
structure, however, is unfavorable because Gly299 would clash with the effector
side of loop 2 (Fig. V.10). Because TPP is smaller, Gln294, Ser293 and thus Gly299
can sit further from the active site, allowing room for the repositioning of Gly299 so
that it can now form a hydrogen-bond with N1 of the bulkiest substrate GDP. Thus,
purines are favored over pyrimidine substrates when Gln294 is positioned away
from the active site (Fig. V.10.A), and ADP is favored over GDP when dGTP binding
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stabilizes Ser293 close to the Gly299-G300 backbone, and GDP is favored over ADP
when TTP binding leaves Ser293 unrestrained (Fig. V.10).
V.E. Discussion
Studies of nucleotide binding to the a2 subunit indicate that the affinity of
substrates is increased in the presence of their cognate effector (or effector analog)
(8, 17, 28, 29). The stabilization of loop 2 by both effectors and substrates is
consistent with this observation. All four substrate effector pairs share a set of
anchoring residues that stabilize either side of loop 2. On the effector side of loop 2,
Cys292 is anchored by the van der Waals interaction with the effector base. This
observation is consistent with binding studies that show the affinity for all
specificity effectors is decreased when Cys292 is mutated to alanine (30). Arg298
provides another stabilizing interaction. Arg298 is anchored by the n-cation
interaction with the substrate base and interaction with substrate phosphates. A
general stabilization of loop 2 by the specificity effector appears to help poise
Arg298 to make these interactions. Although the lack of metal dependence on
substrate binding is in some ways surprising, it might be this lack of metal
dependence that allows Arg298 to exert its effect, increasing substrate affinity in an
effector-mediated manner.
When no substrates or effectors are bound (for example in the previously solved
structure with PDB ID 3R1R (12)), loop 2 is not found in any of the conformations
seen in the effector-bound structures (Fig. V.9F). It also has high relative B-factors
indicating that it is not highly ordered in the observed conformation (average for
whole chain is 46.3 A2 and average for residues 292-298 is 94.4 A2). In the presence
of specificity effectors alone (for example in the a 2-dATP structure reported in
chapter IV), loop 2 is not observed in any of the conformations seen in the presence
of substrate (Fig. V.9E), and the relative B-factors are again high (average for whole
chain is 47.8 and average for residues 292-298 is 64.4 A2). In contrast, for the E. coli
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substrate and effector structures, the B-factors for loop 2 are more similar to the
rest of the protein. The respective whole chain/loop 2 B-factors for a 4p4-dATP-CDP
are 60.8 A2/64.7 A2 , for a41 4-dGTP-ADP are 70.8 A2/74.7 A 2 , for a4p 4-dATP-UDP are
84.7 A2/94.1 A 2, and for a4p 4-TTP-GDP are 76.6 A2/83.7 A2 .
Specificity regulation is not an all or nothing event, with one effector strongly
favoring one nucleotide over all other possibilities. Activity assays testing single
effector/substrate combinations show that dATP, at low concentrations, can increase
the reaction rate of pyrimidines (CDP and UDP), dGTP can increase the reaction
rate for purine substrates (ADP and GDP) and CDP to a lesser extent, and TTP can
increase the reaction rate for all four NDP substrates relative to having no
specificity effector (8). These results are consistent with the structures described
above. In particular, dATP binding orients Gln294 towards the active site,
stabilizing the binding of both pyrimidine substrates, CDP and UDP, but not
discriminating between them. This position of Gln294 also precludes binding of
larger purine bases. The lack of discrimination between CDP and UDP substrates
by RNR is not problematic for the cell as cytidine deaminase provides another level
of control for dCTP/TTP ratios (31, 32). In contrast, dGTP binding stabilizes Gln294
away from the active site, so pyrimidine binding is not favored and there is now
room for the larger purine substrates to bind. The further positioning of Ser293 by
dGTP close to Gly299-Gly300 creates the preference for ADP. In contrast, TTP,
which makes no significant contacts with loop 2 allows for the highest degree of
flexibility within this loop. TTP binding does order loop 2 enough, however, for
Arg298 to stabilize substrate binding via interaction with the phosphate portion of
the molecule. These observations are consistent with the ability of TTP to increase
the reduction reaction for multiple substrates (8).
We can now compare these new structures to previously reported structures of RNR
with substrates and effectors bound. The active site and allosteric specificity site of
the class II enzyme is architecturally homologous to the class Ia enzyme and
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specificity effector communication is believed to be conserved (23, 33). Of the four
substrate/effector-bound structures reported from the T. maritima class II RNR,
only the TTP/GDP structure has loop 2 fully modeled. The lack of order for loop 2
residues in these structures precludes a full analysis. The four substrate/effector-
bound structures reported for the S. cerevisiae class Ia RNR do have loop 2 fully
modeled in all cases. Models and structure factors were obtained from the Protein
Data Bank (www.pdb.org) and likelihood-weighted electron density maps were
generated using obtained structure factors with model phases and bulk solvent
correction in the program Phenix (34). These maps reveal that the loop 2 electron
density is poor for all but the ADP/dGTP-bound structure, which is the only
structure for which electron density was presented in the paper (Fig. V.11). For the
remaining structures, the positions of the loop 2 residues are not known with
certainty. Thus, similar to the T. maritima structures a full analysis of loop 2
contributions to substrate selection cannot be made.
Despite poor electron density for loop 2, we note similarities in the interactions
between RNR and the ribose and phosphates of the bound specificity effectors and
substrates in the T. maritima, S. cerevisiae and our E. coli structures. The
hydrogen-bond between Asp232 and the 3'-OH of the dNTP effector ribose observed
for E. coli a2 (Fig. V.6B) is conserved. Arg262 and Leu234 in E.coli a2 and their
interactions with the dNTP effector phosphates (Fig. V.6B) are also conserved.
Arg269 of E. coli a2 interacts with the effector phosphates (Fig. V.6B), but this
residue is not conserved (it is an Ala in both T. maritima and S. cerevisiae) and a
lysine from a neighboring helix makes a similar, compensating, interaction in both
organisms. Two interactions are unique to the E. coli specificity site. His275 (Fig.
V.6B) is not conserved (it is a Ser in S. cerevisiae and Ala T. maritima) giving one
more hydrogen-bond to the ribose in E. coli compared to other species considered
here. In addition, Cys292 is not conserved (Fig. V.12). This residue is a Val in the
other reported structures and, in the current set of structures, is not close enough to
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the effector base to make the significant van der Waals interaction observed in the
E. coli structures.
We also note similarities in the interactions between protein and the ribose and
phosphates of substrates. Asn437, Cys439 and Glu441 (E. coli numbering), proposed
to be involved in the catalytic mechanism are conserved residues and have
conserved interactions with the substrate ribose in structures from all three
organisms. Substrate phosphate binding, which is mediated mostly by backbone
amides, is also similar for all reported structures. In the S. cerevisiae structures, a
water was observed within hydrogen-bonding distance of the 2'-OH of the substrate
ribose. We also observe a water in the same position for our highest resolution
(dATP/CDP) structure, but modeling it in the three lower resolution structures is
inconclusive as described above. It is possible that this water is conserved in class
Ia RNRs and this observation merits further study.
One main distinction between our structures and those previously reported is the
Arg298 interaction that is conserved in all substrate/effector pairs for E. coli.
Although a movement of this arginine was observed previously, (ADP/dGTP in T.
maritima and GDP/TTP in S. cerevisiae), in these cases, the arginine did not reach
far enough to make a direct interaction with the p-phosphate of the substrate and a
water was modeled to bridge the two. We propose here that the movement required
to fully stabilize the arginine was prevented by lattice contacts in these crystal
forms, consistent with the lack of loop 2 stabilization in these structures despite the
binding of substrate and effector. In contrast, in the E. coli crystal form, the packing
of the a4p4 allows for the full range of movement required to stabilize the substrate
via Arg298 interactions.
As has been described, Gln294 and Arg298 are highly conserved and mutational
studies have revealed they strongly affect substrate and effector binding (23, 35). In
our structures, Gln294 interacts directly with CDP and UDP and its positioning
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near the substrate binding site appears crucial for distinguishing purine from
pyrimidine substrates as its position occludes the binding of purines. The GDP and
CDP structures from T. maritima with a relatively ordered loop 2 show a consistent
result. These structures also show Gln203 in T. maritima (equivalent to Gln294 in
E. coli) interacts directly with CDP and is moved away from the active site when
GDP/TTP are bound. In contrast, Gln288 in S. cerevisiae a2 (equivalent to Gln294
in E. coil) was found to directly interact with ADP when dGTP is bound. Structural
comparisons suggest that restraints imposed by the crystallographic symmetry in
the S. cerevisiae RNR crystal structure (due to the presence of only one a monomer
in the asymmetric unit) prevent loop 2 from moving close enough to the substrate
binding site for (1) Arg293 (equivalent to Arg298 in E. coli) to interact with
substrate phosphates and for (2) Gln288 to block ADP binding. Discrimination
between pyrimidine and purines can only be accomplished when loop 2 is free to
move, unrestrained by a crystal lattice.
The importance of interactions between substrates and effectors and the conserved
Arg and Gln residues in loop 2 was further probed in a study of the S. cerevisiae
RNR c2 mutants R293A and Q288A. The results of this ITC binding study showed
that R293A has decreased affinity for both CDP and ADP, consistent with a role in
substrate phosphate binding. Mutation of Gln288 to Ala also weakened binding of
both ADP and CDP. In both cases, the effect of the mutations was greater on ADP
binding. At first glance this result seems inconsistent with the E. coli structures,
because these structures would predict that the Arg mutation would influence both
substrates equally, and that Gln mutation should have a larger effect on CDP (not
ADP). However, the specificity effector used in the CDP study was AMP-PNP,
which binds very weakly to the specificity site, whereas the strong binder dGTP was
used in the ADP study. Thus, the magnitude of the mutation effect that was
measured correlates with the affinity of the protein for the effector. The identity of
loop 2 residues only matters when an effector is bound, and matters most when the
effector site is fully occupied. Although these initial studies clearly show the
216
importance of Arg298 and Gln294 (E. coli numbering), repeating these types of
studies with different effectors and substrates will provide the most valuable
information
In conclusion, our a4p 4-dATP crystal form allows for the movements required to
stabilize substrate and effector binding. With these newly described structures of
the E. coli RNR with substrates and their cognate allosteric specificity effectors
bound, we can now describe the previously enigmatic molecular basis for substrate
specificity rules.
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V.F. Materials and Methods
V.F.1. Reagent preparation
Cytidine 5'-diphosphate (CDP), Adenosine 5'-diphosphate (ADP), Uridine 5'-
diphosphate (UDP), and Guanosine 5'-diphosphate (GDP) were purchased from
Sigma-Aldrich and dissolved into assay buffer (50 mM HEPES pH 7.6, 15 mM
MgCl 2 , 1 mM EDTA). The pH was slowly adjusted to 7-8 with NaOH and the
concentration was determined spectroscopically using 8271 of 9.1 mM-1 cm 1 for CDP,
E269 of 15.4 mM 1 cm-1 for ADP, 8262 of 10.0 mM 1 cm-1 for UDP, and 8253 of 13.7 mM-1
cm-1 for GDP. High purity solutions 100 mM sodium salts of adenosine 5'-
triphosphate (ATP), 2'-deoxyadenosine-5'-triphosphate (dATP), 2'-deoxyguanosine-
5'-triphosphate (dGTP), and 2'-deoxythymidine-5'-triphosphate (TTP) were
purchased from USB Corporation or Invitrogen.
V.F.2. Protein Preparation
The a2 and p2 proteins were prepared as described (36, 37). The concentrations of a2
and p2 were determined using 8280 of 189 and 131 mM-1cm-1, respectively; unless
noted otherwise, all molar concentrations are dimer concentrations (i.e., a2 or @2).
For all work described in this chapter, hydroxyurea (HU)-inactivated P2 (met-@2)
was used in place of active P2. Met-@2 was prepared from purified active P2 as
described (11). a2 had a specific activity of 3800 nmol/min/mg. Prior to HU
treatment, @2 had a specific activity of 7700 nmol/min/mg as determined by a
coupled spectrophotometric assay (38).
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V.F.3. Crystallization of a4P4-dATP
Crystals were grown using the hanging drop vapor diffusion technique by mixing 1
1tL of protein (25 tM a2 and 50 [tM met-2 in 50 mM HEPES, 15 mM MgCl2, 1 mM
EDTA pH 7.6, supplemented with 10 mM dATP and 5 mM DTT, 1% w/v IPTG) with
1 .tL of precipitant solution and equilibrating over a reservoir of 500 [iL of
precipitant at room temperature (~25'C). For the CDP soaked crystals the
precipitant solution was 9.5% PEG 3350, 100 mM MOPS pH 7.5, 250 mM
Mg(CH 3COO) 2, 25 mM MgCl2, and 5% glycerol. For the dATP/UDP, dGTP/ADP, and
TTP/GDP soaks the precipitant solution was 12% PEG 3350, 100 mM MOPS pH
7.5, 300 mM Mg(CH 3COO) 2, 30 mM MgCl 2 , 5% glycerol and freshly prepared drops
were streak seeded with microcrystals grown under the same conditions with the
exception of the MgCl2 concentration in the precipitant being 100 mM MgCl2.
Streak seeding was used to obtain larger single crystals.
After two days of growth, crystals were transferred to a drop of soaking solution.
For the CDP soak the solution was 10.5% PEG 3350, 100 mM MOPS pH 7.5, 25 mM
MgCl2, 250 mM Mg(CH 3COO)2, 5% glycerol, 5 mM DTT, and 10 mM CDP. For the
TTP/GDP, dATP/UDP and dGTP/ADP soaks, the soaking solution was the same
except for having 13% PEG 3350, and each nucleotides at 10 mM. Crystals were left
in the soaking solution for 2 min. and then cryo protected. For the CDP soak,
crystals were looped through a solution of 12% PEG 3350, 100 mM MOPS pH 7.5,
250 mM Mg(CH 3COO)2, 60 mM MgCl2, and 10, 15, and 20% glycerol in succession
then plunged directly in liquid N 2. For the TTP/GDP, dATP/UDP and dGTP/ADP
soaks crystals were looped through a solution of 14% PEG 3350, 100 mM MOPS pH
7.5, 300 mM Mg(CH3COO)2, 100 mM MgCl 2 , and 10, 15, and 20% glycerol in
succession then plunged directly in liquid N2 .
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V.F.4. Structure Solution and Refinement
Diffraction data were collected at the Advanced Photon Source at Argonne National
Labs. The dATP/CDP data set was collected on beamline 241D-C at 100 K on a
ADSC Q315 detector. The dATP/UDP, dGTP/ADP, and TTP/GDP data sets were
collected on beamline 241D-C at 100 K on a Pilatus 6M detector. All data were
processed using HKL2000 (39) (Table V.2).
All four a4p 4-dATP complex structures soaked with substrates and effectors were
solved to the full extent of the data resolution using isomorphous replacement
methods from the previously published 3.95 A resolution structure (25) with all
nucleotides removed. Rfree test sets were chosen to have the same reflections for all
data sets. For all structures, iterative rounds of data refinement and model building
were performed in CNS 1.3 (40) or Phenix (34) and COOT (41) respectively.
Refinement consisted of rigid body, simulated annealing, positional and individual
B-factor refinement with no sigma cutoff. Loose non-crystallographic symmetry
(NCS) restraints were used throughout refinement. Simulated annealing composite
omit maps generated in CNS 1.3 were used to verify the models. All figures were
made using the PyMOL Molecular Graphics System, Version 1.5.0.4 (Schr6dinger,
LLC).
The crystal structure of c4P4-dATP soaked with CDP was solved to 2.97 A resolution
with Rwork/Rree values of 19.0/23.3 (Table 2). One Mg-dATP is bound at each
specificity site and one Mg-dATP is bound at each activity site. Six PEG molecules,
14 PO 42- molecules, 17 Mg 2+ ions, 8 Fe3+ions, and 78 waters have been modeled. The
crystal structure of a 4p4-dATP soaked with UDP and dATP was solved to 3.25 A
resolution with Rwork/Rfree values of 19.2/22.7 (Table V.2). One Mg-dATP is bound at
each specificity site and 2 dATPs are bound at each activity site with one Mg 2+
coordinated between them. 4 PEG molecules, 1 glycerol, 7 PO42- molecules, 24 Mg 2+
ions, 4 Cl- ions, 8 Fe3+ions, and 55 waters have been modeled. The crystal structure
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of a4p 4-dATP soaked with GDP and TTP was solved to 3.20 A resolution with
Rwork/Rree values of 18.1/23.7 (Table V.2). One Mg-dATP is bound at each specificity
site and 2 dATPs are bound at each activity site with one Mg 2+ coordinated between
them. 5 PEG molecules, 2 CH 3CO2 molecules, 8 P0 4 2 molecules, 18 Mg 2 + ions, 2 Cl-
ions, 8 Fe 3+ions, and 46 waters have been modeled. The crystal structure of a4p4-
dATP soaked with ADP and dGTP was solved to 3.40 A resolution with Rwork/Rree
values of 19.5/22.1 (Table V.2). One Mg-dATP is bound at each specificity site. In
three chains, there is one Mg-dATP bound at the activity site while in the fourth
there are 2 dATPs bound with one Mg 2+ coordinated between them. 8 PEG
molecules, 13 PO42- molecules, 22 Mg 2+ ions, 2 Cl ions, 8 Fe3+ions, and 63 waters
have been modeled. Refinement statistics are given in Table V.2.
The observation of two dATPs binding at one of the allosteric activity sites of the
four a chains in the asymmetric unit is distinct from the binding of two ATPs at this
site in the free a2 (described in Chapter IV). The residues that must rearrange to
form the second ATP binding site in the free a2 structure (Trp28, His59, Phe87) do
not do so here in the a4p4 complex. The phosphates coordinate one Mg 2+ between
them in a similar arrangement, but the ribose and base of the second dATP in the
a4p4 structure sit on the surface of the protein (Fig. V.13). Our structural data
suggest that the conformational changes associated with formation of the second
ATP binding site require ATP in the first binding site (see chapter IV), and serve to
shift the equilibrium away from the a4p4 state toward an a2 state. In particular, we
never observe movements of Trp28, His59, or Phe87 in any a4p4 structure,
indicating that rearrangement of these residues is incompatible with the a4p4 state,
prompting speculation that these changes may represent a driving force for the
disassembly of the a4p4 ring. It is interesting to consider whether this second
surface-dATP site could represent an intermediate state in which a second
nucleotide is bound but rearrangement has not yet occurred. Here, this state is
captured due to the use of much higher than physiological concentrations of dATP
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(10 mM) for crystallization in conjunction with the biding of dATP at the first site,
which unlike ATP, does not promote the necessary rearrangement of residues at the
activity site for binding of a second nucleotide. In cases where only one dATP was
modeled at this site, positive difference density observed near the Mg 2+ could not be
sufficiently accounted for with waters and P0 42- molecules were modeled
coordinating to the Mg 2 +.
One feature common to all four structures was the observation of positive difference
density near Tyr731 that was best accounted for by modeling a molecule of HP0 4 2-
(HP042- A in Fig. V.14). This HP0 42- is adjacent to the face of the aromatic ring of
Tyr731 and also interacts with Arg411 and Asn733. Tyr731 is one of the radical
transfer pathway residues and is solvent exposed in the a4p4 state. Additionally, a
second HP0 4 2- has been modeled in the active site (HP042- B in Fig. V.14). Its
position is less conserved between the four structures but in all cases, it interacts
with Arg411, Asp334 and the hydroxyl group of Tyr731. Because the active site is
solvent exposed in the a4p4 state and the interface required to allow electron
transfer and thus enzymatic activity has not been formed, the relevance, if any, of
these ions is not known.
V.F.5. Calculation of difference distance matrix plots
Difference distance matrix plots were produced using the DDMP program from the
Center for Structural Biology at Yale University, New Haven, CT. Residues 5 to 725
of chain A from each structure were used for the analysis.
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V.H. Figures and Tables
RNR dATPIO
CDP dCDP -+dCTP
UDP dUDP -- TTP
GDP dGDP -+dGTP
ATP ADP dADP -dATP
dATP high
Figure V.1. Regulation of the E. coli class Ia RNR is achieved through changes in
subunit interactions. A general scheme for regulation is shown. Light blue lines
indicate how specificity effector binding enhances the reduction of a particular
substrate. Red and green arrows indicate how dATP and ATP affect overall activity.
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dNTP
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Figure V.2. Structural features of the E. coli class Ia RNR. A) The catalytic
subunit, (a2, a 172-kDa homodimer shown in grey surface representation) and the
radical generating subunit (p2, an 87-kDa homodimer shown in green surface
representation) form an a42p complex in the presence the allosteric activity effector
ATP and is most active in the presence of the correct specificity effector and
substrate pair . The structure of a 2@2 shown is a model based on small-angle X-ray
scattering data (11). The enzyme is inhibited when dATP binds the allosteric
activity site, promoting formation of the inactive a4@4 species. Nucleotide binding
sites are indicated with nucleotides shown as spheres with ATP in cyan, dATP in
red, NDP substrate in yellow and dNTP specificity effector in blue. B) A ribbon
representation of the a2 subunit at a 900 angle from the orientation shown in panel
A). One a chain is colored blue and the other in cyan. Nucleotides are shown as
spheres and colored as in panel A). Loops 1 & 2, which are involved in specificity
effector binding and recognition, are colored in red and labeled. The active site
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finger loop is colored green with Cys439 where the active site thiyl radical is
formed, shown in orange spheres. A black box indicates the location of the active
site containing ten stranded p/a barrel. C) Zoom in of the active site barrel with
strands from the N-terminal half of the barrel colored red and strands from the C-
terminal half of the barrel colored pink. The finger-loop that inserts into the barrel
is colored green with the side chain of Cys439 shown in orange spheres. Substrate is
shown in yellow spheres.
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Figure V.3. Structural movements are observed between the a subunit of free a2
and the substrate binding a4p4. Overlay of one a chain from the structure of a4p4-
dATP-CDP (N-terminus and one half of active site barrel in purple and the other
half of the active site barrel in blue) and a 2-dATP that will not bind soaked
substrates (N-terminus and one half of active site barrel in pink and the other half
of the active site barrel red). The active site finger loop that was used for alignment
of the two chains in colored green. CDP is shown as sticks. The N-terminal helices
(top of figure, colored in purple and pink) move towards the active site barrel
(colored red and blue) in the substrate-bound a4p4 compared to the free a2.
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Figure V.4. C, difference distance matrix plot reveals movements that occur
concurrent with substrate binding. A) Distances in chain A of the a4p4-dATP-CDP
structure were subtracted from chain A of the a 2-dATP structure (reported in
chapter IV) for residues 4-729. Scale is shown on the top and is + 3.0 A (positive
values in blue indicate a shorter distance in the a4p 4-dATP-CDP structure and
negative values in red indicate a longer distance). Regions that move in a concerted
fashion are indicated with colored lines and numbered with residue ranges listed to
the left of the plot. B) Structure of a2 in cartoon representation with residue ranges
from A) colored for one chain. The second chain is colored cyan and nucleotides are
shown as grey spheres. Region 1 (blue), the N-terminal 225 residues, contracts
towards region 2 (yellow). Region 3 (red) includes loop 2 residues and moves
towards the active site (in region 4). A flexible loop, region 5 (green), undergoes a
large motion towards regions 2 and 4 whereas region 4 undergoes little movement
with respect to the rest of the structure.
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Figure V.5. Local movements stabilize substrate binding to the active site of a2. A)
a4p 4-dATP-TTP-GDP (cyan) is overlayed with substrate free a2 (pink, a2-ATP
structure from chapter IV). Distances are given in A. GDP and relevant hydrogen
bonding residues are shown as sticks with GDP carbons in yellow, protein carbons
in cyan or pink, oxygen in red, nitrogen in blue and phosphate in orange. Ser622,
Ser625 and Thr209 move to form hydrogen bonds to the phosphates of CDP. Arg298
of loop 2 reaches over the guanine base. B) Previously reported a2 with GDP bound
with occupancy of 0.5 (PDB ID 4R1R (12)) is shown. GDP and relevant hydrogen
bonding residues are shown in sticks with GDP carbons in yellow and protein
carbons in green. All other atoms colored as in panel A).
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Figure V.6. Interactions between the ribose and phosphates of specificity effectors
and RNR. A) The overall structure of a2 from a4p 4-dATP-CDP is shown in cartoon
representation colored as in Fig. V.2B. dATP is shown at the specificity site in
sticks, highlighted at one specificity site with a black box. B) Zoomed in stereo
figure of dATP ribose and phosphate interactions. dATP is shown with carbons in
cyan. Protein side chain carbons are in light blue. Other atoms are colored as in
previous figures. The side chain of L234 is omitted for clarity. Bonding interactions
are shown with black dashed lines.
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Figure V.7. Interactions between the ribose and phosphates of substrates and
RNR. A) The overall structure of aL2 from a 4p-dATP-CDP is shown in cartoon
representation colored as in Fig. V.2B. CDP is shown at the active site in yellow
sticks, highlighted at one active site with a black box. B) Zoomed in stereo figure of
CDP ribose and phosphate interactions. CDP is shown as sticks with carbons in
yellow. Protein side chains carbons are colored light purple. and loop 2 residue,
R298, carbons are colored tan. Other atoms are colored as in previous figures. Water
is shown as a red sphere. Bonding interactions are shown with black dashed lines.
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A ADP/dGTP 3.4 A resolution
B GDP/TTP 3.2 A resolution
GDP"
TTP
C UDP/dATP 3.25 A resolution
D DP/T 2 r TP
DCDP/dATP 2.97 A resolution
Figure V.8. Electron density confirms loop 2 is ordered in the presence of
substrate and specificity effector in E. coli RNR structures. Shown in stereo. Protein
is in grey cartoons with substrate, loop 2, and specificity effector in sticks and
labeled. Carbon is colored in yellow, oxygen in red, nitrogen in blue, phosphorus in
orange. 2Fo-F, density is shown contoured at 1.0 o (blue mesh) and F-F, density
contoured at +3.0 a (green mesh) and at -3.0 u (red mesh). Resolution and average
B-factors (in A2) for the whole chain and loop 2 (residues 292-299) of the chain
shown are given above each structure. A) a4p4-dATP-ADP-dGTP structure. B) a4p4-
dATP-GDP-TTP structure. C) a4p 4-dATP-UDP structure. D) a4p 4-dATP-CDP
structure.
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Figure V.9. Communication between substrate and effector via loop 2. Substrates
are shown with carbons in yellow (left), effectors are shown with carbons in cyan
(right) and loop two is shown with interacting residues shown as sticks with carbons
in grey. Other atoms colored as in previous figures. Non-interacting residues are
shown in cartoon representation. Hydrogen-bonding interactions are shown in black
dashed lines with distances given in A. Numbering for relevant atoms (from the
text) is shown for all nucleotides.
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Figure V.10. Overlay of structures shown in Fig. V.9 highlight the basis of
specificity. A) a4p4-dATP-GDP-TTP (protein carbons colored grey, GDP carbons
yellow and TTP carbons cyan) is overlayed with a4p4-dATP-CDP (protein carbons
colored blue, CDP carbons in orange and dATP carbons in teal). The Q294 sidechain
carbonyl oxygen is marked with a 'A' to highlight its dramatic rearrangement in the
two structures. The sidechain of Q294 in the CDP/dATP structures occupies the
same physical space as GDP in the GDP/TTP structure. B) a4P4-dATP-GDP-TTP
(colored as in A) is overlayed with a4p4-dATP-ATP-dGTP (protein carbons colored
magenta, ADP orange and dGTP blue). The movement of the G299 carbonyl away
from substrate GDP moves the backbone into a position that would clash with S293
when in the position stabilized by dGTP (clashes are shown with black lines, with
distances shown, measured in A). When TTP is bound, the backbone of S293
undergoes rearrangement (marked with a 'v' for each structure) into a new
conformation allowing G299 and G300 to move further from substrate binding site,
favoring GDP binding at the active site.
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A ADP/dGTP 2.2 A resolution (PDB ID 2CVX)
d tP
BGDP/TTP 2.4 A resolution (PDB ID 2CVW)
C UDP/AMP-PNP 2.9 A resolution (PDB ID 2CVV)
D CDP/AMP-PNP 2.9 A resolution (PDB ID 2CVU)
NP CDP
Figure V.11. Electron density reveals loop 2 is not ordered in structures of S.
cerevisiae a2. Shown in stereo. Protein is in grey cartoons with substrate, loop 2,
and specificity effector in sticks and labeled. Carbon is colored in yellow, oxygen in
red, nitrogen in blue, phosphorus in orange. 2F-F, density is shown contoured at
1.0 o (blue mesh) and F-K density contoured at +3.0 o (green mesh) and at -3.0 o
(red mesh). PDB ID's are given above each structure with resolution and average B-
factors (in A2) for the whole chain and loop 2 (residues 286-294). A) Density reveals
loop 2 is ordered for the a-ADP-dGTP structure. B) a-GDP-TTP structure. C) a-
UDP-AMP-PNP structure. D) ax-CDP-AMP-PNP structure. The lack of density and
high B-factors in panels B)-D) indicate the position of the modeled residues is
uncertain.
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E. coli
H. sapiens
S. cerevisiae
T. maritima
S. typhimurium
(289)
(283)
(283)
(298)
(242)
VKSCSQGG-VRG' T
ARYVDQGGNKRP FA
ARYVDQGGNKRP FA
ISVVKQGS-RRR LM
FSYANQLG-ARN3GA
Figure V.12. Sequence alignment of loop 2 in the a2 subunit for which X-ray
crystal structures are available. Absolutely conserved residues are starred and
highlighted. Arg298 (E. coli numbering) stabilizes substrate binding and Q294
stabilizes pyrimidine binding when dATP is bound to the specificity allosteric site.
The eukaryotic RNRs have one additional residue inserted into the loop.
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(303)
(298)
(298)
(212)
(256)
AFigure V.13. Two dATPs are observed at the activity site. The modeled dATPs are
shown in stereo view. A) 2Fo-Fc density contoured at 1.0 o (blue mesh) and F--Fc
density contoured at +3.0 a (green mesh) and -3.0 o (red mesh) is shown. Protein is
shown in green cartoon with dATP shown as sticks, oxygen colored in red, nitrogen
in blue, phosphorous in orange, and carbon in magenta (first dATP) or teal (second
dATP). Mg 2 + is shown as a grey sphere. B) An overlay of two dATPs bound in the
a 4 p4-dATP-UDP with ATP-bound a2. The ATPs are shown as translucent sticks
with carbons in cyan (first ATP) and yellow (second ATP). The first nucleotide
(magenta and cyan) roughly overlays, but the second (teal and yellow) sits in a
different conformation.
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Figure V.14 Phosphates are observed near the active site of a2. Chain A of the
a 4p4-dATP-CDP structure is shown. Protein backbone is shown in cyan ribbons with
relevant interacting sidechains shown as sticks. Carbons are colored cyan, oxygen in
red, nitrogen in blue, and phosphorous in orange. CDP is shown as sticks with
carbons in yellow. One HP0 42- (labeled A) sits below Tyr731 and interacts with
Arg411 (4.3 A away) and Asn733 (2.6 A away). A second HP0 42 (labeled B) is
modeled near the substrate (CDP, N4 is 3.5 A away) as well as Tyr730 (3.6 A away),
Tyr731 (2.8 A away), and Arg411 (4.4 A away). Electron density maps are shown for
the modeled HP0 42-molecules. 2F-F density is show in blue mesh, contoured at
1.0 a. F-F density is show contoured at 3.0 o in green mesh, and contoured at -3.0
o in red mesh.
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Table V.1. Residues modeled for each chain of
substrates and effectors in a (from 1-761) and P (from
the a 4p4-dATP soaked with
1-375).
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Chain
Structure A (a) B (a) C (a) D (a) E (p) F (p) G (p) H (p)
CDP/ 5-736 4-737 5-737 4-737 1-339, 1-341, 1-341, 1-344,
dATP 363-375 360-375 360-375 361-375
UDP/ 1-339, 1-341, 1-341, 1-341,
dATP 4-737 4 4-737 4 363-375 359-375 360-375 361-375
ADP/ 1-339 1-341, 1-341, 1-340
dGTP 5 4-737 4737 4-737 363-375 360-375 360-375 361-375
GDP/ 4-737 4-737 5-737 1-737 1-339, 1-341, 1-341, 1-344,
TTP 363-375 357-375 360-375 361-375
Table V.2. X-ray data collection and refinement statistics for substrate and
effector bound a4p4 complexes
Soaked with
Data collection
Space group
Cell dimensions
a b, c(A)
a, P, Y (0)
Wavelength (A)
Resolution (,) a
Rsym a
<I/oI> a
Completeness (%)a
Redundancy a
Refinement
Resolution (A)
Number of reflections
Rwork/Rree (%)
Number of atoms
Protein
Nucleotides
Fe/Mg
Water
Average B-factors (A2)
Protein
Nucleotides
Fe/Mg
Water
r.m.s deviations
Bond lengths (A)
Bond angles (o)
Ramachandran plot (%)
Favored
Allowed
Generously allowed
Disallowed
dATP/CDP
C2
274.2, 157.8,
164.5
90.0, 118.8,
90.0
0.9792
50.0 - 2.97
(3.08 - 2.97)
9.3 (52.7)
9.5 (2.2)
98.9 (99.6)
3.7 (3.5)
50.0 - 2.97
123378
19.0/23.3
35028
340
8/17
78
60.3
75.2
44.6/88.0
60.2
0.015
1.40
91.8
8.0
0.2
0.0
a4p4-dATP
dATP/UDP
C2
274.6, 157.3,
164.2
90.0, 119.3,
90.0
0.9795
50.0 - 3.25
(3.37 - 3.25)
9.6 (57.7)
5.7 (2.2)
98.8 (99.2)
3.9 (3.8)
50.0 - 3.25
95123
19.2/22.7
35029
485
8/24
55
83.9
112.6
66.5/95.7
76.9
0.016
1.41
90.5
9.4
0.1
0.0
complex
TTP/GDP
C2
274.8, 157.8,
165.8
90.0, 119.5,
90.0
0.9795
50.0 - 3.20
(3.31 - 3.20)
11.0 (61.9)
5.6 (2.1)
98.8 (99.3)
3.5 (3.6)
50.0 - 3.20
99976
18.8/23.6
35084
468
8/18
46
76.5
99.4
58.1/79.1
51.0
0.007
1.43
91.1
8.7
0.2
0.0
dGTP/ADP
C2
274.3, 157.1,
166.0
90.0, 119.7,
90.0
0.9795
50.0 - 3.40
(3.52 - 3.40)
12.7 (49.9)
5.3 (2.0)
93.6 (95.2)
3.0 (2.9)
50.0 - 3.40
78651
19.5/22.1
35011
409
8/22
63
70.7
94.4
52.6/90.3
56.4
0.014
1.39
92.4
7.4
0.2
0.0
a) Value in parentheses is for highest resolution bin
b) Rsym=( ci ite (hk)- < I(hk) > |)/(Zttl Zi li (hkl))
c) Rfree was calculated from 5% of the total reflections
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Chapter VI
Final thoughts and some remaining questions in
allosteric regulation by ribonucleotide reductases
Portions of the introduction of this chapter were previously published in similar
form in Brignole EJ, Ando N, Zimanyi CM, & Drennan CL. (2012) The prototypic
class Ia ribonucleotide reductase from Escherichia coli: still surprising after all
these years. Biochem Soc Trans 40:523-530.
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VI.A. Summary
Ribonucleotide reductase (RNR) is an enzyme that has amazed and confused
biochemists for decades and continues to do so even after many of its tricks have
been uncovered. The work presented in this thesis has shed light on how binding of
allosteric effector nucleotides alters the structure of the class Ia ribonucleotide
reductase from Escherichia coli to produce a desired regulatory affect. Many
questions, however, remain to be answered to gain a full understanding of how this
enzyme carries out such amazing control of its reactivity. Pressing questions that
remain for this E. coli RNR are discussed and experiments to test new hypotheses
put forward by this work are proposed. In addition to the advances reported here,
work from multiple groups, using diverse techniques, has indicated that the
structural mechanisms of allosteric activity regulation are distinct in RNRs from
other organisms. Recent findings on the correlation of activity and oligomeric states
in eukaryotic RNRs are discussed and differences briefly described to highlight how
they provide a target for a class of RNR inhibitors that affect allosteric mechanisms
in a species-specific manner. Finally, based on our findings, ideas for stabilizing the
active E. coli class Ia RNR complex in a manner amenable for crystallographic
studies are presented.
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VI. B. Revisions to the scheme for allosteric regulation of the E. coli class Ia RNR
The work described in this thesis highlights recent progress in understanding
mechanisms of allosteric regulation in the class Ia ribonucleotide reductase (RNR)
from E. coli. A general scheme incorporating our findings with the previously
established understanding of allosteric regulation is illustrated in Fig. VI.1. RNR is
comprised of two subunits, the active site containing subunit, a2 (that also binds
allosteric effectors), and the radical generating subunit, P2. As discussed in detail in
Chapter I, these subunits must come together to catalyze the reduction of
ribonucleotides. We now know that the prototypic class Ia RNR from E. coli exists in
at least three states that are supported by direct structural observation: the
dissociated C2 and 12 subunits (1, 2), the a2@2 complex that is active in the presence
of substrate/effector pairs (3, 4), and the inhibited a4@4 complex (3, 5) (Fig. VI.2).
Furthermore, it was shown by analytical ultracentrifugation (AUC) and small-angle
X-ray scattering (SAXS) that in the presence of activating effectors or in the absence
of any effectors, the E. coli enzyme exists as an equilibrium mixture of a2, P2, a2@2,
and c4@4, whose distributions are sensitive to protein concentration. When ATP,
substrate and the proper allosteric specificity effector are bound to a2@2, electron
transfer and thus catalysis can take place. The reaction is gated by conformational
changes within a2@2, hence this complex can exist in "not-active" (where the radical
is not able to move between the subunits) or "active" (where the radical moves from
12 to the C2 subunit) states (6). Although these distinct a2@2 states have been
observed spectroscopically using mutant forms of c2 with amino-tyrosine residues
substituted along the electron transfer pathway (7, 8), they are indistinguishable by
many of the low resolution structural methods that have been used to observe this
complex (such as AUC and SAXS). In contrast, dATP is uniquely able to push the
equilibrium towards a single a4@4 state (3). From these data, a three-state model
emerges for the allosteric regulation of overall activity in E. coli class Ia RNR. Here,
the turnover-capable C2@2 complex is an intermediate between the dissociated state
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and the inhibited a4p4 complex (Fig. VI.1 and Fig. IV.2). Whereas increases in
protein or dATP levels shift the equilibrium towards a4p4, according to this model,
ATP may upregulate the E. coli enzyme by competing with dATP for binding at the
activity site and shifting the equilibrium away from the inhibited c4p4 complex. We
observe that two ATPs bind at the allosteric activity site in contrast to binding of
one dATP at this same site. This newly established binding stoichiometry, however,
does not change the allosteric scheme, but simply adds molecular level details of
how this regulation is achieved. These data suggest that in the cell, RNR can act as
a molecular thermostat that senses the balance between ribonucleotide and
deoxyribonucleotide pools by the competitive binding of ATP and dATP for the
activity site, which in turn modulates the equilibrium between the active a2p2 and
inhibited a4 p4 complexes.
We note, based on the structures presented in chapter IV, that ATP does not
significantly contribute to specificity regulation in the presence of other effector
nucleotides and we propose that only dNTPs bind to the allosteric specificity site in
vivo. This result eliminates the previously proposed redundant role of dATP and
ATP as specificity effectors that promote CDP or UDP reduction. Structures of
substrate- and specificity effector-bound E. coli RNR reveal local conformational
changes within flexible loops that stabilize binding of the preferred substrate over
other substrates. Our structures are consistent with previously reported data on
substrate selection by allosteric specificity effectors and thus require no further
modification of the existing specificity regulation 'rules' but provide the molecular
level detail of how that regulation is achieved within the a2 subunit. Substrate
preference is communicated by just a few interactions and is likely dependent on a
fine-tuned matching of binding affinities and cellular concentrations of nucleotides,
consistent with the observation that unbalanced NDP pools can result in
unbalanced dNTP pools (9). These observations suggest that through specificity
regulation, RNR can sense the balance of dNTPs through competitive binding at the
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allosteric specificity site to modulate the preference of substrates from the NDP
pool.
VI. C. Unresolved issues in allosteric regulation of the E. coli class Ia RNR
There are experimental observations that are at odds with the simple regulation
scheme shown in Fig. VI.1. In early studies of RNR, Larsson and Reichard reported
that the combination of ATP at low mM concentrations, in combination with TTP at
concentrations above 100 pM, leads to enzyme inhibition (10, 11). As a positive
allosteric activity effector, ATP is expected to stabilize the active form of the enzyme
and TTP does not have an otherwise reported role in activity regulation.
Subsequently, Brown and Reichard demonstrated, using AUC, that under these
conditions, a heavy complex was formed (5). The ATP/TTP induced heavy complex
observed by AUC was more recently investigated using mass spectrometry methods
by Rofougaran et. al. (12) who determined its composition to be an a4p4 oligomer.
Neither of these structural techniques, however, provide sufficient resolution to
distinguish whether it has the same structure as the dATP induced a4p4. The
stoichiometry and sites of nucleotide binding are not known under these conditions.
These issues are easily addressed with the techniques described in this thesis (such
as SAXS, equilibrium binding assays with radioactive nucleotides, X-ray
crystallography, and AUC). The concentrations of ATP at TTP in the cell (-3 mM
and -250 jiM, respectively, at mid-log phase (13)) are within the range where this
inhibition is observed, but it is impossible to know if this complex is physiologically
relevant due to the possibility of differing local concentrations of nucleotides as well
as the unknown affects of other nucleotides competing for binding. Understanding
the mechanism of this inhibition by nucleotide binding, however, could be useful for
designing allosteric inhibitors of the E. coli enzyme (as will be discussed in more
detail below).
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Additionally, substrate binding studies carried out by von D6beln and Reichard
indicated that ADP can bind to sites other than the active site (14). The locations of
the putative ADP binding sites and possible effects have not been established. As a
further complication, it has been reported in multiple studies that buildup of dADP
during in vitro activity assays leads to enzyme inhibition (11, 12, 14). It has not
been shown whether dADP is binding at the allosteric activity site to confer this
inactivation. Although there is value in understanding how molecules like dADP
inhibit RNR activity in isolation, this will not address the biological function, if any,
of this phenomenon because the affect of other competing nucleotides must be taken
into consideration. Although it is difficult to model complex pathways with many
parameters, this approach may be a useful way to understand how binding
affinities are fine-tuned to give a desired output in a cellular context. There are
many parameters involved in such calculations that we do not yet know, such as the
concentrations of nucleotides at different stages of the cell cycle, and the
stoichiometry of subunits within the cell, but with a large body of quantitative data
already at hand for the E. coli class Ia RNR, as more data becomes available, this
approach should be considered.
A further unresolved issue is the crosstalk between the allosteric specificity and
activity sites reported by Reichard et. a]. for mouse RNR. In this study, mutation of
residues at the activity site led to a decrease in the binding affinity of dATP to this
site as well as to the specificity site, suggesting the two sites are connected (15). The
results of this study, however, are difficult to interpret, especially considering that
the stoichiometry of nucleotide binding is not yet fully established for mouse RNR,
and the purity of the protein used in these experiments was low (15, 16). Additional
studies of allosteric activity regulation to clarify this issue should be pursued.
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VI. D. Testing the two-ATP hypothesis
In chapter IV, we asked how the differential binding of dATP and ATP at the
allosteric activity site of c2 affects conformational changes that promote a4p4
formation. Using a new crystallization condition for the a2subunit, a2-dATP and a2-
ATP co-crystal structures were solved. These structures revealed that the
stoichiometry of nucleotide binding is distinct for the two allosteric activity
effectors. One dATP binds at the activity site whereas two ATPs bind, the second of
which occupies a newly described binding pocket. Solution equilibrium binding
studies support the binding of 2 ATPs at each allosteric activity site. A structure-
based alignment of the E. col a 2-ATP with human a 2-ATP shows that the residues
that form the second ATP binding site are not conserved. However, a re-refinement
of the human a2 model with a second ATP modeled as in the E. coli structure, using
the deposited data indicates that a second ATP is bound in this structure as well.
Therefore, it may be general that nucleotide stoichiometry is what distinguishes
dATP and ATP binding at the allosteric activity site of class Ia RNRs whereas the
details of how this difference affects oligomer formation may be distinct for different
RNRs within the class.
The observation of multiple ATPs at the allosteric activity site of the free a2 is
intriguing, as is the lack of a direct effect of nucleotide binding on residues involved
in a4p4 formation. It is possible that some of the changes we observe are more
relevant to formation of the active a2p2 species, but we lack structural information
to address this question. This missing information highlights another reason
obtaining a high resolution structure of the active a2p2 is so important. Another
interesting observation is the presence of two dATPs at the activity site of a4p4 but
not in the same arrangement as two ATPs (as described in Chapter V). At the
concentrations used in those soaking experiments (10 mM dATP), this binding is
likely not physiological but reveals the propensity for nucleotides to bind at this
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site. This result indicates that in the a4p4 complex, two nucleotides cannot bind to
the activity site the way they do in the free a2 subunit, suggesting that when two
nucleotides are bound stably, the a4p4 is disfavored. Elimination of this second ATP-
binding site through mutagenesis and testing the resulting effect on activity and
inhibition by dATP could reveal its importance. Recently, Ahluwalia et. al have
described in vivo random mutagenesis studies that have been successful in finding
mutations in the E. coli class Ia RNR that affect overall DNA mutagenesis rates
(likely due to impaired allosteric regulation of RNR) (17). This in vivo system seems
well suited to introduce designed mutants known to bind only one ATP at the
allosteric activity site in vitro and observe the associated phenotypes. Based on our
results, it would be expected that mutants that only bind one ATP will be less
active, and may cause cells to grow at a slower rate or not be viable if this step in
dNTP biosynthesis is rate-limiting.
The orientation of two nucleotides in the structure, joined together by coordination
of their phosphate groups, is reminiscent of endogenous second messengers such as
cyclic-di-AMP (Fig. VI.3B) and cyclic-di-GMP. These molecules, however, lack a 3'-
OH on the ribose (the oxygen is instead involved in a phosphodiester bond) and the
small ring formed by monophosphates does not allow for binding of this specific
molecule in a mode similar to that observed for two ATPs (Fig. VI.3). One could
envision, however, designing a small molecule dinucleotide that would mimic the
binding of two ATPs at the activity site. Larger, cyclic di-adenosine scaffolds could
be designed, synthesized, and tested for binding to provide a chemical tool for
studying activity regulation by RNRs.
Further insight into activity effector binding could also be gained by studying
proteins other than RNRs with similar regulatory domains. The allosteric activity
site is housed in a domain named an "ATP-cone". The ATP-cone has been shown to
be an evolutionarily mobile regulatory unit that, based on sequence analysis, is
found in RNRs as well as transcription regulators (18). An E. coli RNR transcription
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regulator, NrdR, has been described (19) and based on sequence analysis, is
predicted to have an ATP-cone domain (18). This transcriptional regulator has not
yet been extensively studied, but is homologous to other known regulators of RNR
gene expression that contain both a DNA-binding zinc-finger and an ATP-cone
domain (20). It would be interesting to see how ATP or dATP binding to the ATP-
cone of these regulators affects transcription and if there are any parallels with
nucleotide binding at the allosteric activity site of the RNR catalytic subunit. There
are currently no structures of a nrdR gene product.
VI. E. Understanding allostery in RNRs from other species
Despite the conservation of chemistry and similarity in the outcomes of allosteric
regulation, it is not yet known how many RNRs will share the same structural
mechanisms that control this regulation. Early studies of RNR revealed that many
of the primary sequences were dissimilar both within and between different classes,
making it unclear if the different classes emerged from convergent or divergent
evolution (21). Studies of the catalytic mechanism of RNRs indicated highly
conserved chemistry for all classes, arguing for a divergent evolution from a
common ancestor (22). Subsequent crystallographic work provided structures of
reductases from all three classes revealing a high degree of structural homology,
further supporting this hypothesis (23). Striking similarity in the structure of the
activity site (located in an ATP-cone domain) and the specificity site (located at the
dimer interface) suggested common mechanisms for allosteric regulation, but a lack
of substrate and effector bound structures left this question unresolved for many
years. A recent resurgence in interest in the atomic level mechanisms of allosteric
regulation has revealed that the divergence of RNRs may be greater than can be
appreciated from single snapshots of individual subunits (3, 12, 24, 25).
In the case of allosteric specificity regulation, there are inconsistencies between our
substrate- and effector-bound structures and analogous structures reported for two
253
other RNRs (26, 27). This observation suggests that either similar rules may be
enforced using the same structural features but using a slightly altered molecular
mechanism or that the previously reported structures utilized a crystal lattice that
did not allow for the range of movements needed to fully stabilize soaked
nucleotides. These discrepancies emphasize the need for further studies of
specificity regulation in multiple RNRs. The case of allosteric activity regulation is
even more dramatic.
A study from the Cooperman group in 2002 resparked interest in the oliogomeric
states of active and inactive RNRs. Light scattering data invoked a2, a4a, a4b, a6,
a2@2 and as6 oligomers in mouse RNR. Further, activity data showed a triphasic
dependence on ATP concentration leading to the proposal of a third allosteric
binding site that the authors called the "hexamerization site" (16). Concerns have
been raised about the interpretation of this data because the enzyme activities were
low with large associated errors, activity data were over fitted, and light scattering
techniques that cannot distinguish mixtures of states, and are easily
misinterpreted, were employed (24, 28). This study, however, highlights the need
for characterization of nucleotide binding and associated changes in activity and
oligomerization in RNRs other than E. coli. Also, a possible relationship between
their "hexamerization site" and the second ATP binding site we observe at the ATP-
cone (described in chapter IV) should not be overlooked. Binding of multiple ATPs
at the allosteric activity site has not been reported for any class Ia RNR other than
E. coli and the residues that form this site in the E. coli RNR are not conserved in
the mouse RNR making it unclear if these two observations are related. The
correlation, if any, between the putative mouse hexamerization-site and our second
ATP binding site may be revealed upon further investigation of allosteric effector
binding to eukaryotic RNRs.
A scheme of what is currently known about allosteric regulation by oligomerization
in eukaryotic RNRs is shown in Fig. VI.4 (29). (30) Subsequent to the study
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described above, work from other groups has shown that mouse as well as human
and yeast RNR catalytic subunits can form a6 hexamers (a trimer of a2 dimers)
under conditions where the enzyme should be both active and inactive (25, 31). A
low resolution X-ray crystal structure of the yeast RNR L6 hexamer was recently
reported by Fairman et. al. (24). In this structure the allosteric activity site is
implicated in dimer-dimer contacts. Similar to the E. coli RNR, the ATP-cone is
involved in oligomer formation, but in E. coli, the interactions are with 12 subunits
not between two a2 subunits. In E. coli, formation of higher order oligomers of the a2
subunit on its own has not been observed (3). Electron microscopy studies have
validated a model of aM in human RNR mediated by contacts with the ATP-cone
(32). Thus, there is a common involvement of the activity site in oligomer formation
but the details are not conserved. Hopefully, continued studies of activity regulation
in mammalian RNRs will clarify how common architectures allow for distinct
structural mechanisms to control activity allosterically. Futhermore, it is not known
if similar mechanisms are used within bacterial class Ia reductases. Although E.
coli has long served as the prototype for RNRs, less is know about regulation in
other bacterial class Ia enzymes. Establishing whether the structural basis of
activity regulation is conserved within taxa or if it evolved late in species
differentiation is work that should be pursued.
One experimental setup that could provide insight into how different ATP-cones
confer different structural mechanisms of regulation is the use of chimeric a2
constructs, swapping the ATP-cone domains between species. If the N-terminus of
the human c2 is swapped onto the E. col a2, can aM hexamers be formed? The
inverse experiment would be more difficult to interpret because the E. coli N-
terminus appears to only interact with @2, not other a2 subunits. Interactions
between the as and 12 subunits would be affected for such chimeric proteins because
of species-specific differences in the @2 subunit. However, these types of experiments
could help to establish the determinants for subunit oligomerization.
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VI.F. The role of dynamics in allostery
Recent work has questioned the model of conformational changes as the sole source
of allosteric effects. NMR studies have indicated that protein dynamics, affected by
the protein as a whole, including residues distal to allosteric effector binding sites
can have an affect on allosteric regulation (33, 34). It would not be surprising if this
were also the case in RNR regulation. Methods such as NMR may not be amendable
to proteins as large as RNR subunits, but computational modeling and dynamics
simulations can address these same questions. Performing such calculations on
effector bound states observed in X-ray crystal structures would be valuable and
may be an accessible technique for this system. As a long-term goal, understanding
the role of dynamics in allosteric regulation should be considered for this system.
VI. G. Drug design: a potential application of these results
As described in chapter I, the development of species-specific inhibitors of RNR for
use as anti-microbial drugs, has not yet had clinical success. Published attempts
targeted a-p interactions, which are the best characterized species-specific
differences between RNRs. Drug molecules that interrupt protein-protein
interactions are believed to have therapeutic potential but have met with limited
success, in general (35). Our studies, in combination with the recent studies of
allostery in mammalian RNRs (31), highlight another target for species-specific
differences in RNR, namely allosteric activity regulation. In fact, the report from
Aye and Stubbe that the clinically used anti-cancer therapeutic clofarabine
triphosphate (ClFTP) inhibits human RNR by binding to the allosteric activity site
but does not inhibit the E. coli enzyme provides optimistic hope that allosteric
regulation can be a species-specific target for RNR inhibition (31). Our structural
studies provide a starting point for designing such inhibitors. In addition, a high
throughput method for testing RNR activity in microwell format was recently
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described by Tholander and Sj6berg (36). This method uses a polymerase chain
reaction (PCR)-based assay where three of the four required dNTPs are added to a
PCR mixture and RNR generates the missing dNTP. Because the RNR-supplied
dNTP is limiting, RNR activity can be quantified by measuring the amount of the
limiting nucleotide incorporated into DNA polymers during the reaction. Using high
throughput methods such as this to screen rationally designed libraries has the
potential to lead to a new class therapeutics that target RNR's allosteric
mechanisms.
VI. H. Obtaining a high-resolution structure of the E. col a2P2
In chapter III, attempts to use the mechanism-based inhibitor, gemcitabine
diphosphate (F2CDP), to trap an a2@2 complex crystallographically were described.
The resulting crystals contained the same a4P4 ring structure observed in the
presence of dATP that was described in chapter II. In addition, crystallization
precipitants led to the formation of a two-ring catenane or (a4p4)2 with two rings
closed around one another (Fig. VI.5)(37). This unique observation led us to probe
the solution behavior of inhibitor treated RNR using SAXS. A titration series of
increasing concentrations of as and 12showed that high protein concentrations shift
the equilibrium towards the a4p4 species, even in the presence of F2CDP and ATP,
when formation of an a2@2 should be favored (38). A second titration experiment,
where increasing amounts of the crystallization precipitant were added to protein at
the concentrations used for crystallographic experiments, showed that addition of
the precipitant led to formation of the (a4p4)2 catenane in solution prior to crystal
lattice formation. The observation of concatenation in response to crowding agents,
as opposed to formation of other compact species, revealed the stability of this a4p4
structure and underscored the propensity for formation of this complex in
crystallization experiments. Traditional techniques using native proteins, therefore,
are extremely unlikely to yield a structure of the a2@2.
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These observations, however, allow for the design of rational approaches to obtain a
structure of the active holocomplex. We now have high-resolution (sub 3.0 A) details
of the a-P interface of a4p4 (described in chapter IV) that provide a starting point for
disrupting contacts to shift the equilibrium away from the c4P4 state. Interface-
disrupting mutations could also prove useful for other studies that require high
protein concentrations, where formation of a4p4 makes data interpretation difficult
(spectroscopic techniques, for example). Additionally, Minnihan et. aL. recently
described a mutant of the a2 subunit with the unnatural low-potential tyrosine
analog, 3-aminotyrosine, incorporated into the radical transfer pathway. This
mutant forms a2p2 complexes with a radical stabilized on the aminotyrosine on the
minute time scale (39). SAXS analysis indicated that the almost complete
conversion of a2p2 to a4p4 observed in the presence of dATP with wild type protein
was slower for the aminotyrosine mutant, with incomplete conversion to a4p4 even
after 20 minutes (39). Although these time scales are short for crystallization
experiments (taking hours to months), these observation show that the equilibrium
distribution of states can be adjusted and an active a2@2 can be locked into a stable
conformation, giving promise that high resolution data of this active complex is
obtainable. It is possible that a combination of stabilization by radical trapping in
combination with mutations that abrogate a4p4 formation and/or the use of covalent
crosslinking techniques could yield a crystallizable complex.
We now know the molecular details for how specificity effector- and substrate-
binding stabilize flexible loops at the interface of the a2 dimer. Structures of
substrate- and effector-bound a2, described in chapter V, reveal for the first time in
the E. coli enzyme, common conformational changes that stabilize the loops
bridging the active site and specificity effector binding site. This stabilization may
be vital to formation of the active a2p2. Thus, any attempts at obtaining a crystal
structure of the a2p2 should include substrates and effectors (or nucleotide
combinations that stabilize the loops in a way similar to the cognate pairs). By
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combining some or all of these ideas, the likelihood of obtaining high-resolution
structural data on the active a2@2 seems more probable now than ever before.
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VI.I. Conclusions
The work presented in this thesis has clarified many aspects of allosteric regulation
in E. coli RNR. The dramatic structural changes that modulate activity are
achieved, in part, by changes in the stability of an a-p interface within an a4p4
complex, regulated by differences in ATP and dATP binding at the activity site. In
specificity regulation, we observe how effector binding leads to smaller structural
changes, confined to loop regions within the catalytic subunit, to influence substrate
preference. The affect is subtle and mediated by few interactions, consistent with
observations that substrate preference is influenced by both cellular substrate and
effector concentrations. Questions about a-p interactions specific to the active
complex remain to be answered. A structure of the active complex remains a major
goal in this field and rational attempts to obtain it are ongoing. Additionally,
anomalous observations have yet to be explained, but we can now probe them in a
more informed manner.
These allosteric mechanisms are also intriguing in light of apparently unique
structural mechanisms adopted by eukaryotic class Ia RNRs that achieve the same
regulatory results. In understanding allostery, it is of general interest to compare
how enzymes with conserved chemistry and structural features carry out similar
tasks in different ways. Due to the work of many groups, much progress has been
made in this area recently. The work described here advances our understanding of
allostery in this prototypical RNR and exemplifies how future progress can continue
to reveal surprising features of this amazingly complex enzyme.
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Figure VI. 1. Revised scheme of allosteric regulation for the class Ia RNR from E.
coli. Binding of effector nucleotides facilitates complex formation from free c2 and P2
subunits (state one). The identity of the nucleotide at the activity site affects the
equilibrium between a2P2 (state two) and a4P4 (state three) with the stoichiometry
being 2 ATPs to one dATP. a2p2 can exist in a form where the radical remains in the
P2 subunit ('not-active') or in the 'active' form with a radical transfer path formed
where the radical can be transferred to the a subunit. The location of the radical is
indicated by a black dot above the subunit where it is found in each state (although
when in the a subunit, the radical is transient). The difference between the two a 2p2
species relies on conformational changes within the a 2p2 complex. Matched
specificity effector and substrate binding facilitates formation of the 'active' a 2 62 but
is not necessary for formation of the 'not-active' form (indicated with dNTP in
parentheses). Formation of the a 4P4 is also not dependent on effector binding to the
specificity site, but this complex can bind both specificity effectors and substrates.
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ATP
a2 + 2 a2P2
a4P4
Figure VI.2. Structural interconversions govern allosteric activity regulation.
Space filling models are shown for different states of the E. coli RNR. The a2
subunit (modeled from the a 2 -ATP structure presented in chapter IV) is colored in
cyan and blue with the N-terminal activity site ATP-cone (residues 1-100) colored
green. The P2 subunit (modeled from PDB ID 1RIB (2)) is colored in red and orange.
The a2p2 is modeled from the structures of the individual subunits fit to the docking
model validated by SAXS and EM (1, 3, 7)). This active form of the enzyme
interconverts with the inhibited a4p4 (modeled from PDB ID 4ERM (34)). The
equilibrium distribution of states is shifted in the presence of allosteric activity
effectors ATP and dATP.
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Figure VI. 3. Two ATPs bound at the allosteric activity site is reminiscent of
cyclic-dinucleotide molecules. A) The 3-dimensional orientation of the two ATPs
found at the activity site of the E. coli RNR is shown with one ATP molecule in cyan
and the second in yellow. Together they coordinate one Mg 2+ ion, shown as a grey
sphere. B) The structure of the cellular second messenger cyclic-di-AMP is shown.
The monophosphate ring joins the nucleotides via the 3' and 5' positions of the
ribose. The monophosphate ring is too small to allow positioning of the bases at the
same distance apart as two free ATPs. Also the lack of a hydroxyl group at the 3'
position would affect interactions seen in ATP binding.
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Figure VI.4. Structural interconversions governing allosteric regulation appear to
be different in eukaryotic and E. coli RNRs. Structures are shown in space filling
with subunits colored as in Fig. VI.2. A) X-ray crystal structures have been reported
for the human a2(PDB ID 3HNF (21)) and for a dATP induced a6 from yeast (PDB
ID 3PAW (21)). The inactive a 6 P2 is modeled based on an EM structure of an a 6 p2
that has been reported for yeast RNR (using PDB ID 3PAW (21) and 1JKO (27)). In
eukaryotic systems, a2 dimers are in equilibrium with monomeric a, and a6 has
been observed by low-resolution techniques in the presence of ATP or dATP (21).
Whether these a6 hexamers have the same structure, has not been resolved. While
dATP inhibited a62 has been observed by EM, the P2 binding stoichiometry is not
clearly established and structures of RNR in the presence of ATP have not been
reported. Whether a202 is an active form of the eukaryotic RNR in the cell is not
known. B) In contrast, states of the E. coli RNR are shown, with the structural
identity of the putative a4p4 formed in the presence of combinations of ATP and TTP
unresolved. No complexes of the a subunit larger than an a2 have been observed (3).
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Figure VI.5. In E. coli class Ia RNR crystallization experiments, the distribution
of oligomeric states is altered. Space filling representations are colored as in
Fig. VI.2. The c4p4 complex is stabilized in the presence of dATP or when RNR
concentrations are increased (3, 34). Under crowding conditions, such as addition of
crystallization precipitants, two a4p4 rings can become concatenated to form an
(a4p4)2(PDB ID 4ERP (34)). The full second ring is colored in grey.
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